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Abstract 
P2X receptors represent the third superfamily of ligand gated ion channels with ATP as their 
natural  ligand. Most  of  the  mammalian  P2X  receptors  are  non-selective  cation  channels, 
which  upon  activation,  mediate  membrane  depolarization  and  have  physiological  roles 
ranging  from  fast  excitatory  synaptic  transmission,  modulation  of  pain-sensation,  LTP  to 
apoptosis etc. In spite of them being an attractive drug target, their potential as a drug target is 
limited  by  the  lack  of  basic  understanding  of  the  structure-function  relationship  of  these 
receptors. 
In my thesis, I have investigated the behavior of homomeric P2X receptor subunits with the 
help  of  photolabeling  and  fluorescence  techniques  coupled  to  electrophysiological 
measurements  using  Xenopus  laevis  oocytes  heterologous  expression  system.  Concurrent 
photolabeling by BzATP and current recordings from the same set of receptors in real time 
has revealed that the gating process in homomeric P2X receptors is contributed individually 
by each subunit in an additive manner.  
Our study for the first time describes the agonist potency of Alexa-ATP (a fluorescent ATP 
analog) on P2X1 receptors. The use of Alexa-ATP in our experiments elucidated that receptor 
subunits are not independent but interacting with each other in a cooperative manner. The 
type  of  cooperativity,  however,  depended  on  the  type  and  concentrations  of 
allosteric/competing  ligands. Based on  our  results,  in  my  thesis  we  propose  an allosteric 
model for ligand-receptor interactions in P2X receptors. When simulated, the model could 
replicate our experimental findings thus, further validating our model. Further, correlation 
between occupancy of P2X1 receptors (determined using binding curve for Alexa-ATP) with 
the steady-state desensitization suggests that binding of three agonist molecules per receptor 
are required to desensitize P2X1 receptors. 
We further extended the approach of fluorescence with electrophysiological measurement to 
assign  the  role  for  different  domains  in  P2X1  receptors  with  the  help  of  environmental 
sensitive, cysteine reactive fluorophore (TMRM). Cysteine rich domain-1 of P2X1 receptors 
(C117-C165)  was  found  to  be  involved  in  structural  rearrangements  after  agonist  and 
antagonist binding. In contrast to the present understanding, that the binding of an antagonist 
cannot induce desensitization in P2X1 receptors and the receptors need to open first before 
undergoing desensitization, we propose based on our results that a competitive antagonist can 
also induce desensitization in P2X1 receptors by bypassing the open state. Abstract 
  v 
We have attempted to answer few intriguing questions in the field of P2X receptor research 
and  we  think  that  our  answers  provide  many  avenues  to  the  basic  understanding  of 
functioning of P2X receptors. 
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1. Introduction 
1.1 Study of neurotransmitter gated ion channels 
1.1.1 Ligand gated ion channels and their functions 
Fast synaptic neurotransmission, both excitatory and inhibitory, is mediated by extracellularly 
activated ligand gated ion channels. These channels are oligomeric transmembrane proteins 
made  of  several  subunits.  Depending  on  the  occupancy  state  of  the  receptor,  these  ion 
channels exist in at least two conformations i.e. open and closed. The equilibrium between 
various conformations is affected by the binding of ligands on these channels. Upon selective 
binding  of  an  agonist  in  the  extracellularly  located  ligand  binding  site,  a  series  of 
conformational  changes  would  open  the  central  ion-selective  pore,  this  process  is  called 
gating. In general, excitation from resting membrane potentials is associated with the opening 
of  cation-influx  channels (depolarization),  while  inhibition  of  neuronal  firing  is  generally 
associated  with  increased  chloride  ion  permeability  (hyperpolarization)  [1].  A  number  of 
different  receptors  are  responsible  for  these  actions.  Fast  synaptic  transmission  includes 
channels directly gated by the neurotransmitter including L-glutamate, acetylcholine, glycine, 
ATP, serotonin (5HT), GABA. Based on our current understanding about these receptors, 
there are three different superfamilies of extracellularly activated ligand gated ion channels 
[2]: 
1.  Cys-loop superfamily: The receptors of this superfamily are made of five homologous 
subunits,  each  with  four  transmembrane  segments  e.g.  nicotinic  receptors,  5HT3 
receptors, serotonin activated anionic channels. 
2.  Ionotropic glutamate activated cationic channels superfamily (iGluR): The receptors 
of  this  superfamily  are  made  of  four  homologus  subunits,  each  with  three 
transmembrane segments e.g. NMDA receptors, AMPA receptors, Kainate receptors 
etc. 
3.  Ionotropic  ATP  gated  channels superfamily:  The  receptors of this  superfamily are 
made of three homologous subunits, each with two transmembrane segments e.g. P2X 
receptors. 
 Introduction 
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Fig.  1.1  shows  the  schematic  representation  of  families  of  neurotransmitter  gated  ion 
channels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  1.1  Families  of  neurotransmitter  gated  ion  channels:  Cys-loop  receptors  have  pentameric  subunit 
arrangements, with each subunit having four transmembrane domains. Ionotropic glutamate gated ion channels 
have tetrameric subunit arrangements, with each subunit have three transmembrane domains. Ionotropic ATP 
gated ion channels have trimeric subunit arrangements, with each subunit have two transmembrane domains. 
The members of each superfamily have extracellular ligand binding site. 
 
1.1.2 Consequence of the ligand-receptor interactions 
Ligand gated ion channels offer a unique opportunity to study the effect of drugs/ligands as 
the ligand binding site and the machinery to generate a response are contained in a single 
macromolecule. According to the classical receptor theory [3], it is assumed that the effect of 
a drug is proportional to the fraction of receptors occupied by the drug and that maximal 
response occurs when all the receptors are occupied. In molecular terms, a physiologically 
relevant measure of response (channel activity) is the total fraction of time that the channel is 
open upon binding of agonist molecules (Po) i.e. an ion channel responds to an agonist by 
briefly permitting particular ions to flow along their concentration gradient from one side of 
the membrane to the other. Reflecting the fact that ion channels cannot be open more than 
100%  of  the  time,  dose  response  curves  constructed  from  plot  of  Po  versus  agonist Introduction 
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concentrations often results in S shape curves on  log concentration axes (Fig. 1.2a). The 
concentration  dependence  or  steepness  of  these  functions  can  be  expressed  in  terms  of 
conventional Hill slope. The Hill coefficient gives a rough estimate of number of agonist 
molecules required to open the channel. In a kinetic scheme of the ligand-receptor interactions 
[4], association of agonist to the closed state of the receptor gives rise to the agonist-receptor 
complex.  This  complex  could  undergo  conformational  changes  that  result  in  the  channel 
opening. Under this scheme, potency is a term used to describe the dependency of agonist’s 
effect  on  its  concentration,  while  affinity  is  the  term  used  to  describe  the  microscopic 
equilibrium (or rate) constants for the binding of agonist to the inactive closed state(s) of the 
receptor. An efficacy is the term used to describe microscopic equilibrium (or rate) constants, 
which describes all the transduction events that follow the initial agonist binding reaction [5]. 
At equilibrium, efficacy (ε) would be equal to the ratio of the two microscopic rate constants 
(β/α).  Both  these  constants  can  be  determined  from  the  distribution  of  open  and  closed 
channel lifetimes i.e. α is simply the reciprocal of the average open channel lifetime, and β is 
the reciprocal of the average time when the channel is closed during the burst [6]. 
Therefore, based on the above concepts, a full agonist is a ligand whose binding would lead 
to  an  increase  in  the  open  probability  of  the  ion  channel  (maximum  open  probability), 
whereas, a partial agonist is a ligand that would lead to the less open probability of the ion 
channel i.e. the relative opening and closing rates of the ligand-bound channel in which open 
state(s) are less frequent and the channel spends most of its time in closed state(s). In contrast, 
an  antagonist  would  be  a  ligand,  whose  binding  would  not  lead  to  opening  of  the  ion 
channels.  An  antagonist  can  be  competitive  or  non-competitive.  Competitive  antagonists 
compete for the agonist binding sites and their inhibition can be overcome by increasing the 
concentration  of  the  agonist,  ultimately  achieving  the  same  maximal  effect.  A  non-
competitive antagonist binds to different binding sites other than agonist binding sites and 
reduces the maximal response of  an agonist. Its inhibitory effect cannot be overcome by 
increasing the concentration of agonist. 
Therefore,  the  partial  agonists  that  also  compete  for  the  same  binding  sites  are  often 
considered as competitive antagonists for the full agonists. Because, once there in the receptor 
binding sites, they not only producing weak response of their own but also prevent the access 
of full agonists to these sites. Agonists and antagonists could have same affinity for a receptor 
binding sites, but the former would have a high and the latter would have no efficacy. Fig. 1.2 
shows the schematic representation of various terminologies used in this thesis. Introduction 
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Fig. 1.2 Ligand-receptor interactions: (A) A sigmoidal dose-response curve results when the magnitude of 
effect observed is plotted versus the logarithm of ligand (agonist) concentration. Various important parameters 
are  highlighted  here.  Potency  is  dependency  of  ligand’s  effect  on  its  concentration.  Efficacy  is  response 
produced by the ligand on the receptor. (B) Hypothetical dose-response curves. Interpretation of Curves A and 
C: Both agonists (A and C) have similar efficacy but differing in potency (A is more potent than C) or the dose-
response curve of an agonist in the absence (curve A) and in the presence (curve C) of a competitive antagonist. 
Interpretation of Curves A and B: Both agonists (A and B) have similar potency but differing in efficacy (A is 
full agonist, and B is partial agonist) or the dose-response curve of an agonist in the absence (curve A) and in the 
presence (curve B) of non-competitive antagonist. 
 
1.2 Historical perspective 
1.2.1 Discovery of purinergic receptors 
Early investigations into the effects of adenosine and ATP were made in a variety of tissues 
particularly in heart and vasculature. In a comprehensive report, Drury and Szent-Györgyi 
showed that adenosine and AMP extracted from heart muscles have pronounced biological 
effects including heart block, arterial dilation, lowering of blood pressure, and inhibition of 
intestinal contraction [7]. Further insight into different action of adenosine and ATP came 
from the studies of Gillespie [8]. His studies showed that ATP caused an increase in blood 
pressure in rabbits and cats which was rarely or never observed with AMP or adenosine. He 
also showed that ATP was more potent than AMP and adenosine in causing contraction of 
Guinea  pig  ileum  and  uterus.  These  studies,  for  the  first  time  indicated  the  existence  of 
different purine receptors in higher organisms. 
Early lines of purine research elucidating the physiological roles of extracellular purines and 
pyrimidines came from the studies of their biological sources and the stimuli for their release. Introduction 
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Experiments by Holton [9] showed that ATP could be released from sensory nerves in the 
rabbit ear. Berne [10] showed that adenosine is released from the heart during hypoxia to play 
an important role in reactive hyperemia.  
In early 1970s, Burnstock et al. [11,12] suggested that ATP or related nucleotides might be 
neurotransmitters, released by non-adrenergic or non-cholinergic neurons in the gut. The idea 
behind the concept of “purinergic transmission” was the existence of specific “purinergic 
receptors” present in the post-junctional cell membrane.  
Since  then,  the  active  research  in  the  field  of  purinergic  signaling  has  established  that 
numerous blood cells, immune and cardiovascular system are important source of purines that 
can be released under physiological and pathophysiological conditions, which may act on the 
purine receptors associated with these or neighboring cells [13-16]. Contrary to purine, not 
enough is known about the sources and release of pyrimidines which limits our understanding 
of the role played by the widely distributed receptors that are activated by pyrimidines.  
 
1.2.2 Classification and nomenclature of purinergic receptors 
Purines  and  pyrimidines  mediate  their  effects  by  interacting  with  distinct  cell-surface 
receptors. Burnstock (1978) [17] for the first time formally recognized “Purinergic” receptors 
and suggested a basis  for classifying them.  He  proposed that purinergic receptors can be 
divided  into  two  classes  termed  as  “P1-purinoceptors”  having  adenosine  as  the  principal 
natural ligand and “P2-purinoceptors” having ATP and ADP as principal natural ligands. This 
division was based on the criteria that ATP was acting directly on P2 receptors, whereas its 
ecto-enzymatic  breakdown  products  were  active  on  P1  receptors.  Other  important 
considerations behind this suggested classification were the relative potency of ATP, ADP, 
AMP and adenosine, selective antagonism of the effects of adenosine by methylxanthines, 
activation of adenylate cyclase by adenosine and stimulation of prostaglandin synthesis by 
ATP and ADP.   
Again in 1985, Burnstock and Kennedy [18] proposed the first subdivision of P2 receptors 
into P2X and P2Y purinoceptors. This subdivision was based solely on the pharmacological 
action  of  αβ-MetATP  on  the  visceral  smooth  muscle.  It  was  then  suggested  that  P2X 
receptors were involved in vasoconstriction and contraction of smooth muscles, whereas P2Y 
receptors were involved in mediating vasodilation and relaxation of smooth muscle upon αβ-
MetATP  application.  Soon  after  the  introduction  of  this  subdivision,  Gordon  tentatively Introduction 
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proposed  two  more  P2  purinoceptors:  P2T  (ADP  selective  and  involved  in  platelet 
aggregation)  and  P2Z  (which  were  activated  by  ATP
4-  and  are  prominent  in  mast  cells, 
macrophages and lymphocytes) [15]. With the growing interest and commercial availability 
of  adenosine  and  ATP  analogs,  several  further  subclasses  were  proposed  including  P2U 
purinoceptors (where ATP and UTP were equipotent [19]), and P2D purinoceptors (selective 
for diadenosine polyphosphate [20]). 
In  the  recommendations  of  International  Union  of  Basic  and  Clinical  Pharmacology 
(IUPHAR)  subcommittee  concerning  the  nomenclature  of  P2  purinoceptors  [21]  it  was 
emphasized that the current  purinoceptor  sub-classification  with  so  many  alphabets  being 
used was unsatisfactory because of randomly added new receptor subtypes. The committee 
supported a new system of classification proposed by Abbracchio and Burnstock [22]. In that 
proposal, it was suggested that P2 receptors should be placed in two major families: P2X 
(consisting  of  ligand  gated  cation  channels)  and  P2Y  (consisting  of  G-protein  coupled 
receptors).  Soon thereafter, Fredholm et al. [23] suggested “P1 receptors” and “P2 receptors” 
in order to replace “P1/P2-purinoceptor” terminology. This classification then brought ATP 
into line with most other neurotransmitters such as ACh, GABA, glutamate and 5HT where 
ligand-gated and G-protein mediated receptor sub-classification has already been established. 
Recently, International Union of Pharmacology Committee on Receptor Nomenclature and 
Drug Classification (NC-IUPHAR 2008) has issued revised guidelines for ligand gated ion 
channels [24]. It was decided by the subcommittee chairs to drop the use of subscripts from 
all of the subunit names for P2X receptors. Therefore, in this thesis this guideline will be 
followed.  
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1.3 The P2X receptor family 
1.3.1 Gene family 
There are seven genes for P2X subunits. The chromosomal locations of human subtypes of 
P2X genes are listed below (HUGO denotes Human Genome): 
Receptor subtype  HUGO gene name  Chromosomal location 
P2X1  P2RX1  17p13.3 
P2X2  P2RX2  12q24.33 
P2X3  P2RX3  11q12 
P2X4  P2RX4  12q24.32 
P2X5  P2RX5  17p13.3 
P2X6  P2RX6  22p11.21 
P2X7  P2RX7  12q24 
 
1.3.2 Protein family 
Early pharmacological studies established a strong basis for discriminating various subtypes 
of P2X receptors, which later in mid 1990s, coupled with molecular cloning of these receptors 
from native excitable tissues has continuously broaden our understanding of  P2X receptors. 
Till date seven P2X receptor proteins (P2X1 to P2X7) have been cloned [25] and expressed in 
Xenopus oocytes or in mammalian cells. Pharmacologically they all show distinct profiles. 
Due to the lack of considerable sequence homology with any known protein to date, and 
absence  of  motifs  (e.g.  Walker  motif)  their  structure  prediction  is  not  possible.  Among 
themselves they share less than 50% protein sequence homology. Based on the available data 
and  analysis  of  hydrophobic  pattern,  it  is  predicted  that  P2X  subunits  have  two 
transmembrane domains, with a large extracellular loop containing the putative ATP binding 
site (Fig. 1.3). This type of subunit topology has been seen with acid-sensing-ion-channels 
(ASIC) [26]. Thus, P2X receptors constitute one of the main receptor family that is distinct 
from Cys-loop and glutamate receptor families [27]. 
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Fig.  1.3  Schematic  representation  of  various  domains  of  human  P2X1:  The  putative  topology  of  P2X 
receptors in general has both N and C terminals facing towards cytosolic side. There is a one large extracellular 
domain  connecting  the  two  putative  transmembrane  domains.  The  N  terminal  domain  of  P2X  receptor  has 
conserved PKC site. Many conserved amino acids are present in the extracellular region as shown in red. It has 
been suggested that positively charged residues (K, R) are involved in ATP binding. There is a characteristic 
pattern of cysteine bonds as judged by mutagenesis studies. The diagram shows human P2X1 numbering [28]. 
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1.4 P2X receptor channels 
1.4.1 Molecular structure 
1.4.1.1 Membrane topology 
The membrane topology of the P2X receptors has been addressed by various approaches. In 
the first approach, locations of glycosylation sites have been determined. The studies on P2X2 
receptors  indicated  that  asparagines  (N182,  N239  and  N298)  were  localized  to  the 
extracellular  domain  (Fig.  1.3).  Glycosylation  had  been  observed  at  newly  introduced 
asparagine sites on the P2X2 receptors in which these three natural asparagine sites had been 
removed. These studies provide direct support for the proposed topology of P2X receptors 
with a large extracellular domain between two membrane spanning regions [29,30]. Further 
evidence that N and C terminals reside on the same side of the membrane came from the 
studies in which two cDNAs have been joined in tandem [29,30]. Such constructs express 
fully functional channels. The cytosolic location of the amino and carboxy termini is also 
supported by the finding that an amino-terminal asparagine residue is not glycosylated at all. 
Finally, confocal immuno-fluorescence microscopy has been carried out on HEK293 cells 
transfected with P2X2 receptors carrying FLAG epitope at the N and C terminus. In either 
case the epitope was accessible to antibody only when the cells were permeabilized [30].  
 
1.4.1.2 Amino-terminal tail 
The amino-terminal tail of P2X receptors is short (20-30 residues) compared to carboxy-
terminal tail (28-242 residues). P2X receptors are sensitive to changes in the intracellular 
environment  [31]  and  can  also  be  regulated  by  a  phosphorylation  mechanisms.  All  P2X 
subunits contain a conserved YxTxR/K motif in the intracellular N-terminus that incorporates 
a consensus protein kinase C site (T-X-K/R) (Fig. 1.3). Phosphorylation of serine, threonine 
or  tyrosine  residues  is  thought  to  control  the  receptor  activity  [32-34].  Apart  from  the 
conserved PKC site, other intracellular domains of P2X receptors can also interact with and 
regulate the properties of other ion channels.  
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1.4.1.3 Extracellular loop 
1.4.1.3.1 ATP binding pocket 
P2X receptors have a large extracellular ligand binding loop comprising ~280 amino acids. 93 
of these amino acids are conserved in at least six P2X family members and could therefore be 
involved in ATP binding, because ATP gates P2X receptors when applied extracellularly.  In 
addition, a purified extracellular loop obtained from P2X2 receptors binds ATP with  low 
affinity [35]. ATP is generally complexed with magnesium, which suggests that negatively 
charged  amino  acids might  coordinate  ATP  binding  via magnesium. But,  experiments  in 
P2X1 [36] and P2X2 [37] suggested that 11 out of 12 point mutants designed to neutralize the 
conserved negative charges of receptors had a less than two fold effect on ATP potency thus 
indicating that these residues are not essential for mediating the actions of ATP. Aromatic 
amino acids are associated with recognition of adenine nucleotides in many ATP binding 
proteins [38]. Along the same lines, recent studies showed that conserved residues F185 and 
F291 regulate ATP potency at P2X1 receptors and suggested that they coordinate the binding 
of adenine ring or ATP (Fig. 1.3) [39]. Mutations of conserved adjacent residues to alanine 
(T184, N288, and R290) in P2X2 (R292 in P2X1) also affect the ATP potency indicating a 
NF(R/T) motif in the agonist binding site. This is similar to NWK motif in synapsin for which 
crystal structures have shown that aromatic tryptophan binds to the adenine ring of ATP [40].  
Sequence homology between human P2X1 and rat P2X2 receptors suggests that conserved 
positively  charged  amino  acids  K68,  R292,  and  K309  (P2X1  receptor  numbering),  are 
associated with the binding of phosphate chain of ATP [37,41]. Therefore, there were two 
possibilities that K68, K71, K309 etc (conserved positively charged residues), which has been 
shown  to  directly  affect  ATP  potency  (hence  thought  to  contribute  to  the  ATP  binding 
domain), comes from the same subunit or contributed by adjacent subunits. Marquez-Klaka et 
al. [42] used disulfide cross-linking approach and non-reducing SDS-PAGE to answer this 
question. Their data demonstrated that K68C/F291C double mutant (both mutations in each 
subunit) resulted in the formation of trimer on the non-reducing SDS-PAGE, consistent with 
the  formation  of  intersubunit  disulfide  bridges.  In  the  functional  studies  on  the  P2X2/1 
receptor chimera, it was found that ATP activated currents from these double mutants were 
small, indicating that formation of intersubunit disulfide bond either prevented ATP binding 
to  the  binding site  or  induced  constraints  to  the  gating.  However,  significant  increase  in 
current was observed after the extracellular application of reducing agent (DTT), indicating 
breakage of intersubunit disulfide bond. In the light of earlier mutagenesis evidences [39] Introduction 
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which suggests involvement of these positions to influence ATP potency, their observations 
support the hypothesis of intersubunit ATP binding sites. 
Some  attempts  have  been  made  in  recent  past  to  model  the  structure  of  P2X  receptors 
especially  the  ATP  binding  domain.  A  structural  similarity  between  first  half  of  the 
extracellular  domain  (residues  170-330)  of  P2X  receptors  and  class  II  aminoacyl-tRNA 
synthetase  has  been  suggested  [43]  whose  catalytic  site  is  composed  of  seven  stranded 
antiparallel  β-pleated  sheet  [44].  But,  in  the  absence  of  any  template  protein,  homology 
modeling of P2X receptors remains a difficult task. The number of ATP molecules required to 
open the P2X receptors is also currently not known, however dose response curves of P2X 
receptors generally have a Hill coefficient of more than one, which suggests that at least more 
than one ATP binding is required to open the channel. It is also interesting to note that not all 
the  nucleotides  are  active  on  P2X  receptors  e.g.  adenosine,  polyphosphates  or  other 
nucleotides such as GTP and UTP exhibit neither agonist nor antagonist action. In addition, 
heteromeric  P2X  receptors  can  have  agonist  sensitivity  and  time  courses  (activation  and 
deactivation)  that  are  distinct  from  that  of  their  constituent  subunits.  These  observations 
suggest that probably interactions between the subunits are also important in determining the 
properties of the channels.  
 
1.4.1.3.2 Conserved amino-acids 
P2X receptor subunits have a large extracellular domain. A striking feature of which is the 
presence  of  10  conserved  cysteine  residues  between  P2X1-7.  It  was  thought  that  these 
cysteines  in  an  extracellular location contribute to  the  tertiary  structure of the protein by 
disulfide bond formation. However, there is no direct evidence for this because of the fact that 
treatment with reducing agents has no effect on channel function [45,46]. The possible pattern 
of  disulfide  bond  formation  has  been  approached  by  systematic  cysteine  to  alanine 
substitutions. Mutagenesis studies on human P2X1 by Ennion et al. [46] and on rat P2X2 by 
Clyne et al. [45] unraveled a specific pattern of disulfide bonds between these conserved 
cysteine residues (Fig. 1.3).  
There are several other conserved glycine and proline residues that enable flexibility in the 
extracellular loop, raising the possibility that they are involved in conformational changes in 
P2X  receptors  upon  agonist  binding.  Indeed  channel  function  was  abolished  in  P2X2 
receptors with the mutations G247A [47] and P225A [48] indicating that the flexibility was Introduction 
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required in these regions. However further studies will be necessary to determine the role of 
other conserved proline and glycine residues in conformational changes.  
The other striking feature which is common among all the subtypes of P2X receptors is the 
presence of consensus N-linked glycosylation (Asn-X-Ser/Thr) sites on the extracellular loop. 
The P2X1 subunit sequence has five such consensus sites, four of which are conserved among 
human, rat and mouse sequences (N153, N184, N284, and N300 with rP2X1 numbering) [49]. 
The P2X2 subunit has three  such sites common among  human, rat and mouse sequences 
(N182,  N239,  and  N298  with  rP2X2  numbering).  All  these  sites  were  found  to  be 
glycosylated in oocytes [29] and in HEK293 cells [30]. Some of these glycosylation sites are 
essential for receptor trafficking to the plasma membrane [50]. The consequences of removal 
(by  mutagenesis)  or  prevention  (by  tunicamycin)  of  glycosylation  on  trafficking  and 
functionality of P2X2 receptors indicated that the receptors in which any two of the three sites 
were glycosylated traffic to the cell surface and were fully functional, while receptors in 
which only one site or no site is glycosylated are failed to traffic to the plasma membrane 
[29,30].  
P2X receptors can be regulated allosterically by extracellular protons [51-53], divalent cations 
and various other ions [53-55]. However their effects are variable among receptor subtypes 
which is reflected by the lack of consensus among the contributing residues identified by 
mutagenesis.  
 
1.4.1.4 The pore 
P2X receptors gate upon agonist binding which enables the movement of monovalent cations 
and Ca
+2 through the open channel [55]. Substituted cysteine accessibility mutagenesis has 
been extensively used to identify residues that line the pore walls of various channels. The 
pattern of accessibility to the modifying reagent is informative because the detection of an 
accessible residue in every 3-4 residues implies that the domain under investigation is α-
helical.  Based  on  such  studies  TM2  of  P2X2  receptors  seems  to  have  an  α-helical 
conformation in the closed state but not when the channels are open. The narrowest part of the 
channel pore is probably near a glycine residue at position 342 about halfway through TM2 
[56,57]. On the basis of macroscopic current measurements on P2X2, P2X4 and P2X7, these 
channels  can  have  at  least  two  open  states  (I1  and  I2)  with  distinct  permeabilities. 
Permeability  was  shown  to  increase  with  sustained  activation  i.e.  during  longer  ATP Introduction 
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applications  the  channels  could  allow  larger  cations  such  as  N-methyl-D-glucamine 
(NMDG
+)  and  propidium  analog  YO-PRO-1  depending  on  subtypes.  The  pore  of  P2X7 
receptors was found to dilate upon receptor activation on a time scale of seconds [58].  
 
1.4.1.5 Carboxy-terminal tail 
Different P2X subtypes show different length of C-terminal tail (28 to 242 amino acids). The 
P2X7 subunits have the longest C-terminal tail with additional hydrophobic domain (residues 
510-530) that is sufficiently long to cross the plasma membrane. Orientation of C-terminal tail 
in  P2X7  is  currently  unknown;  however,  membrane  topology  algorithms  suggest  an 
intracellular location. The presence of conserved YxxxK motif at the C-terminal tail is shown 
to be involved in efficient receptor trafficking to the plasma membrane [59]. Additionally C-
terminal residues could also regulate the number of available channels at the cell surface by 
internalization of some P2X receptor isoforms [60-62]. Splice variants and mutants of C-
terminal tail suggest that this region could also be involved in modifying the gating and pore 
properties (including pore dilation) [63,64]. Studies on co-expression of P2X2 receptors with 
excitatory nicotinic acetylcholine receptors [65], 5HT3 receptors [66] and inhibitory GABA 
receptors [67] of Cys-loop superfamily leads to inhibitory crosstalk between the channels. 
These studies highlighted the role of C-terminal domain of P2X receptors in the process of 
cross-inhibition. Sub cellular targeting studies on P2X2 receptors revealed that they were 
localized at the terminals but not in the cell body of hippocampal interneurons [68], thus 
indicating the possible interactions with other cellular proteins. Therefore, it seems likely that 
P2X  receptors do not  exist  in  isolation  in  the  membrane  but  contribute  to the organized 
regulatory signaling domains through these intracellular sites. Taken together, these studies 
highlighted the multiple role of C-terminal domain of P2X receptors. 
 
1.4.2 Channel stoichiometry 
Different techniques have been used to determine the channel stoichiometry of P2X receptors. 
Kim et al. [35] have purified His-tagged ectodomain of the rat P2X2 receptors (K53-K308) 
using bacterial expression system. After sulfitolysis and refolding, they specifically labeled 
the refolded protein domain with [α-
32P]ATP. Based on the molecular size of the labeled 
protein  which  was  four  times  (132kDa,  as  estimated  by  equilibrium  sedimentation 
centrifugation)  the  calculated  size  of  ectodomain  (29  kDa),  they  suggested  that  the  P2X Introduction 
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receptors might assemble functionally as tetramers in the membrane. However later it was 
shown  that  multimerization  of  full-length  P2X2  subunits  into  trimeric  arrangement  is 
determined by the second transmembrane domain, and not by the extracellular loop [69].  
Since the last decade, a growing number of accumulated evidences have been indicating that 
P2X  receptors  functionally  assemble  as  trimers  into  the  membrane.  At  least  5  different 
approaches have been used to conclude the trimeric channel stoichiometry of P2X receptors.  
In the first approach, Nicke et al. [49] used bifunctional cross-linking reagents and BN-PAGE 
methods to show the trimeric topology of P2X1 and P2X3 receptors. In that study, digitonin 
solubilized,  His-tag  purified  receptors  migrated  entirely  as  non-covalently  linked  homo-
trimers on BN-PAGE. Support to the trimeric topology also came when these receptors were 
cross-linked by chemical cross-linking agents on the intact oocytes (before purification) or 
during His-tag purification (on the Ni-NTA column) and analyzed by non-denaturing SDS-
PAGE gel. It was found that P2X receptors were cross-linked to dimers and trimers. 
Later, Jiang et al. [70] used functional characterization of single and double cysteine mutants 
of  TM1  and  TM2  regions  of  P2X2  and  P2X3  receptors  to  determine  the  channel 
stoichiometry. From the pattern of current generated by these single or double mutants from 
the homo or heteromeric channels, it was deduced that TM1 of one subunit is adjacent to TM2 
of the next subunit in homomeric P2X2 channels in a head-to-tail orientation. They also found 
that the coexpression of P2X2 double cysteine mutants with the wild type P2X3 subunits gave 
essentially normal P2X2/3 currents and these were unaffected by DTT. But, the coexpression 
of  P2X3 double cysteine  mutants  with the wild  type P2X2  subunits  gave  the oligomeric 
channel currents that were much smaller than control currents and these were augmented 
greatly by DTT. Thus, their results indicated trimeric arrangement of P2X2/3 heteromers with 
composition of one P2X2 and two P2X3 subunits.  
In  the  third  approach,  based  on  selective  cell  surface  radio-iodination  and  the  use  of 
glutaraldehyde-based  in  situ  cross-linking  of  plasma  membrane  bound  P2X  receptors, 
Aschrafi et al. [71] showed that homomeric P2X2 and heteromeric P2X1/2 receptors share 
trimeric subunit organization on the plasma membrane. In their study, they found that the 
plasma membrane bound His-tagged homomeric P2X2 migrated as several defined oligomers 
on BN-PAGE. However these oligomers were dissociated into monomers, dimers and trimers 
when  denatured  with  urea  and  (or)  DTT.  These  results  suggested  that  the  functional 
homomeric P2X2 receptors arranged in oligomeric state on the plasma membrane. It was 
believed  that  these  subunits  were  bound  by  weak  interactions  that  could  be  lost  during Introduction 
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receptor  purification.  Thus,  in  order  to  capture  potentially  existing  loosely  associated 
subunits,  they  cross-linked  the  functional  receptors  on  the  intact  oocytes  (prior  to 
purification). When analyzed on reducing SDS-PAGE gels, these  adducts were visible as 
three  bands  at  ~65,  ~130  and  ~190kDa  corresponding  to  monomer,  dimer  and  trimer  in 
homomeric P2X2 receptors. Similarly, when they expressed His-tagged P2X1 subunits with 
the non-tagged P2X2 subunits, they co-purified P2X2 subunits with His-tagged P2X1 under 
non-denaturing conditions, which migrated as one single protein complex on the BN-PAGE 
with a mass slightly larger and smaller than the P2X1 and P2X2 homotrimers respectively. 
Thus, together these results showed trimeric topology of homomeric P2X2 and heteromeric 
P2X1/2 receptors on the membrane.  
Barrera et al. [72], used chemical crosslinking (Disuccinimidyl  suberate, DSS) and direct 
imaging of individual receptors by atomic force microscopy (AFM) to demonstrate that P2X2 
receptors are trimers. They studied the images of His-tagged P2X2 receptors cross linked with 
anti-hexa-His antibodies. For receptors with two bound antibodies, the mean angle between 
the antibodies was 123
o, indicating that the receptor was trimeric.  
Similarly, Mio et al. [73] imaged glutaraldehyde cross linked FLAG-tagged P2X2 receptors 
using electron microscopy. The images demonstrated inverted three-sided pyramid with the 
dimensions of 215 Å in  height and 200 Å in width. The threefold symmetrical top view 
demonstrated the first visual evidence that P2X2 receptors have trimeric topology. 
 
1.5 Properties of P2X1 receptors 
1.5.1 Ligand binding 
1.5.1.1 Agonists 
P2X receptors are well expressed and studied in heterologous systems like Xenopus laevis 
oocytes  and  HEK293  cells  [74-76].  The  homomeric  P2X1  receptor  is  a  cation-selective 
channel that shows little selectivity for sodium over potassium [77]. It has a low permeability 
to larger organic cations such as Tris (PTris/PNa 0.18) or N-methyl-D-glucamine (PNMDG/PNa 
0.04) at least when tested with brief agonist application. Extracellular calcium (up to 100mM) 
has  little  or  no  inhibitory  effect  on  P2X1  receptor  currents  [77].  The  single  channel 
conductance of P2X1 channels is reported as ~18 pS [75,77].  Introduction 
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Two defining characteristics of the homomeric P2X1 channels are its rapid desensitization 
kinetics and its sensitivity to activation by αβ-MetATP. These characteristics are also shared 
by homomeric P2X3 channels, and therefore cannot be used to uniquely define P2X1. It is 
reported  that  βγ-MetATP  is  equipotent  as  αβ-MetATP  at  P2X1  receptors,  but  it  is 
approximately 30-50 fold less potent at P2X3 and more than 100 fold less potent on other 
P2X receptor subtypes [58,74,78-81]. Consequently, βγ-MetATP has been used as a selective 
agonist in some studies investigating P2X1 mediated smooth muscle contraction (e.g. urinary 
bladder, vas deferens, saphenous vein) [82-85]. ADP was originally reported to be an agonist 
of P2X1 with moderate potency (EC50 = 10-70µM) [74,86], however it has been shown that 
this activity was imparted by ATP impurities. Later, purified ADP at concentrations as high as 
1mM failed to elicit currents in oocytes expressing human P2X1 [87].  
P2X1 receptors are fast desensitizing receptors in which desensitization overlaps the channel 
activation.  Due  to  this,  sensitivities  of  various  ligands  cannot  be  studied  in  steady-state 
condition. Therefore, Rettinger et al. [88] used non-desensitizing P2X2/1 receptor chimera, 
which included the entire P2X1 ectodomain. It was found that different agonists activated the 
chimera with nanomolar potencies. Thus, it was suggested that the ectodomain of P2X1 has 
nanomolar  sensitivity  to ATP which  is masked by desensitization in  the wild  type P2X1 
receptors.  Their  results  on  the  time  course  of  deactivation  of  chimera  was  found  to  be 
inversely related to the agonist potency (e.g. For ATP: τ = 63s, EC50 = 3nM; while for αβ-
MetATP: τ = 2.5s, EC50 = ~60nM). Thus, it was thought that the rate limiting step in the 
deactivation process was the rate of agonist unbinding. In the  light of these results from 
chimera, it is expected for the wild type P2X1 receptors that the rate limiting step in the 
recovery of desensitization is the rate of agonist unbinding.  
Diadenosine polyphosphates (APnA) are also known to bind P2X1 receptors with potencies 
similar to ATP. In case of rat P2X1 receptors, it was found that APnA activity increases with 
increasing number of phosphate moieties: AP6A was a full agonist, whereas AP5A and AP4A 
were partial agonists, AP3A had a weak effect and AP2A had no effect at 30µM on hP2X1 
[89]. The structures of some of the P2X agonists are shown in Fig. 1.4. 
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Fig. 1.4 Structure of various agonists of P2X receptors: Listed here are various agonists of P2X receptors. 
αβ-MetATP is a non-hydrolysable ATP analog used to differentiate between fast desensitizing P2X1 from non 
desensitizing  P2X2.  BzATP  is  a  Benzophenone  based  ATP  analog  (BzATP)  which  could  be  used  as  a 
photoaffinity ligand. 
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1.5.1.2 Antagonists 
Initially, Suramin and pyridoxal-phosphate-6-azophenyl-2', 4'-disulfonate (PPADS) were used 
as antagonists of P2X1 channels [75,90,91]. Subsequently several analogs of both suramin 
and PPADS were synthesized that had increased selectivity and potency against P2X1.  
NF023 is a suramin analog that was first used to inhibit αβ-MetATP evoked vasoconstriction 
in pithed rats [92]. Later, NF023 was shown as a potent antagonist of P2X1 (IC50 = ~300nM) 
with selectivity over P2X2, P2X3 and P2X4 [93]. Even greater potency was achieved with the 
discovery of another suramin analog, NF279 which had an IC50 value of ~20nM and increased 
selectivity towards P2X1 over P2X2, P2X3 and P2X4 [94]. Further modification of NF279 
compound yielded NF449. NF449 showed the IC50 value of 0.3nM on rP2X1 expressed in 
oocytes [95]. The mechanism of antagonism of NF279 was investigated on P2X2/1 receptor 
chimera  which  maintains  the  ectodomain  of  P2X1  receptors  and  represents  the  non 
desensitizing  phenotype.  In  the  presence  of  NF279,  dose  response  curve  for  ATP  was 
rightward shifted consistent with the competitive antagonism [88].  
PPADS analogs with increased potency and selectivity have also emerged. The first PPADS 
analog identified with modest selectivity for rP2X1 over other P2X and P2Y receptors was 
MRS2220.  It  showed  IC50  =  10µM  for  rP2X1  [96].  PPNDS,  another  analog  of  PPADS, 
inhibited αβ-MetATP induced isometric contraction of rat vas deferens and inward currents in 
rP2X1 expressing oocytes with IC50 value of ~10nM (vs ~200nM for PPADS) [97]. Thus, 
indicating that PPNDS is a potent P2X1 antagonist. 
TNP-ATP is another potent antagonist of P2X1 receptors, which has an IC50 value of ~1-6nM 
[98,99]. Diinosine polyphosphates (IPnI) (synthesized through deamination of APnA by the 
AMP-deaminase  of  Aspergillus  sp.)  are  also  potent  P2X1  antagonists  with  nanomolar 
potencies  [100].  Extracellular  pH  also  regulates  the  agonist-induced  currents  in  P2X1 
receptors. Lowering the pH to 6.3 reduced the current, but increasing the pH to 8.5 has no 
effect on current responses [77,101]. The structures of main antagonists are shown in Fig. 1.5.  
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Fig.  1.5  Structure  of  various  antagonists  of  P2X  receptors:  Listed  here  are  various  antagonists  of  P2X 
receptors. The general mode of action of these compounds is through competitive inhibition.  
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1.5.2 Desensitization and recovery 
Desensitized state of a receptor represents an electrophysiologically silent state where even in 
the continuous presence of an agonist  no response can be elicited. The desensitized state 
corresponds  most  likely  to  a  ligand  bound  closed  state  of  the  receptor.  The  process  of 
recovery from desensitization is believed to occur in two steps. The first step must involve 
agonist  unbinding  and  the  second  step  then  involves  recovery  from  the  agonist  free 
desensitized to the resting state where the channel can be activated again. 
Human leukemia cells (HL60) and rat basophilic leukemia cells (RBL) express P2X1 receptor 
mRNA  and  protein,  but  inward  currents  in  response  to  extracellular  ATP  can  only  be 
observed after treating the cells with apyrase [102]. This surprising observation suggested that 
ATP was being continuously released from the cells which could induce desensitization. 
P2X1  and  P2X3  receptors desensitize  in  the  presence of ATP (EC50  or  more) with  time 
constants  of  300ms  and  50ms  respectively  [77].  The  time  course  of  recovery  from 
desensitization is 10-20min [76,103]. Generally second and subsequent applications of ATP 
do not elicit currents equivalent to the first application. Experiments on non-desensitizing 
P2X2/1 receptor chimera indicated that desensitization require both TM regions of the P2X1 
receptors.  If  either  of  the  regions  was  replaced  by  the  equivalent  segment  from  P2X2 
receptors, desensitization no longer occurred [76]. These results suggest that the closure of the 
channel during continued presence of the agonist requires concerted conformational changes 
involving both TM segments.  
In studies on recombinant rat P2X1 receptors expressed in oocytes, Rettinger et al. [104] 
revealed  some  of  the  important  findings  about  the  desensitization  and  recovery  of  the 
receptors from desensitization. They found that in the presence of near saturating micromolar 
ATP concentrations (e.g. 30µM), P2X1 receptors quickly activate and the current declines to 
baseline in less than 1s, suggesting that P2X1 receptors undergo fast desensitization in the 
continuous presence of ATP. Even at an ATP concentration as low as 100nM, which elicits 
only  10%  of  the  maximum  current  response,  they  found  that  receptors  could  be  fully 
desensitized in few seconds. Under these non-steady-state conditions i.e. when virtually all 
activated P2X1 receptors were closed rapidly by desensitization and not by direct transition to 
the re-activable closed state, the EC50 value of receptor activation was found to be 0.7µM. In 
their  search  for  the  lowest  ATP  concentration  to  desensitize  P2X1  receptors,  they  pre-
equilibrated P2X1 receptors with different nanomolar ATP concentrations until steady-state 
binding was achieved. Functional response by near saturating ATP concentration (30µM) Introduction 
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from these equilibrated receptors gave 3nM as a K1/2 value of steady-state desensitization, 
indicating that the desensitized state of P2X1 receptors has nanomolar affinity to agonists. 
Due to the high affinity of desensitized state to bound agonist, the bound agonist dissociates 
very slowly  from the desensitized state, thus, suggesting that the rate limiting step in the 
recovery of P2X1 receptors from desensitization is the agonist unbinding step. 
When  they  compared  the  mechanism  of  desensitization  in  P2X1  receptors  and  nicotinic 
receptors,  they  found  that  both  show  different  mechanisms  of  desensitization.  Nicotinic 
receptors already have high affinity desensitized state in equilibrium with the resting state, 
thus, the agonist can bind directly to the desensitized state before opening of the receptor. 
However, P2X1 receptors can be desensitized by nanomolar concentrations of agonists, but 
the area under the current traces elicited by different agonist concentrations (18-300nM) was 
found  to  be  similar  indicating  that  P2X1  receptors  must  open  first  before  undergoing 
desensitization. 
Further support to these observations came from their work on a P2X2/1 receptor chimera 
which indicates that the ectodomain of P2X1 receptors has nanomolar affinity for ATP and 
that an inverse relationship existed between EC50 value of agonist and the time course of 
deactivation of current [88]. These results suggest that unbinding of agonist is the prerequisite 
for channel deactivation. By eliminating the desensitization from the P2X1 receptors (i.e. use 
of  chimera),  the  stationary  currents  become  amenable  to  analysis  that  allows  for  a 
determination of the EC50 value under steady-state conditions. Thus, on chimera, the EC50 
value of receptor activation was found to be 3nM. However, the additional processes which 
regulate the slow unbinding of agonists from the desensitized state of P2X1 receptors are 
currently unknown.   
 
1.5.3 Internalization 
Direct visualization of agonist mediated internalization of P2X1 receptors comes from the 
study of P2X1-coupled green fluorescent protein (GFP) chimeras. The work of Dutton et al. 
[105]  showed  that  P2X1-GFP  chimera  undergoes  internalization  in  HEK293  cells  upon 
prolonged exposure (~40s) to ATP. The observed co-localization of an endosome marker with 
P2X1-GFP confirmed the role of  endosomes in internalization of these chimeras. Similar 
results  using  P2X1-GFP  chimera  transfected  and  expressed  in  sympathetic  neurons  from 
superior cervical ganglion showed that upon exposure to αβ-MetATP, formation of clusters Introduction 
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occur  under  the  plasma  membrane  [106].  The  loss  of  GFP  fluorescence  upon  receptor 
activation was possibly due to quenching of GFP fluorescence by the acidic environment of 
endosomes. Thus, pretreatment of transfected ganglia with 5µM monensin (which disrupts the 
pH gradient in endosomes) prior to the addition of αβ-MetATP resulted in retention of GFP 
fluorescence,  demonstrated  the  role  of  endosomes  in  agonist  mediated  receptor 
internalization. Similar conclusion of agonist mediated receptor internalization was drawn by 
Ennion et al. in their studies on rat vas deferens which expressed biotinylated P2X1 receptors 
[107].  
 
1.6 Techniques to study ligand-receptor interactions 
1.6.1 Photolabeling  
Photolabeling and crosslinking refers to a variety of methods developed in the past 30 years to 
probe the structural and functional properties of various biological targets [108]. Photoaffinity 
labeling  is  widely  used  in  structure-function  analysis  of  biological  systems  because  this 
approach  allows  direct  verification  of  spatial  proximity  of  molecular  components.  The 
photolysable group can be attached to a known ligand at a position thought not to interfere 
with binding of ligand to the receptor and the resultant photoaffinity label can be tested for 
pharmacological activity in the dark. Thus, the lack of covalent binding of the ligand before 
photolysis gives this technique a great advantage of reversible binding to the receptors for its 
pharmacological  characterization.  Photolysis  is  usually  achieved  by  the  use  of  ultraviolet 
light. Mercury lamps, which mainly emit wavelengths at 254nm, 313nm and 366nm are often 
used  for  photolabeling,  sometimes  at  a  very  high  intensity  to  minimize  exposure  time. 
Wavelengths  greater  than  300nm  generally  cause  less  damage  to  the  proteins  [109].  For 
detection  of  the  cross-linked  product  i.e.  the  macromolecule,  and  finally  the  sites  of  its 
modification, the probe must contain a reporter (radioactive, fluorescent, or immunoreactive) 
group, as this enables the detection of the specific amino acid residues of a protein which are 
in contact with the ligand. Sometimes the functional response from the receptor itself can be 
used  as  a  reporter  for  covalent  modification  [110,111].  Thus,  photoaffinity  labeling  of  a 
macromolecule can provide valuable information about the location and architecture of the 
ligand binding site and functional state of the receptor [112-114].  
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1.6.1.1 Requirements of the photoprobe 
The  photoprobes  used  in  photoaffinity  labeling  should  have  the  following  distinctive 
properties [112]: 
1.  Reasonable stability under ambient light.  
2.  Life  time  of  photochemically  generated  excited  state  should  be  shorter  than  the 
dissociation of ligand-receptor complex, but long enough to spend sufficient time in 
the  close proximity  of target  site for  covalent  linkage,  so  that the excited  species 
should  get  cross-linked  to  the  receptor  before  the  dissociation  of  ligand-receptor 
complex. 
3.  An unambiguous photochemistry to provide a single and stable adduct.  
4.  Excited state should react indiscriminately with various chemical groups and should 
form a stable adduct so as to survive under various analytical conditions.  
5.  Activation wavelength of the photoprobes should be (preferably) longer than 300nm, 
thus reducing protein degradation and allowing studies on cell cultures or other living 
systems.  
6.  It should not induce significant disorders in the biosystem. 
 
1.6.1.2 Photolysable groups 
There  are  three  photolysable  groups  commercially  available  viz.  Azido,  Diazo  and 
Benzophenone. Highly reactive, photo-generated species which are suitable for use in photo-
affinity labeling are the electron deficient Carbenes (produced by the loss of nitrogen during 
the  photolysis  of  diazo)  [115],  Nitrenes  (produced  by  the  loss  of  nitrogen  during  the 
photolysis of azido) [116] or biradical triplet state (produced by the absorption of photon by 
Benzophenone)  [112].  In case  of  Benzophenone  based photo probes, the  life  time  of  the 
excited state (triplet state) containing two unpaired electrons is much longer than that of the 
singlet state. The triplet state readily relaxes to the ground state if it does not find a proton-
donor with the required geometry. This relaxation process does not require a scavenger and 
this constitutes one of the major advantages of Benzophenone based photoprobe [112]. Other 
photoreactive groups are activated in a photodissociative mode, i.e. activation is irreversible. 
In contrast to Carbene and Nitrenes, Benzophenone photoprobes show reversible activation 
i.e. they may undergo excitation-relaxation cycles until a favorable geometry for covalent Introduction 
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modification  is  achieved.  The  probability  of  achieving  an  optimal  geometry  for  covalent 
attachment can be further improved by using a flexible linker, although more rigid linkers 
should give superior data in topographic mapping of an active site. Therefore, Benzophenone 
photochemistry  in  biological  systems  can  be  most  regio-selective  when  the  flexibility  is 
limited only to  that  extent  which  is  necessary  to achieve  efficient H-abstraction.  General 
mechanism of photolabeling by Benzophenone group is shown in Fig. 1.6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  1.6  Mechanism  of  photolabeling  by  Benzophenone:  Diradicaloid  triplet  state  forms  after  the 
Benzophenone absorbs light of wavelength 366nm. The electron deficient oxygen n-orbital is electrophilic and 
therefore interacts with weak C-H  σ-bonds, resulting in hydrogen abstraction to  complete the half filled n-
orbital. The ketyl and alkyl radicals that are formed readily recombine to generate a new C-C bond producing 
benzpinacol-type compounds. The triplet state readily relaxes to the ground state if it does not find an H-donor 
with the required geometry. This relaxation process does not require scavenger and constitutes one of the major 
advantages of this photoprobe.  
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1.6.1.3 Photoaffinity labeling with purine based analogs 
Purine photoaffinity analogs with nearly all the photolysable groups are now commercially 
available and have been successfully used in structure-function studies of various receptors 
and purinergic receptors [109,117,118]. The first purine based photoaffinity analog (carbene) 
was synthesized by Brunswick and Cooperman in 1971 [119]. A carbene based analog of 
cAMP was used to label the cAMP binding sites of phosphofructokinases [120]. It was also 
used to label cAMP binding sites in intact ghost from human erythrocytes [121]. Later, Haley 
and Hoffman [122] synthesized the azido based purine photoaffinity analog by substituting 
the C8 position with the simple nitrene precursor. But due to the inherent disadvantage of the 
requirement of a strong 280 nm wavelength to photolyze (which often damages the protein 
under  investigation),  only  limited  studies  have  been  performed  on  intact  cells.  Now, 
benzophenone  based  ATP  analog  i.e.  3’(2’)-O-(4-benzolybenzoly)-ATP  (BzATP)  is 
commercially  available.  Earlier,  BzATP  has  been  demonstrated  to  label  purinoceptors 
[118,123-125]. In the current study, I have used BzATP as an agonist and photolabeling agent 
to label P2X receptors heterologously expressed in X. laevis oocytes. 
 
1.6.2 Fluorescence labeling 
Spectroscopic techniques such as X-ray diffraction, nuclear magnetic resonance spectroscopy, 
electron microscopy and scanning probe techniques allow measurements with resolution of an 
angstrom (Å). In general, these techniques require large quantities of purified protein and they 
are often performed under non-physiological conditions and are seldom suitable to observe 
the  molecular rearrangements  in  real  time. Recent  developments  have  made  fluorescence 
based techniques suitable for real time analysis of molecular interactions under physiological 
conditions such as in the live cells.  
 
1.6.2.1 Strategies of fluorescence labeling 
A  prerequisite  for  the  fluorescence  techniques  is  that  the  molecules  of  interest  must  be 
strongly fluorescent and distinguishable from natural background fluorescence. The system 
(ligand/receptor) of interest is rarely fluorescent by itself; therefore, much effort has been 
devoted  to  the  synthesis  of  fluorescent  systems  (ligand/receptor)  that  feature  the 
pharmacological profile of the non-labeled probes [126]. Introduction 
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Methods, to make the system of interest (ligand or receptor) a fluorescent one, can be based 
on three general ways (1) the use of receptor subunits fused to genetically engineered green 
fluorescent protein (GFP) or their  mutants,  (2) covalently  attaching  a  fluorophore on  the 
protein of interest and (3) the use of fluorescent analogs of natural ligands to study ligand-
receptor interactions.  
Method 1: In the recent years the green fluorescent protein from Aequorea victoria has been 
used  as  a  unique  tool  to  monitor  and  localize  gene  expression,  proteins  and  molecular 
interactions in living cells [127]. The versatility of GFP as a biological marker is based on the 
fact  that  its  intrinsic  strong  green  fluorescence  requires  no  co-factor;  the  fluorophore 
fluoresces after correct folding of the protein. By genetic engineering, GFP can be fused as a 
tag to the protein of interest often without altering its normal function. The obvious advantage 
of these proteins is that one can selectively label the protein of choice in-vivo. However, the 
molecular mass of these probes (~26 kD for GFP alone) might be problematic, owing to the 
interference with the  expression and the  folding of the labeled protein and with the  non-
specific interactions between different cellular components.   
Method 2: One of the oldest and still most widely used strategies is to attach a fluorophore to 
a particular functional  group in the target protein by  spontaneous covalent reaction. Most 
amenable to such modification are amines and thiols. Depending on the structure of the target 
protein, chemical labeling can be selective to a single site or to multiple sites. Proteins that 
contain a single cysteine [128] or a single primary amino group (the N-terminal) [129] have 
been constructed by mutagenesis which allows selective, single-residue chemical labeling.  
Method 3: The use of fluorescent analogs of natural ligands offers a great advantage that they 
can be applied directly to the receptors or systems of interest in a reversible fashion i.e. the 
binding of fluorescence ligands is not covalent [130]. A limitation to this method is that the 
chemical  attachment  of  bulky  fluorophore  groups  to  natural  ligands  could  affect  binding 
properties of ligands. Nucleotide triphosphates are crucial mediators of life. ATP is not only 
used to drive unfavorable chemical reactions to fuel biological machines, and to regulate a 
number  of  processes  via  protein  phosphorylation  but  it  also  acts  as  neurotransmitter  by 
regulating purinoceptors. GTP in turn is used almost exclusively for the regulation of signal 
transduction and transport processes. Thus, considerable efforts have been made on modifying 
these  nucleotides  to  improve  their  utility  as  fluorescent  probes  for  investigations  of 
nucleotide-binding proteins [131,132]. Many fluorescent ATP analogs are now commercially 
available [133]. The first fluorescent ribose-modified ATP was TNP-ATP [134]. TNP-ATP is Introduction 
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a known antagonist of P2X receptors. It has been used as a fluorescent ATP analog to study 
extracellular localization of P2X receptors on isolated cochlear hair cells [135] and in kinetic 
studies  of  P2X  receptors  [98].  To  study  various  aspects  of  P2X  receptors  activation,  a 
fluorescent ATP analog with  agonist potency would be desirable, as there  is  no reported 
fluorescent ATP analog which has agonist potency on P2X receptors. In the current study, I 
have described the agonist property of Alexa-647 ATP and its use to study the desensitized 
state of P2X1 receptors. 
 
1.6.2.2 Real time assessment of receptor function 
Electrophysiology provides direct measurement of receptor function by the virtue of its ability 
to  measure  the  response  (ionic  conduction  in  form  of  currents)  generated  by  protein 
(channels/pumps) upon external stimuli. Since channels and pumps are the integral part of all 
excitable cells, their structure-function analysis under physiological conditions in real time 
has been a great interest for scientists since decades. In the recent years with the progress in 
site-specific  fluorescence  labeling  and  the  cloning and expression of the  various  proteins 
(channels/pumps), it has been possible to monitor conformational changes at specific location 
at single amino acid level in a physiological environment with a technique known as Voltage-
clamp-fluorometry (VCF) or Patch-clamp-fluorometry (PCF). The method was pioneered in 
the labs of Isacoff [136] and Bezanilla [128] where it was initially applied to voltage gated K
+ 
channels. Subsequently it was extended to a variety of other systems like hERG potassium 
channel [137], Na
+/glucose co-transporter [138], serotonin transporter [139], GABA receptor 
[140], GABA transporter (GAT1) [141], glutamate transporter [142], nicotininc acetylcholine 
receptor [143] and Na
+ pump [144].  
 
The technique of VCF 
The  basic  methodology  of  VCF  includes  the  engineering  a  cysteine  into  an  otherwise 
cysteine-free  protein.  The  protein  is  then  labeled  with  a  cysteine  reactive  fluorophore 
(methanethiosulphonate or maleimide moiety). Many robust cysteine reactive fluorophores 
are now commercially available with Alexa, rhodamine or fluorescine derivatives. Thus, a 
readily  accessible  docking  site  (free  cysteine  residue)  to  the  environmentally  sensitive 
fluorophore allows the fluorophore to attach to these engineered sites. As the emission from 
the  fluorophore  is  sensitive  to  the  change  in  the  local  environment  (the  accessibility  to Introduction 
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quenching  molecules,  or  the  changes  in  proximity  of  fluorophores  upon  conformational 
changes)  the  change  in  the  fluorescence  emission  reflects  the  real  time  observation  of 
conformational rearrangements in the channel proteins. Therefore, concurrent recording of 
fluorescence and current allows to investigate the correlation between changes in channel 
structure and changes in channel function. Fig. 1.7 shows the schematic representation of 
principle of VCF measurement. 
 
 
 
 
 
Fig. 1.7 General mechanism of voltage clamp fluorometry: Free cysteines are generated by mutagenesis at the 
site of interest. Functionally expressed mutants are labeled with environmentally sensitive fluorescent dye, where 
accessible  cysteines  are  covalently  labeled  by  the  fluorophore  (e.g.  tetramethylrhodamin-6-maleimide 
fluorophore, TMRM). Any local change in environment/surrounding of the fluorophore due to structural changes 
associated with the receptor function could be sensed by the environmentally sensitive fluorophore in real-time. 
Thus, concurrent measurement of current (receptor function) and fluorescence change (conformational change at 
that position) upon external stimulus (ligand/voltage etc) gives insight into the mechanism of receptor activation. 
 
Important considerations in VCF experiments 
Expression  system:  Xenopus  laevis oocytes  have  been  the  preferred choice of expression 
system  because  they  offer  large  surface  area,  easy  handling,  generate  very  little 
autofluorescence  and  provide  high  expression  levels.  However,  VCF  experiments  using 
mammalian cells would be more desirable, but it imposes a lot of technical limitations i.e. 
their smaller surface area leads to reduced signal-to-noise and signal-to-background ratio.  
Chamber:  VCF  experiments  with  ligand  gated  ion  channels  impose  additional  technical 
challenges, because they require a constant perfusion and fast solution changes. This requires 
a more rigid positioning of the oocyte to minimize the artifacts induced by the movement of 
oocytes caused by the solution exchange.  
Light  source:  The  choice  of  the  fluorescent  light  source depends  mainly  on  the  spectral 
properties of the dye in use, but generally mercury, xenon and halogen lamps provide good 
results for a range of dyes.  Introduction 
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Fluorophore: The fluorophore selection is largely a matter of trial and error. However, the use 
of variable linkers attached to the fluorophore could enhance the chance of fluorophore to 
reach the docking site. As the lifetime of the fluorophore’s excited state is on the nanosecond 
scale, but the dynamics of ion channels occurs on the microsecond scale, VCF can provide 
real-time  information on protein motions. As fluorophores molecules can attach to native 
membrane  proteins  or  non-specifically  incorporate  into  the  membrane  itself,  the  labeling 
procedure has to be optimized by varying dye concentrations (typically 5-50µM), labeling 
time (60s to 60 min) and temperature (4-25 
0C).  
Detection system: For most VCF applications, a standard epifluorescence microscope fitted 
with  an  appropriate  filter  set  and  a  powerful  objective  will  be  sufficient.  Photodiode, 
photomultiplier  tubes  (PMTs)  or  fast  charge-coupled  devices  (CCDs)  can  be  used  for 
fluorescence detection. The combined use of spectrophotometers and CCD cameras could 
allow real-time monitoring of the spectral emission of the fluorophore in use. This can be 
useful because many organic fluorophores change their spectral properties depending on the 
hydrophobicity of their environment e.g. the emission peak of rhodamine derivates is blue-
shifted  when  exposed  to  a  more  hydrophobic  environment.  Thus,  the  use  of 
spectrophotometers  could  allow  to  differentiate  between  (de)quenching  events  caused  by 
changes in the positions of nearby quenching groups and changes in the hydrophobicity of the 
microenvironment of the fluorophore [128,145]. 
 
1.6.3 Electrophysiology 
1.6.3.1 Electrical characteristics of biological membranes 
Electrophysiology deals with the investigation of the electrical properties of cell membranes. 
The lipid bilayer represents a resistor with a very low conductance between cytoplasm and the 
extracellular fluid, and consequently the membrane current generates a potential difference 
across the membrane in the range of several tens of millivolts which is governed by Ohm’s 
law. According to Ohm’s law the magnitude of a current (I) flowing between two points in a 
closed circuit is determined by the potential difference between those points and the resistance 
(or inverse of conductance, G) to current flow. 
G
I
IR V = =            Equation 1.1 Introduction 
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Therefore,  if  a  biological  cell  follows  ohm’s  law,  the  potential  difference  across  the 
membrane would be zero in the absence of an externally applied current. However, biological 
cells often do not show a linear relationship between current and voltage (I-V relationship). 
Instead, most cells maintain a negative potential difference across their plasma membrane at 
the  steady-state  condition.  This  membrane  potential  at  the  resting  state  is  called  resting 
membrane potential (Vm) and results from the three factors (1) unequal distribution of ions at 
each side of the plasma membrane, (2) difference in the permeability to these ions, (3) the 
action of active and passive pumps that helps in maintaining the ion gradients. The membrane 
is “hyperpolarized” when Vm is more negative than the resting membrane potential and is 
“depolarized” when Vm is more positive than the resting membrane potential.  
The resting membrane potential of a cell can be changed by the extracellular binding of a 
ligand, which leads to the opening of ion channels i.e. change in the membrane conductance. 
This results in a net flow of ions across the membrane until an equilibrium between chemical 
and electrical gradient is reached. The potential difference in this steady state is defined by 
Nernst potential (equation 1.2) [146]. 
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In the equation 2, R is the gas constant (8.314 V C K
-1 mol
-1), T is the absolute temperature, 
Za is the charge of ion A, F is Faraday’s constant (9.648 x 10
4 C mol
-1) and [Ao] and [Ai] are 
the concentrations of ion A outside and inside the cell, respectively.  
 
1.6.3.2 The voltage clamp technique 
The  voltage  clamp  technique  was  developed  by  Keneth  Cole  in  1949  to  establish  the 
membrane potential of neurons for experimental purpose [147]. The principle of the technique 
is to inject a current which is equal in amplitude but opposite in sign to the current flowing 
across the cell. This results in no net current flow across the membrane, and the membrane 
potential  remains  constant.  By  passing  current  across  the  cell  membrane,  the  membrane 
potential can be stepped rapidly to a predefined level (command voltage). Voltage clamp does 
not mimic a process found in nature, however it offers the following advantages (1) Clamping 
the voltage eliminates the capacitive current, except for a brief time following a step to a new 
voltage (2) The currents that flow are proportional only to the membrane conductance i.e. 
number of open channels, (3) if channel gating is determined by the transmembrane voltage Introduction 
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alone, voltage clamp offers control over the key variable that determines the opening and 
closing of ion channels [148]. 
Xenopus  laevis  oocytes  are  widely  used  as  an  expression  system  for  the  expression  of 
membrane proteins to study the structure-function relationship by voltage clamp technique. 
One-electrode-voltage-clamp, however, cannot be successfully performed in oocytes because: 
(1) the membrane capacitance is around 200nF, (2) the input resistance is as low as 1kΩ 
during peak currents of expressed ion channels, (3) the use of glass electrodes that have ohmic 
resistance greater than 1MΩ could lead to an unacceptably long charging time of the oocytes 
capacitance. Slow current injection can also lead to the improper voltage clamp clamping 
when currents are activating and/or deactivating rapidly, resulting in a membrane potential 
that  deviates  from  the  command  potential.  Therefore  a  second  electrode  serving  for  the 
independent determination of the actual membrane potential is needed. This is achieved by 
the use of “two electrode voltage clamp” (TEVC) (Fig. 1.8).  
 
 
 
 
 
 
 
 
 
Fig.  1.8  Schematic  representation  of  a  two  electrode  voltage  clamp:  (A)  Voltage  clamp  operates  by  a 
negative feedback mechanism. The membrane potential electrode measures the membrane voltage and sends 
output to the feedback amplifier which subtracts the membrane voltage from the command voltage. This signal is 
amplified and the output is sent into the cell through the current electrode. (B) Two electrode voltage clamp 
circuit with a current electrode (CE) and a potential electrode (PE). 
 
The electrodes 
The two intracellular electrodes in TEVC are pulled from glass capillaries with a tip diameter 
of ~10µm, which allows penetration of the cell membrane without much harm to the cell. The 
electrical contact between cytoplasm and the electronics is achieved by filling the capillaries 
with an electrolyte solution (3M KCl) and via Ag/AgCl connection. The charge carriers in the Introduction 
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wire are the electrons (e
-) and in the solution are chloride ions. The electrode reaction is 
governed by: 
- - Cl     Ag     e     AgCl + ⇔ +        
3M KCl brings the resistances of  pipettes to the mega-ohm range, and makes liquid-junction 
potentials occurring at the tip of the electrode nearly independent of changes in the outer 
solution  due  to  the  similar  mobility  of  potassium  and  chloride  ions.  As  a  reference,  an 
extracellular bath electrode also made of Ag/AgCl is used. A separation made by agar can be 
used to avoid direct contact between electrode solution and cytoplasm or bath.  
 
The operational amplifiers 
The voltage clamp, as described above, is a negative feedback system in which the value of 
the output of the system, is “fed back” to the input of the system, where it is compared to a 
command signal for the desired output. Any difference between the command potential and 
the output signal has to be re-adjusted in order to reduce the difference. Electronically this is 
done  by  devices  called  “operational  amplifiers”  (op-amp)  (Fig.  1.9A  and  B),  which 
automatically reduce the difference between command potential and the output signals and 
maintain the membrane potential exactly equal to the command potential [149]. The main 
characteristic of an op-amp is its ability to amplify the difference between its two inputs by a 
factor A (gain).  
0 - 0 e   tage output vol with             ) e   - A(e e + =  
When the negative input is connected to the output, the op-amp works as a voltage follower 
meaning that the output signal equals the signal at the negative input (Fig. 1.9B). These two 
op-amp variants can be used to complete the TEVC circuit as shown in Fig. 1.9C.  
 
 
 
 
 
 
 Introduction 
  33
 
 
 
 
 
 
 
 
Fig. 1.9 Schematic  drawing  of  an  operational  amplifier  and two  electrode  voltage clamp circuits: (A) 
Operational  amplifier (op-amp). (B) Voltage  follower (op-amp with unity  gain). (C)  Two  electrode  voltage 
clamp circuit using op-amps and voltage follower for performing voltage clamp by feedback mechanism.  
 
The voltage follower serves as a high resistance input in order to minimize the current flow 
through the voltage electrode. The second op-amp amplifier is used as a negative feedback 
amplifier with high gain. The current which flows from the feedback amplifier is identical to 
the membrane current and can be measured at the output of the op-amp. Two bath electrodes 
are  commonly  used  to  minimize  the  series  resistance  errors  if  large  currents  are  to  be 
measured.  
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2. Materials and Methods 
A) Molecular Biology materials 
Balance: Sartorius BL310 and Sartorius 2007 MP, Sartorius AG, Germany. 
Centrifuges: Eppendorf centrifuge 5415R and 5417R, Eppendorf AG, Hamburg, Germany. 
Centrifuge: Sigma 3-18K, Sigma, Osterode am Harz, Germany. 
Concentrator: Eppendorf 5301, Eppendorf AG, Hamburg, Germany. 
Refrigerators 4
0C and -32
0C: Kälte Klima Anlagen GmbH, Germany. 
Gel documentation system: Biometra-UV solo, Biometra GmbH, Gottingen, Germany. 
Gel electrophoresis: Powerpac 300, Bio-Rad Laboratories GmbH, Munich, Germany. 
Glassware: Schott Duran, Germany. 
Ice machine: Ziegra Eismaschinen, Isernhagen, Germany.  
Incubator: Heraeus Instrument, Hanau, Germany.  
Milli Q water: Millipore GmbH, Eschborn, Germany. 
Oocyte incubator 18
0C: Heraeus Instrument, Hanau, Germany. 
Petridish for oocytes: Nunclon Surface, Nunc, Denmark. 
pH meter: Metrohm, Deutsche Metrohm GmbH and Co, Filderstadt, Germany. 
Pipets: Pipetman, Gilson, France. 
Shaker: Aerotron, Infors AG, Bottmingen, Switzerland. 
Spectrometer: ND-1000 Nanodrop, NanoDrop Technologies, Wilmington, USA 
Syringes: Omnifix, B Braun, Roth, Germany. 
Thermo shaker: Schutron thromoshaker, MS Laborgeräte, Heidelberg, Germany. 
Tips and tubes: Eppendorf AG, Hamburg, Germany. 
Vortex mixer: Heidolph REAX-2000, Germany. 
 
B) Chemicals 
αβ-MetATP: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Alexa-647 ATP: Molecular Probes, Invitrogen. 
Alexa-C6 maleimide: Molecular Probes, Invitrogen. 
Ampicillin: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
ATP: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
ATP-γS: Sigma-Aldrich Chemie GmbH, Munich, Germany. Materials and Methods 
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ATTO-550 maleimide: ATTO-TEC GmbH, Seigen, Germany. 
BzATP: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
CaCl2: Merck Chemicals Ltd, Darmstadt Germany. 
Collagenase: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
DMSO: Merck Chemicals Ltd, Darmstadt Germany. 
DNA purification kit: Roche Diagonostics GmbH, Mannheim, Germany. 
EDTA: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Ethidium bromide: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Gentamicin: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
H2O2: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
HEPES: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
KCl: Merck Chemicals Ltd, Darmstadt Germany.  
MgCl2: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
NaCl: Carl Roth GmbH, Karlsruhe, Germany. 
Neomycin: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Nuclease free water: Applied Biosystems/Ambion, Austin, USA. 
PAO: Sigma-Aldrich Chemie GmbH, Munich, Germany.  
Peptone: Carl Roth GmbH, Karlsruhe, Germany.  
Plasmid purification kit: Qiagen GmbH, Hilden, Germany. 
Propionic acid Maleimide (PAM): Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Restriction enzymes and buffers: New England Biolabs, MA, USA. 
RNA synthesis kit: Applied Biosystems/Ambion, Austin, USA. 
TNP-ATP: Sigma-Aldrich Chemie GmbH, Munich, Germany. 
TMRM: Molecular Probes, Invitrogen. 
Tricaine (for anesthesia): Sigma-Aldrich Chemie GmbH, Munich, Germany.  
Tris: Carl Roth GmbH, Karlsruhe, Germany. 
Yeast extract: Carl Roth GmbH, Karlsruhe, Germany. 
 
C) Electrophysiology materials 
Amplifier TEVC: TURBO TEC-03X, npi Electronics, Germany. 
Computer for fluorescence: HP Compaq, Intel IV, Windows XP, Germany. 
Computer for photolabeling: Madex, Intel IV, Windows 2000, Germany. 
Computer for TEVC: Compaq Presario, AMD Athlon, Windows ME, Germany. Materials and Methods 
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Custom made oocyte chamber: Workshop, Max Planck Institute for Biophysics, Germany. 
Digidata: INT-20X, npi Electronics, Germany. 
Drip tube system (solution perfusion): Intrafix Air, B Braun, Melsyngen, Germany. 
Electrode holders: Science Products, Hofheim, Germany. 
Epifluorescence (inverted) microscope: Axiovert 35M, Zeiss, Germany. 
Fluorescence filter sets: Omega Optical, Brattleboro, USA. 
Fluorescence microscope objective: 0.75 NA, FLUOR-20X, Zeiss, Germany. 
Glass capillaries (injection): 3-000-203-G/X, Drummond Scientific Co., USA. 
Glass capillaries (TEVC): GB150-8P, Science Products, Hofheim, Germany. 
Injection binocular: Leica M26, Leica. 
Injection needle puller: Model 700D, David Kopf Instrument, USA. 
Lamps: Osram GmbH, Germany. 
Nanoliter injector: World Precision Instruments, USA. 
Magnetic foot: Drummond Scientific Company, USA. 
Magnetic valves: ESF Electronics, Germany. 
Manipulators: Drummond Scientific Company, USA.  
Microfil syring needle: World Precision Instruments Inc, USA. 
Optical bench and stuff: Linos photonics GmbH and Co. KG, Goettingen, Germany. 
Patch clamp amplifier: EPC-5, HEKA Electronics, Germany. 
Photodiode: PIN-022A photodiode, United Detector Technologies, USA. 
Pipette puller (TEVC): PC-10, Narishige, Japan. 
Pipette puller (TEVC): PE-1642, Philips, Belgium. 
Power supply: Delta Electronika, Schulz Electronics GmbH, Baden, Germany. 
Pump: KNF Neuberger GmbH, Germany 
Quartz optic fiber (1mm ID): FOC GmbH, Stuttgart, Germany. 
Shutter: D-122 UniBlitz, Optilas, USA. 
Silver wire: Science Products, Hofheim, Germany. 
Software (analysis): OriginLab, Northampton, MA, USA 
Software (electrophysiology): Cell works/reader, npi Electronics, Germany.  
Software (modeling): Gepasi 3.0, http://www.gepasi.org/ 
Solution manifold: ALA MLF-8, ALA Scientific Instruments Inc, USA. 
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D) Animals and related stuff 
Animal fed: Local butcher shop, Frankfurt, Germany.  
Surgical instruments: Finescience Tool GmbH, Heidelberg, Germany. 
Water tanks for frog: Chemowerk GmbH, Weinstadt, Germany.  
Xenopus laevis frogs: Nasco International, Fort Atkinson, WI, USA.  
 
2.1 Molecular biology 
2.1.1 cDNA construct of P2X2/1 receptor chimera 
The  complete  cDNA  construct  of  P2X2/1  receptor  chimera  (here  onwards  referred  as 
chimera) was generously provided by Prof. Günther Schmalzing, Department of Molecular 
Pharmacology, University Hospital Aachen, Germany. The construction of chimera has been 
described  previously  [49,88].  Briefly,  plasmid  pNKS2-rP2X1  encoding  rat  P2X1  subunit 
(GeneBank/EBI accession number: X80477) and plasmid pNKS2-His6-rP2X2A encoding rat 
P2X2A subunit (GeneBank/EBI accession number: U14414) were used to construct chimera. 
The chimera was constructed in such a way that the first 47 N-terminal amino acids of the 
rP2X2 subunit were joined in-frame with Val48-Ser399 of the 399 amino acids of rP2X1 
subunit. For this SnaBI sites were introduced by site-directed mutagenesis, cutting just before 
the corresponding Val48 codon in both plasmids. Then the N-terminal of Hexa-His-rP2X2A 
sequence was excised with HindIII and SnaBI and ligated in-frame between the HindIII site of 
the vector containing the inserted SnaBI cleavage site of pNKS2-rP2X1 plasmid to generate 
pNKS2-rP2X2/1 plasmid. The full sequence of chimera is downstream to SP6 promoter. Fig. 
2.1 represents schematics of P2X2/1 receptor chimera. 
 
 
 
 
 
 
 
 
Fig. 2.1 Schematic representation of P2X2/1 receptor chimera: The chimera consisted of N-terminal and 
TM1 of P2X2, while full extra cellular loop, TM2 and C-terminal are from P2X1. As ATP binding pocket is Materials and Methods 
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located in the extracellular loop and the chimera has extra cellular loop from P2X1, it maintains ligand binding 
properties of P2X1.  
 
2.1.2 cDNA constructs of cysteine mutants of P2X2 and chimera 
These clones were generated by Benjamin Marquez-Klaka at the Max Planck Institute for 
Brain Research, Germany. All the single substituted cysteine mutants were generated by PCR 
amplification of the primers containing corresponding mutation  in the pNKS2-rP2X2 and 
pNKS2-rP2X2/1 plasmid for rP2X2 and chimera respectively. 
•  P2X2 2
nd TM mutants: S326C, L327C, T330C, I331C, I332C. 
•  Chimera  binding  site  mutants  (P2X1  numbering  without  His-tag):  K68C,  K70C, 
F185C, K190C, F291C, R292C, K305C, K309C, I328C. 
•  Chimera 1
st TM mutants (P2X1 numbering without His-tag): W46C, V47C, V48C, 
F49C, V50C. 
 
2.1.3 cDNA constructs of cysteine mutants of P2X1 
Two types of cysteine mutants were generated in the P2X1 receptors: 
In  the  first  type,  cysteine  mutants  were  generated  by  individually  mutating  the  first  six 
conserved cysteines in the extracellular loop to serine i.e. C117S, C126S, C132S, C149S, 
C159S,  C165S.  These  clones  were  generously  provided  by  Prof.  Günther  Schmalzing, 
Department of Molecular Pharmacology, University Hospital Aachen, Germany.  
In the second type, individual amino acids from position 118 to 125 were mutated to cysteine 
residues  i.e.  A118C,  E119C,  N120C,  P121C,  E122C,  G123C,  G124C  and  I125C.  These 
clones were generated by Benjamin Marquez-Klaka at the Max Planck Institute for Brain 
Research, Germany. All these clones (both types) were generated by PCR amplification of the 
primers containing corresponding mutations in the pNKS2-rP2X1 plasmid.  
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2.2 Bacterial culture and cDNA purification 
2.2.1 Culture medium and transformation 
Standard techniques were used for growing E.coli DH5α bacterial cells in LB (Luria Bertani) 
medium (10 g peptone, 5 g yeast extract, 10 g NaCl per 1 L distilled water). 15 g agar per litre 
was  added  to  the  respective  medium  for  agar  plates.  Cultures  were  grown  in  a  shaker 
incubator  at  37°C.  cDNA  constructs  were  transformed  into  chemically  competent  E.coli 
DH5α cells in the presence of appropriate antibiotic as follows: 50µl aliquots of chemically 
ultra-competent E.coli DH5α cells were mixed with plasmid (~100 ng) and incubated on ice 
for 30 min. Then, cells were heat shocked for 90s at 42°C and immediately kept on ice for 3 
min. After addition of 950µl LB medium the cells were incubated at 37°C for 1 hour. 100µl 
out of 1ml of the transformed cell suspension was streaked out on LB agar plates containing 
100µg/ml Ampicillin and incubated overnight at 37°C. 
 
2.2.2 Plasmid DNA purification 
Single bacterial colonies were picked from agar plates with a sterile toothpick and incubated 
overnight  in  LB  culture  medium  supplemented  with  100µg/ml  Ampicillin  at  37°C  with 
vigorous agitation (220 rpm). For large scale DNA preparation the Qiagen® plasmid midiprep 
kit  was  used  according  to  manufacturer’s  instructions.  Following  purification,  the  cDNA 
concentration was determined by measuring absorbance at 260nm (A260) on the NanoDrop® 
ND-1000 spectrophotometer. All cDNAs were stored at -20°C for later use.  
 
2.2.3 cRNA synthesis 
Linearization of template DNA of corresponding mutants was performed with 3µg plasmid 
DNA in 50µl volume with appropriate enzyme (1hr, 10U) (wild type and all the mutants of 
P2X2: XhoI; chimera and its all mutants, wild type and all the mutants of P2X1: EcoRI). 
Linearized DNA was purified using the Roche High-Pure-PCR purification kit according to 
manufacturer’s instructions and concentrated in speed-vac. Capped cRNAs were synthesized 
from linearized DNA templates with SP6 RNA polymerase using the Message Machine kit. 
Integrity of purified cRNAs was checked by gel electrophoresis using 1% agarose gel in TAE 
buffer. Concentration of purified cRNA was determined by measuring absorbance at 260nm Materials and Methods 
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(A260) on the NanoDrop® ND-1000 spectrophotometer. All cRNAs were stored at -20°C for 
later use.  
 
2.3 Heterologous expression in Xenopus laevis oocytes 
2.3.1 Frog maintenance 
10-15 frogs were placed in a large tank of capacity ~200 liters filled ~2/3 with fresh water 
free from chlorine. To avoid frog escape, each tank was covered with a grid in a wooden 
frame. For their well-being, each tank was bare bottom and contained few hiding sites (open 
ends cylinders of baked clay). Individual arrangements were made in each tank for continuous 
fresh water circulation. Temperature of water was maintained in the range of 16-19
0C. 12/12h 
light/dark cycle was maintained by the use of one tungsten lamp. Beef heart pellets were used 
to feed the frogs twice a week. Tanks were regularly cleaned from any food debris in order to 
reduce microbial growth. 
 
2.3.2 Surgical preparation 
A small fish net was used to capture a healthy female from the tank and transfer it to a small 
box with a  lid containing ~500ml of general anesthetic. 0.2% solution (pH 7) of tricaine 
methanesulfonate  (MS-222)  in  tap  water  was  used  as  general  anesthetic.  Anesthesia  was 
applied by transferring the frog into the anesthesia solution for 10-15min. The anaesthetized 
frog was then rinsed with distilled water to remove excess of MS-222. The frog was placed on 
an ice box with dorsal side facing down. The ventral surface of frog was covered with clean 
wet paper towels in order to protect the skin from drying. A small trans-section cut was made 
with a sterile scissor in one of the two lower quadrants of the abdomen by lifting the skin with 
sterile tweezers. Ovarian lobes were pulled out with the help of tweezers. A cut was made 
through the ovarian lobes in order to detach them from the frog’s body. Ovarian lobes were 
then placed in calcium supplemented Oocyte Ringer solution until further use. The wall of the 
coelom (surgical cut in the abdomen) was closed using two to three simple interrupted sterile 
synthetic sutures which included the skin, serosa and muscles. After the surgical procedure, 
the frog was placed in a small recovery tank for post surgical monitoring. Complete recovery 
usually occurs within 2-4 hours.  
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2.3.3 Oocyte preparation and heterologous expression 
Extracted ovary lobes (as described above) were subjected to collagenase (2mg/ml) treatment 
(2-3 hrs or overnight) in calcium supplemented Oocyte Ringer’s solution (CaSORI) in order 
to isolate the oocytes. After collagenase treatment oocytes were washed several times with 
calcium-free  ORI.  Defolliculated  oocytes  of  stage  V  or  VI  were  manually  selected  and 
injected with 50nl of cRNA. To get optimal expression for each clone, different amounts of 
cRNA was injected e.g. 25ng/cell for wild type P2X1 and cysteine mutants of P2X1; 5ng/cell 
for chimera; 2.5ng/cell for binding site cysteine mutants of chimera and TM2 mutants of 
P2X2; 0.5ng/cell for wild type P2X2. Injected cells were incubated in calcium supplemented 
Oocyte Ringer solution (CaSORI) containing 0.05mg/ml gentamicin at 18°C for 1-3 days 
depending on the clones. 
 
Table 2.1: Oocyte buffer compositions: 
Magnesium Oocyte Ringer’s solution (MgORI): 
Chemical  mM 
NaCl  90 
KCl  1 
MgCl2  2 
HEPES  5 
pH 7.5 by NaOH   
 
Calcium supplemented Oocyte Ringer’s solution (CaSORI): 
Chemical  mM 
NaCl  110 
KCl  5 
CaCl2  2 
MgCl2  1 
HEPES  5 
pH 7.5 by NaOH   
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2.4 Functional measurement of receptors 
Current responses to various ligands were measured 1-3 days after cRNA injection into X. 
laevis oocytes by the two-electrode-voltage-clamp (TEVC) technique. The amount of cRNA 
to be injected and expression time in functional experiments was determined individually for 
each  construct  to  avoid  current  amplitudes  that  were  greater  than  50µA  or  smaller  than 
500nA. As P2X receptors are permeable to calcium ions, calcium salts were omitted from the 
solutions to avoid calcium activated Cl
- currents. Therefore, all measurements were performed 
in  MgORI.  Two  electrode  voltage  clamp  was  performed  in  a  ~50µl  recording  chamber 
perfused at a flow rate of ~10ml/min [104] or by using a custom made chamber as described 
by Chang et al. [140]. Solutions were switched by software controlled magnetic valves. Two 
intracellular glass microelectrodes with resistances of < 1MΩ were used to clamp the oocytes 
at -60mV. Currents were recorded with the TEC-03X amplifier, low pass filtered at 100Hz 
and  sampled  at  >200Hz  (INT-20X  AD/DA  converter)  using  Cell-Works  software.  All 
measurements were performed at room temperature (20-22°C). Data are presented as mean ± 
SE for the indicated number of experiments (n). EC50 values were calculated from a nonlinear 
fit of the Hill equation using Origin software. All graphs were plotted in Origin 7.5 software.  
 
2.4.1 Design of the photolabeling setup 
For concurrent  photolabeling and current  measurement from  the  same set  of  receptors,  a 
custom made oocyte chamber was used which consisted of two partitions connected by a 
~0.6mm hole between them (Fig. 2.2). The oocyte was placed in the upper compartment so 
that a portion of the oocyte via the 0.6mm hole faced the lower compartment. The upper 
compartment allowed the access for intracellular electrodes, while in the lower compartment 
solutions were perfused by gravity flow. A quartz optic fiber transmitted high intensity UV 
light (λmax = 366nm with energy = 10mJ at 410nm) from a 100W HBO lamp to the bottom of 
the chamber in such a way that the portion of the oocyte that was exposed to agonist was also 
entirely within the area of the fiber optic tip. This enabled efficient ligand perfusion and 
photolabeling of the same population of receptors.  
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Fig.  2.2  Photolabeling  setup:  Custom  made  oocyte  chamber  for  concurrent  photolabeling  and  current 
measurement from the same population of receptors in real time. UV light was transmitted from HBO lamp to 
the chamber by quartz optic fiber. Ligands were applied by solution manifold. Oocyte was placed in the chamber 
in such a way that the same population of receptors facing ligand also faces light. 
 
The  custom  made  oocyte  chamber  offered  two  fold  advantages.  It  offered  electrode 
impalement in the upper chamber for electrophysiological measurements, while the flow of 
solution in the lower compartment helped the oocyte to form a seal around the 0.6mm hole 
due  to  venturi  effect,  thus  minimizing  solution  exchange  between  the  upper  and  lower 
partitions and stabilized the oocytes. 
 
2.4.2 Design of voltage clamp fluorometry setup 
For concurrent fluorescence and current measurement from the same population of receptors, 
previously  described  custom  made  oocyte  chamber  was  assembled  on  an  inverted 
epifluorescence microscope equipped with a FLUOR-20X objective (NA=0.75) as shown in 
Fig. 2.3.  
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Fig.  2.3  Voltage  clamp  fluorometry  setup:  Experimental  setup  for  real  time  fluorescence  and  current 
measurement from the same population of receptors expressed in an oocyte. Excitation light was applied to the 
oocyte  after  filtering  by excitation filter. Fluorescence  emission from  oocyte was again  filtered  by dichroic 
mirror and emission filter. Filtered fluorescence light was detected by photo diode placed near eye piece.  
 
Electrophysiological  measurements  were  performed  as  described  in  section  2.4.  The 
fluorescence emission was stimulated by the light from a 100W/12V Halogen (XENOPHOT) 
lamp placed in HAL 100 lamp housing of the microscope and whose intensity was regulated 
with the external amplifier. In order to control the time of irradiation a TTL controlled shutter 
was used. Light was then filtered by a filter set (Table 2.2). The fluorescence emission was 
measured through a PIN-022A photodiode mounted on the eye port of the microscope. The 
signal from the photodiode was amplified by an EPC-5 patch clamp amplifier and filtered at 
0.3 kHz. The fluorescence and current signals were simultaneously acquired through the Cell 
Works software. Fluorescence spectra and filter sets used for the corresponding fluorophores 
is shown in Fig. 2.4. 
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Table 2.2: Omega optical filters used for different fluorescent dyes: 
Dye/Experiments  Excitation  Dichroic 
mirror 
Emission  Filter set 
TMRM  XF1074  XF2017  XF3085  XF101-2 
Alexa-Fluor 647 ATP 
(as Alexa-ATP) 
XF1069  XF2035  XF3076  XF110-2 
FRET (between 
TMRM and Alexa-
ATP) 
XF1074  XF2017  XF3302  --- 
 
Table 2.3: Fluorescence properties of dyes: 
Dye  λ λ λ λabsorption 
(nm) 
λ λ λ λemission 
(nm) 
Extinction 
coefficient 
(M cm)
-1 
Quantum 
yield (%) 
Life time  
(ns) (water) 
TMRM  555  580  110,000  45  1.62 
ATTO 550 
maleimide 
554  576  120,000  80  3.2 
Alexa-ATP  650  665  239,000  33  1.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Materials and Methods 
  46
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4 Spectral properties and filter-sets used for different fluorophores: Absorption (black trace) and 
fluorescence (red trace) spectra of (A) Alexa-ATP, (C) TMRM. Properties of corresponding filter sets (Exciter, 
Dichroic and Emitter filters) are shown in (B) Alexa-ATP, (D) TMRM. (E) Spectral properties of TMRM and 
Alexa-ATP allow their use as a FRET pair. (F) For the FRET measurement between Alexa-ATP and TMRM, 
where the decrease in TMRM fluorescence was used as criteria, only the Emitter filter in the TMRM filter set 
was changed.  
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3. Results 
3.1 Probing allosteric interactions between P2X receptor subunits 
using photolabeling 
In pentameric nicotinic acetylcholine receptors (nAChRs), the acetylcholine binding site is 
formed by the extracellular N-terminal domain and has been localized at the interface of 
neighboring nAChR subunits [150]. The agonist binding site in tetrameric iGluRs is formed 
by two segments (extracellular N-terminus and the loop between TM3 and TM4) of a single 
subunit which are separated by two transmembrane domains and a re-entry loop [151,152]. 
P2X receptors, on the other hand represent the third family of ligand gated ion channels. They 
show trimeric subunit topology and form non-selective cation channels that open in response 
to extracellular ATP binding [49,75]. Recently it was shown that the ATP binding site in P2X 
receptors  is  formed  by  the  loops  from  neighboring  P2X  subunits  [42].  However,  the 
mechanism of P2X receptors activation upon ATP binding at the interface of subunits is still 
unclear. P2X receptors activation is thought to involve a series of allosteric ligand binding 
steps,  albeit  the  contribution of  each  ligand  binding  step  to  the  gating  of  P2X  receptors 
remains unknown.  
Therefore, in my thesis, I have focused on studying the contribution of each receptor subunit 
in  the  process  of  gating.  This  cannot  be  studied  in  isolation  as  the  ligand  binding  and 
unbinding from the receptor occurs continuously. To address this and related questions, I used 
photolabeling  technique,  where  I  used  2'-&  3'-O-(4-benzoylbenzoyl)-ATP  (BzATP,  a 
photoaffinity ATP analog) for concurrent activation and photolabeling of homomeric rat P2X 
receptors  (P2X1,  P2X2)  and  P2X2/1  receptor  chimera  (henceforth  referred  as  chimera)). 
Using  this  approach,  I  could  overcome  the  limitation  of  ligand  unbinding  events  which 
facilitated us to control the occupancy level of binding sites. This also allowed us to study the 
contribution  of  the  remaining unoccupied binding  sites  to  the  gating  process  without  the 
ambiguities  that  arise  from  continuous  binding  and  unbinding  of  ligands  to  the  channel 
subunits.  Change  in  the  efficacy  of  the  partial  and  full  agonists  on  P2X  receptors  upon 
progressive photolabeling by BzATP was determined as the parameter for contribution of 
each subunit towards gating. 
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3.1.1 Photolabeling of wild type P2X1 receptors 
3.1.1.1 Agonist unbinding is required for the recovery from desensitization 
P2X1 receptors desensitize during prolonged application of agonists. It is believed that the 
desensitized  state  is  a  ligand  bound  state  and  the  recovery  from  desensitization  involves 
agonist  unbinding steps. In order  to demonstrate  this, 1µM  BzATP  (a photoaffinity ATP 
analog) was used as an agonist for concurrent photolabeling and to activate and to completely 
desensitize  wild  type  P2X1  receptors using  voltage-clamp  photolabeling  setup  (Fig.  2.2). 
Photoaffinity ligands have characteristic properties that they show reversible binding to the 
receptors in the absence of UV-light, but get covalently cross-linked in the presence of UV-
light. The first application of BzATP (Bz1) in the absence of light for 20s evoked a large peak 
current response. Further applications of BzATP (20s) to the same set of receptors at 5 min 
intervals yielded constant peak responses. For covalent labeling, BzATP was applied for 40s 
in the presence of UV-light (Fig. 3.1B). As a control, BzATP was also applied for 40s in the 
absence of light (Fig. 3.1A).  
 
 
 
 
 
 
 
 
 
Fig. 3.1 Effect of prolonged BzATP application in the presence and absence of light on the P2X1 recovery 
from desensitization: (A) In the absence of photolabeling, prolonged application of BzATP showed similar 
recovery from desensitization as shown by similar peak current responses after treatment of BzATP (20s and 
40s). (B) In the presence of light, covalent attachment of BzATP significantly decreased the subsequent peak 
current response (Bz4) i.e. reduced recovery from desensitization. (C) Ratio of peak current response generated 
by 2
nd (Bz2) to 3
rd (Bz3) application of BzATP was compared with the ratio of 4
th (Bz4) to 3
rd (Bz3) response. 
Data are plotted as mean ± SE of 4-5 cells for each treatment. # P < 0.01 (t-test) 
 
Fig. 3.1 shows that the prolonged application of BzATP without light had no effect on the 
constant peak current responses, indicating that similar number of receptors recovered from Results 
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desensitization.  However, subsequent peak current responses significantly decreased when 
BzATP was applied along with the light, indicating that less number of receptors recovered 
from desensitization due to the covalent attachment of BzATP to P2X1 receptors. Covalent 
attachment of BzATP limits the agonist unbinding which is reflected in the form of decreased 
current response after the light treatment. Thus, the present experiment demonstrates that the 
agonist unbinding is required for the recovery of P2X1 receptors from desensitization.  
 
3.1.1.2 Time course of photolabeling at P2X1 receptors 
After photolabeling, current responses  generated by subsequent BzATP application to the 
same set of P2X1 receptors were found to decrease due to the permanent desensitization of 
the receptors caused by the covalent attachment of BzATP. To determine the time-course of 
covalent modification of P2X1 receptors, 1µM BzATP was applied four times to the P2X1 
receptors designated as Bz1 to Bz4. Between each application, ligand free buffer was applied 
for 5 min. The first application of BzATP (Bz1) (20s) elicited the large peak current; whereas 
subsequent responses were constant till Bz3 application. For photolabeling, different duration 
of BzATP + UV-light was applied during third application (Bz3) (Fig. 3.2A). The effect of 
different durations of BzATP + UV-light i.e. photolabeling, was determined by the BzATP 
induced response after UV-light treatment (Bz4) (Fig 3.2A).  
 
 
 
 
 
 
 
 
 
 
Fig. 3.2 Time course of photolabeling of wild type P2X1 receptors: (A) Representative current traces of P2X1 
receptors  during  BzATP  induced  responses.  Different  applications  of  BzATP  are  denoted  as  Bz1,  2,  3  etc. 
Between each BzATP application, ligand free buffer was applied for 5 min. During the third application (Bz3), 
receptors  were  exposed  to  both  BzATP  +  UV-light  for  different  period  of  time  for  photolabeling.  In  the 
representative current trace (Bz3), BzATP + UV-light were applied for 40s. The level of photolabeling was 
determined by generating Bz4 response after photolabeling. As a control, BzATP was applied for 40s without Results 
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light  (Fig.  3.1A),  which indicated  that  prolonged  application  of  BzATP  (Bz3)  had  no  effect  on  subsequent 
responses (Bz4). (B) Ratio between the current responses generated at Bz4 to Bz3 is plotted against progressive 
photolabeling for different periods of time. The time course of photolabeling was fitted with mono exponential 
equation with a time constant of (τ) 31 ± 7s. Each data point represents mean ± SE of 3-4 cells.  
 
A maximum of about 50% steady state level was reached with a time constant of 31 ± 7s. 
100% desensitization was not observed even after extended period of time (~200s), possibly 
due  to  constant  receptor  trafficking/  turnover  on  the  membrane  or  lateral  diffusion  of 
receptors outside the field of light application (outside the hole). 
 
3.1.2 Photolabeling of wild type P2X2 receptors 
3.1.2.1 Efficacy and potency of BzATP and ATP on P2X2 receptors 
Photolabeling leads to persistent desensitization of P2X1 receptors. Thus, contribution of each 
subunit towards gating could not be studied in P2X1 receptors. Due to this limitation further 
experiments  were  performed  on  P2X2  receptors  which  represent  the  non-desensitizing 
phenotype. Therefore, the efficacy and potency of BzATP was determined on P2X2 receptors 
and compared with ATP (full agonist). Fig. 3.3 shows the comparison between complete dose 
response curves for BzATP and ATP. Saturating concentrations of BzATP (300µM) were 
found to elicit ~20% of the current responses elicited by saturating concentrations of ATP 
(300µM), thus indicating that BzATP is a partial agonist on P2X2 receptors. Table 3.1 shows 
EC50 values and Hill coefficients for ATP and BzATP on the P2X2 receptors. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3 Efficacy and potency of BzATP and ATP on wild type P2X2 receptors: (A) Representative current 
trace of saturating concentration of BzATP (300µM) and saturating concentration of ATP (300µM) on the same Results 
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oocyte expressing wild type P2X2 receptors. (B) Comparison of dose response curves for ATP and BzATP on 
the  P2X2  receptors.  All  dose  response  curves  were  normalized  to  the  response  generated  by  saturating 
concentration of ATP (300µM). Data are presented as mean ± SE of 5 cells for each ligand concentration. 
 
Table 3.1: EC50 values and Hill coefficients for ATP and BzATP on the P2X2 receptors 
Ligand*  EC50 (µM)  Hill coefficient  
ATP (5)  36 ± 2  1.5 ± 0.1 
BzATP (5)  75 ± 2  2.2 ± 0.1 
* Number of cells for each ligand concentration is indicated in parentheses. 
 
3.1.2.2 Each subunit contributes to the gating process 
P2X  receptors  gate  upon  agonist  binding.  Due  to  the  continuous  ligand  binding  and 
unbinding,  a  defined  contribution  of  each  subunit  towards  gating  is  difficult  to  study. 
Therefore, BzATP was used as a photoaffinity analog of ATP to lock the non-desensitizing 
P2X2  receptors  in  partially  liganded  state  and  the  contribution  of  remaining  unoccupied 
subunits towards gating was studied.  
In  the  experiment, 30µM BzATP was used for photolabeling.  At  this  concentration, it  is 
expected  that  BzATP  would  cross-link  P2X2  receptors  in  a  partially  liganded  state.  To 
generate  maximum  response  from  the  P2X2  receptors,  saturating  concentration  of  ATP 
(300µM) was used. Fig 3.4 shows that the ratio of current generated by 30µM BzATP to 
300µM ATP changes only when BzATP gets covalently attached to one or two subunits of 
P2X2 receptors in the presence of UV-light, whereas in the absence of UV-light, the ratio 
remained unchanged. BzATP being a partial agonist also acts as a competitive antagonist. 
Prolonged  BzATP  application  in  the  presence  of  light  lead  to  the  photolabeling  of  the 
receptors and one  or two binding  sites were  permanently  occupied. These sites were not 
available  for  further  action  of  ATP (full  agonist)  and  therefore,  ATP  could  not  evoke  a 
maximal response from the receptors locked with partial agonist in a partially liganded state. 
Thus, these results indicate that each subunit contributes to the process of gating i.e. response 
of a full agonist (gating) was affected if one or two subunits of P2X2 receptors were cross-
linked by BzATP (partial agonist). 
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Fig.  3.4  Effect  of  photolabeling  by  partial  agonist  on  the  maximal  response  of  P2X2  receptors: 
Representative current traces of 30µM BzATP and 300µM ATP applied to P2X2 receptors in (A) Absence of 
light, (B) Presence of UV-light. Progressive photolabeling by BzATP to the P2X2 receptors lead to progressive 
decrease in ATP induced current responses. (C) Corresponding ratio of current responses generated by 30µM 
BzATP to 300µM ATP is plotted against time during prolonged BzATP application in the absence and presence 
of UV-light. The ratio of current responses progressively changed when one or two BzATP gets covalently 
attached to P2X2 receptors. The ratio remained unchanged when there is no photolabeling (in the absence of 
UV-light). Data are presented as mean ± SE of 7 cells (BzATP alone) and 12 cells (BzATP + light). 
 
3.1.3 Photolabeling of the P2X2/P2X1 receptor chimera 
It  was  observed  that  covalent  labeling  by  BzATP  on  P2X1  and  P2X2  receptors  lead  to 
selective modification of the functional receptors. On P2X1 receptors, covalent labeling of 
BzATP lead to persistent desensitization, making them unavailable for functional studies. On 
P2X2 receptors, BzATP is a partial agonist and its covalent attachment lead to significant 
reduction  in  the  maximal  response  of  a  full  agonist  on  the  receptors.  Due  to  the  non-
availability of functional receptors which maintain their full activity after photolabeling, it Results 
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was difficult to continue on these wild type receptors. Therefore, a receptor was required 
which  not  only maintains  the  non-desensitizing  phenotype  but also  retains  the  functional 
activity after covalent attachment of BzATP. To this end, the use of a receptor chimera was 
tested. The chimera was made from a portion of P2X2 (N-terminal and TM1 domain) and a 
portion of P2X1 (full extracellular loop, TM2 and complete C-terminal domain). This chimera 
offered several advantages over wild type counterparts. It has a non-desensitizing phenotype 
similar  to  the  P2X2  receptors  and  shows  nanomolar  potency  for  various  ligands  as  it 
maintains the ligand binding domain of P2X1 receptors. For differences in the potency of 
ATP on P2X1 receptors and the chimera see a detailed description in the introduction section 
1.5.2.  
 
3.1.3.1 Efficacy and potency of various ligands on the chimera 
When the dose response curve for BzATP on the chimera was compared with dose response 
curves for other agonists (ATP and αβ-MetATP), it was found that saturating concentration 
(1µM) of BzATP, αβ-MetATP and ATP elicited the same current amplitude, indicating that 
BzATP and αβ-MetATP are full agonists of the chimera (Fig. 3.5A and C).  
Thus, BzATP could be used as a photoaffinity analog of ATP maintaining the full agonist 
efficacy  on  the  chimera.  On  the  other  hand,  αβ-MetATP  which  shows  a  ~10-fold  faster 
deactivation  time  course  after  washout  as  compared  to  ATP  could  be  used  to  generate 
complete dose response curves before and after photolabeling on the same oocyte. TNP-ATP 
is a known potent antagonist of P2X1 and P2X3 receptors with an IC50 value of 6nM for 
P2X1 receptors [99]. When 300nM TNP-ATP was applied to the chimera, a weak inward 
current (~2% of the response generated by 1µM ATP) was observed (Fig. 3.5B), indicating 
that TNP-ATP acted as a very partial agonist on the chimera. Thus, the effect of progressive 
photolabeling  by  BzATP  (full  agonist)  on  the  efficacy  and  potency  of  αβ-MetATP  (full 
agonist) and TNP-ATP (partial agonist) could be use to study the contribution of each subunit 
of the receptors to the process of gating. Dose response curves for various ligands on the 
chimera indicated that ATP maintains the highest potency on chimera followed by BzATP 
and  αβ-MetATP  (Fig.  3.5D).  Table  3.2  shows  EC50  values  and  Hill  coefficients  of  these 
ligands on the chimera.  
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Figure 3.5: Efficacy and potency of various ligands on the chimera: Representative current traces obtained 
by the application of various ligands on the same oocyte (A) 1µM ATP and BzATP, (B) 1µM ATP and 100nM 
TNP-ATP, (C) 1µM αβ-MetATP and BzATP. (D) Dose response curves for various ligands on the chimera. All 
responses were normalized to the response generated by the saturating concentration of the respective ligands. 
Data are represented as mean ± SE for 4-34 cells for each concentration. 
 
Table 3.2: EC50 values and Hill coefficients for various ligands on the chimera 
Ligand*  EC50 (nM)   Hill coefficient  Relative Efficacy 
ATP (7)  3 ± 0.4  1.2 ± 0.2  1 
BzATP (9)  27 ± 4  1.4 ± 0.2  ~1 
α α α αβ β β β-MetATP (21-34)  137 ± 6  1.6 ± 0.1  ~1 
TNP-ATP (4-7)  20 ± 3  0.9 ± 0.1  ~0.01 
* Number of cells for each ligand concentration is indicated in parentheses. 
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3.1.3.2 Time course of covalent activation of the chimera 
To  determine  the  time  course  of  photolabeling,  covalent  activation  of  the  chimera  was 
determined from the level of persistent current induced by cross-linking of BzATP in the 
binding  sites  of  the  chimera.  Fig.  3.6A  shows  the  representative  current  trace  for  the 
photolabeling  procedure  and  determination  of  persistent  current  after  photolabeling  by 
Neomycin block on the same cell. Fig. 3.6B shows the ratio between persistent current (Ip) 
and the total current from the chimera after photolabeling (Imax) is plotted against different 
lengths of light irradiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.6  Covalent  activation  of  the  chimera by  BzATP:  (A)  Representative  current  trace  on  the chimera 
generated after BzATP activation. UV-light application leads to the photolabeling which is shown by persistent 
current. After photolabeling, the level of persistent current could be specifically blocked by the application of 
Neomycin. Block generated by Neomycin is completely reversible. After photolabeling, the remaining closed 
receptors could be activated by the application of full agonist e.g. αβ-MetATP. (B) Time course of BzATP 
photolabeling. Ratio between persistent current (Ip) and the total current from the chimera after photolabeling 
(Imax) is plotted against different lengths of light irradiation The curve was fitted by a mono exponential equation 
with time constant (τ) = 37 ± 5s. Data are presented as mean ± SE of 3-11 cells for each time point. 
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In these experiments, saturating concentration of BzATP (1µM) was first used to maximally 
activate  the  chimera  (IBz)  in  the  absence  of  UV-light.  It  is  expected  that  during  the  full 
activation (Imax), all receptors are in fully liganded state i.e. all the binding sites are occupied. 
UV-light  was  applied only  when  the  channels  were  fully  activated i.e. in  the  continuous 
presence of 1µM BzATP. Light + ligand were applied for different periods of time. After 
photolabeling, the oocyte was washed extensively with the nucleotide free buffer for at least 
3-5 times the time required for complete deactivation of the chimera in the absence of light 
(i.e. without photolabeling). Neomycin which is described as an open channel blocker of P2X 
receptors [153], also showed a partial block of currents through open channels on the chimera 
when applied externally (unpublished results, Eva Bongartz). Therefore, after the extensive 
washout, 3mM Neomycin was then applied externally to generate block of current through 
permanently open channels i.e. receptors in which all the binding sites were cross-linked by 
BzATP. As the Neomycin block was partial, specific block by Neomycin was determined on 
each oocyte before photolabeling by first activating the receptors with 1µM BzATP in the 
dark, and at the steady-state current level 3mM Neomycin was applied for a short duration 
(5s). Open channel block by Neomycin is expressed as a ratio between current blocked by 
Neomycin  and  the  maximum  current  generated  by  1µM  BzATP  before  photolabeling 
(equation 3.1). It was found that the mean ratio of block generated by 3mM Neomycin was 
0.49 ± 0.01 (n = 34) on different oocytes.  
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=     Equation 3.1 
After the photolabeling, the level of persistent current (Ip) was determined on each oocyte 
using equation 3.2.  
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ing photolabel After I
Ip
Neo )   (
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The level of covalent activation of the chimera was expressed as the ratio between persistent 
current (Ip) and the total current from the receptors (Imax) after photolabeling (whereas, Imax = 
Ip + current that can be activated by applying saturating concentrations of agonists (e.g. αβ-
MetATP) concentration on individual oocytes after photolabeling) (equation 3.3). 
Imax
Ip
activation Covalent         =          Equation 3.3 
It  is  apparent  that  upon  progressive  photolabeling,  more  molecules  of  BzATP  would 
covalently bind to the channels and drive them towards permanently open state. This would Results 
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increase the ratio of Ip/Imax towards unity. However, possibly due to the constant receptor 
trafficking  on  the  membrane  or  lateral  diffusion  of  receptors  outside  the  field  of  light 
application (outside the hole), complete covalent activation of all receptors was not observed. 
 
3.1.3.3 Effect of prolonged application of light and BzATP on the chimera 
In the time course determination, the chimera was also exposed to prolonged BzATP + UV-
light, therefore, as a control experiment  individual effect of  UV-light and BzATP on the 
chimera was determined for an extended period of time (180s) (Fig. 3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7 Effect of various parameters on the response generated on the chimera during such treatments: 
Representative current traces of BzATP induced currents on the chimera, when 180s treatment of (A) Ligand 
free  buffer  (MgORI), (B)  UV-light,  (C) BzATP,  was  given  between  second  (Bz2)  and  third (Bz3)  BzATP 
applications. (D) Ratio of current amplitudes generated by first BzATP (Bz1) to second BzATP application 
(Bz2) i.e. before treatment, is compared with the ratio of current amplitudes generated by third BzATP (Bz3) to 
second BzATP application i.e. after treatment. Data are represented as mean ± SE of 3-4 cells for each treatment 
group.  
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In these experiments, full activation of chimera was performed on the same oocyte three times 
by 1µM BzATP designated as Bz1, Bz2 and Bz3. Treatment of UV-light or BzATP was given 
between second (Bz2) and third response (Bz3) for 180s (Fig. 3.7B and C). In the control 
experiment, ligand free buffer (MgORI) was applied for 180s in the absence of light between 
second (Bz2) and third (Bz3) application (Fig. 3.7A). Ratio of responses generated before 
(Bz2/Bz1) and after treatment (Bz3/Bz2) was compared with the control experiment i.e. when 
ligand free buffer was used (Fig. 3.7D). It was found that prolonged application of BzATP 
alone in the absence of light lead to ~20% decrease in the current response. From the time 
course  of  photolabeling  of  chimera  it  is  also  evident  that  due  to  the  constant  receptor 
trafficking on the membrane, results obtained for more than 120s were not different than 
obtained at 120s. Therefore, experiments involving prolonged 1µM BzATP (more than 120s) 
application were not performed in future. Prolonged application of light to the chimera in the 
absence  of  any  ligand did  not  affect  the  current  response  generated  before  and  after  the 
treatment, indicating that light alone has no effect on receptor functionality. 
 
3.1.3.4 Photolabeling modulates response of the receptors  
The conclusion that gating is a process contributed by each subunit of a receptor came from 
the result that the response of the full agonist (ATP) was decreased when one or two P2X2 
receptor subunits were cross-linked by the partial agonist (BzATP). To further support this 
conclusion, the effect of photolabeling on the  gating response of the chimera by full and 
partial agonist was studied when the receptors were cross-linked by a full agonist. BzATP, a 
full agonist on the chimera was used as a photoaffinity analog of ATP. Dose response curves 
for αβ-MetATP (another full agonist on the chimera) and TNP-ATP (partial agonist on the 
chimera)  were  made  on  the  same  oocyte  before  and  after  different  levels  of  covalent 
activation. The occupancy state of the chimera was controlled by application of UV-light + 
BzATP for different lengths of time.  
 
3.1.3.4.1 Modulation of full agonist response by photolabeling 
Photolabeling on the chimera was used to determine the change in potency of αβ-MetATP. To 
this end, first the dose response curve for αβ-MetATP was determined on the chimera before 
photolabeling. The same cell was then photolabeled by 1µM BzATP for 2, 20 or 40s and the 
dose response curve for αβ-MetATP was then again determined (Fig. 3.8 and Table 3.3). Results 
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After photolabeling, when one or two subunits of the receptor would be permanently occupied 
by BzATP (full agonist), sub-saturating concentrations of another full agonist (αβ-MetATP) is 
expected to become more effective because the probability that these channels will be fully 
liganded at any given αβ-MetATP concentration would be higher. These changes are evident 
in our case that the progressive photolabeling by a full agonist (BzATP) increased the potency 
of  another  full  agonist  (αβ-MetATP)  i.e.  EC50  values  and  Hill  coefficients  reduced 
progressively upon photolabeling. Thus, these results support our earlier conclusion that the 
process of gating is contributed by each subunit of the P2X receptors.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8 Modulation of αβ-MetATP response by progressive photolabeling on the chimera: Dose response 
curves for αβ-MetATP on the chimera were determined before and after different levels of covalent activation. 
The curves get leftward shifted upon progressive photolabeling. Data are presented as mean ± SE of 5-34 cells 
for each concentration. 
 
Table 3.3: EC50 values and Hill coefficient for αβ-MetATP on the chimera 
Time of 
photolabeling* 
% Covalent 
activation 
EC50 
(nM) 
Hill coefficient 
0s (21-34)  0  137 ± 6  1.6 ± 0.1 
2s (5-12)  2 ± 0.3  118 ± 8  1.2 ± 0.1 
20s (5)  33 ± 7  87 ± 12  1.1 ± 0.1 
40s (8-10)  54 ± 4  101 ± 18  0.9 ± 0.1 
* Number of cells for each length of light irradiation is indicated in parentheses.  
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3.1.3.4.2 Modulation of partial agonist response by photolabeling 
Similarly,  the  dose  response  curves  for  TNP-ATP  (partial  agonist  on  the  chimera)  were 
determined before and after photolabeling for 2 or 40s on the oocytes expressing the chimera 
(Fig. 3.9). It was found that 1µM TNP-ATP generated ~2% of the maximum full agonist 
response without photolabeling. The response increased to ~6% after 2s of photolabeling, 
which  further  increased  to  ~12%  when  the  time  of  photolabeling  was  increased  to  40s. 
However, photolabeling had no effect on the apparent affinity (EC50 value) for TNP-ATP 
(Table  3.4).  Thus,  it  is  evident  that  if  one  or  more  binding  sites  of  the  receptor  were 
preoccupied with full agonist, gating process of the receptor becomes more effective for a 
partial agonist. Together these results further support the conclusion that the process of gating 
is contributed by each subunit of the P2X receptors.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9 Modulation of TNP-ATP response by progressive photolabeling on the chimera: Dose response 
curves for TNP-ATP on the chimera were determined before and after different levels of covalent activation. The 
curves  showed  an  increase  in  the  maximal  response  by  TNP-ATP  on  the  receptor  upon  progressive 
photolabeling. All dose response curves were normalized  to the response  generated  by 1µM BzATP  before 
photolabeling. Data are presented as mean ± SE of 3-11 cells for each ligand concentration.  
 
Table 3.4: EC50 values and Hill coefficients for TNP-ATP on the chimera  
Time of photolabeling*  EC50 value (nM)  Hill coefficient 
0s (4-7)  13 ± 3  1.1 ± 0.2 
2s (3-8)  16 ± 2  0.8 ± 0.1 
40s (5-11)  13 ± 4  0.6 ± 0.1 
* Number of cells for each length of light irradiation is indicated in parentheses. Results 
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3.1.3.5  Estimating  the  number  of  bound  ligands  required  for  the  maximal  response 
generated by TNP-ATP on the receptors 
As  the  process  of  gating  is  contributed by  each  subunit  of  the  receptors,  the  number  of 
covalently attached BzATP molecules per receptor can be used to estimate the number of 
BzATP required for the maximal response generated by TNP-ATP i.e. to increase the efficacy 
of  TNP-ATP  to  maximum.  Thus,  the  change  in  ratio  of  current  generated  by  saturating 
concentration (300nM) of partial agonist (TNP-ATP) (Isat.TNP) to the saturating concentration 
(1µM) of full agonist (BzATP) (Isat.BzATP) was determined at each level of covalent activation. 
Fig. 3.10 shows the current traces and the plot of an increase in ratio of (Isat.TNP) to (Isat.BzATP) 
during progressive photolabeling.  
 
 
 
 
 
 
 
 
Fig.  3.10  Effect  of  progressive  photolabeling  on  the  ratio  of  response  generated  by  saturating 
concentration of TNP-ATP and BzATP on the chimera: Representative current traces of BzATP and TNP-
ATP on the chimera (A) Before, (B) After photolabeling. Before photolabeling TNP-ATP elicited negligible 
current compared to BzATP. After photolabeling (for 10s) TNP-ATP elicited significant current from the same 
population  of  receptors  when  compared  to  BzATP.  (C)  Progressive  photolabeling  increased  the  ratio  of 
responses generated by saturating concentration of TNP-ATP to the saturating concentration of BzATP. Change 
in  the  ratio  was  fitted  with  “One-site”  or  “Two-site”  model  equation  3.4  or  “Best-fit”  (with  all  the  free 
parameters) as described in results. 
 
Table 3.5: Summary of fitting results of “One-site”, “Two-site” model and “Best fit”  
Model  Bf(1)  Cf(2) 
One-site  0.1 ± 0.02  0.1 ± 0.01 
Two-site  0   0.17 ± 0.01 
Best fit  0.06 ± 0.02  0.14 ± 0.01  
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To fit the progressive change in the  gating response of the receptor by TNP-ATP during 
different levels of covalent activation, the following equation was used: 
( ) ( ) ( ) 2       1       0      
I
I
.
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BzATP sat
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+ + =         Equation 3.4 
The gating response of the receptor for TNP-ATP at any given time is contributed by the 
statistical  distribution  of  total  population  of  functionally  activable  receptor  under 
consideration at that point of time (i.e. current generated by TNP-ATP from 0, 1, 2 BzATP 
bound receptors). In the equation 3.4, A, B and C are the currents induced by saturating TNP-
ATP concentration through the statistical distribution of receptors (f(x)) with 0, 1 and 2 bound 
BzATP respectively.  
It  is  apparent  that  without  photolabeling,  TNP-ATP  produced  negligible  response  (Fig. 
3.10A), thus the contribution of Af(0) population can be neglected from the equation 3.4. The 
gating response of the receptor for TNP-ATP increased only when the binding sites contained 
one or two covalently attached BzATP (Fig. 3.10B). Thus, we considered two theoretical 
possibilities: 
1) TNP-ATP produced significant response after at least one binding site is labeled by BzATP 
and the TNP-ATP induced current from the population of receptors with two labeled BzATP 
will not be different from the current generated by one bound BzATP. Hence, the response 
generated by Bf(1) population will be equal to the response generated by Cf(2) population. 
Therefore, Bf(1) = Cf(2)  in equation 3.4. This is termed as “One-site model”. 
 
2) TNP-ATP produced significant response only after at least two binding sites are labeled by 
BzATP and the TNP-ATP induced current from the population of receptors with one bound 
BzATP will not be different from the current generated by 0 bound BzATP. Hence, response 
from Af(0) population will be equal to the response generated by Bf(1) population. Therefore, 
Af(0) = Bf(1) = 0. This is termed as “Two-site model”.  
 
As  photolabeling  was  performed  at  the  saturating  concentration  of  BzATP  (1µM),  we 
expected all the binding sites to be occupied at all time irrespective of the individual binding 
site affinity. In order to calculate the fractional distribution of 0, 1, 2 and 3 BzATP bound 
population of receptors, we used binomial equation (equation 3.5). To this end, we considered Results 
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that  at  saturating  concentration  of  BzATP  (1µM)  for  the  chimera,  covalent  crosslinking 
occurs randomly and not with efficiency based on binding sites’ affinity.  
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Where n is the total number of ligand binding sites per receptor, p is the probability that a 
particular site is labeled; q is the probability that a particular site is not labeled (1-p), and x is 
the number of bound BzATP molecules.  
As chimera is a trimeric receptor, therefore we assumed three binding sites per receptor i.e. n 
equals to 3. To calculate the probability (p) that a particular site is labeled, we assumed that 
three ligands per receptor are required to open the channel significantly i.e. below three bound 
ligands, the channel is essentially  closed and will not contribute to any current response. 
Under these circumstances equation 3.5 would give:  
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The level of covalent activation (Ip/Imax) (according to our assumption that three ligands are 
required to open the channel) was determined from the time course of photolabeling e.g. at 
40s, ~47% of covalent activation was observed (Fig. 3.6C).  
Thus, with the help of equation 3.6, p was calculated for each level of covalent activation. 
After determining p, fractional distribution of receptors f(x) with 0, 1 and 2 bound BzATP can 
be calculated from equation 3.5. For example, at fractional covalent activation (Ip/Imax) of 0.47 
(Fig. 3.6C), the probability (p) that a given site is labeled is 0.77, and statistical distribution of 
channels (f(x)) containing 0, 1, and 2 bound ligands is 0.012, 0.12 and 0.40 respectively. In 
this way, at each level of covalent activation, fractional distribution of 0, 1, and 2 BzATP 
bound population was calculated and used in equation 3.4 to fit the increasing trend of gating 
response for TNP-ATP with respect to BzATP on the chimera.  
Thus,  these  fitting results suggest  that  out of  one-site  and two-site model,  change  in  the 
efficacy of TNP-ATP upon progressive photolabeling was well described by two-site model, 
thus  indicating  that  two  BzATP  are  required  to  increase  the  efficacy  of  TNP-ATP  to  a 
significant level.  
 
 Results 
  64
3.2 Probing allosteric interactions between P2X receptor subunits 
using fluorescent ligand 
Upon  activation,  many  ligand  gated  ion  channels  enter  a  desensitized  state  in  which  the 
neurotransmitter remains bound but the ion channel is closed. Over the last few decades, 
research has focused on the mechanisms involved in the desensitization of ligand gated ion 
channels [154]. In nAChRs, subunit composition governs the rate of desensitization, whereas 
the  recovery  from  desensitization  is  an  agonist  specific  phenomenon  [154-156].  High 
resolution structural data for iGluRs suggest that perturbations that destabilize the intradimer 
interface enhance desensitization [157], whereas the rate limiting steps in the recovery from 
desensitization are reassembly of the two dimer interfaces [158]. In case of P2XRs, kinetic 
studies suggest that P2X1 receptors need to open before undergoing desensitization and the 
rate limiting step in the recovery from desensitization is the dissociation of bound agonist 
molecules [104]. However, after agonist binding, the allosteric interactions between subunits, 
which result in desensitization and regulate the dissociation of bound agonist, remains poorly 
understood till date. Therefore, in my thesis, I have studied the nature of contribution of each 
receptor subunit in the process of desensitization and the recovery from desensitization.  
To address these questions on wild type P2X1 receptors, I used Alexa-ATP (a fluorescent 
ATP  analog)  for  concurrent  activation  (represents  the  functional  state)  and  fluorescence 
measurement  (represents  the  occupancy  state)  from  the  same  set  of  receptors.  In  the 
functional  studies,  occupancy  state  of  the  receptor  was  correlated  with  the  level  of 
desensitization.  Change  in  the  rate  of  dissociation  of bound agonist  in  the  presence  of  a 
competing ligand was used as a parameter for the contribution of each subunit in the process 
of recovery from desensitization. 
 
3.2.1 Potency and efficacy of ATP and Alexa-ATP on P2X1 receptors and 
the chimera 
The  desensitized  state  of  P2X1  receptors  is  a  ligand  bound  closed  state,  which  limits 
functional characterization of the desensitized state by current measurement. Therefore, to get 
an  insight  into  the  desensitized  state,  the  level  of  fluorescence  of  the  bound  fluorescent 
agonist  could  be  used  as  a  parameter  for  the  occupancy  level  of  the  receptors  in  the 
desensitized  state.  Because  P2X1  receptors  undergo  desensitization  only  after  activation Results 
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[104], a fluorescent ligand was required which could activate and thus desensitize the P2X1 
receptors. Currently no fluorescent ATP analog is known which can act as an agonist on 
P2X1 receptors. Alexa-ATP is a commercially available fluorescent ATP analog. Therefore, 
to determine the efficacy and potency of Alexa-ATP, current responses were generated by 
Alexa-ATP on P2X1 receptors and the chimera.  
In order to compare the efficacy of 1µM Alexa-ATP with respect to 1µM ATP, following 
protocol was used. First, 30µM ATP was used to completely activate and desensitize P2X1 
receptors. After washing for 1 min in ligand free buffer, peak response was elicited by 1µM 
ATP, followed by 1µM Alexa-ATP and again by 1µM ATP. Each ligand application was 
separated  by  a  1  min  washing  step.  1µM  Alexa-ATP  produced  only  ~50%  of  the  peak 
response as compared to 1µM ATP on the same cell (Fig. 3.11A, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11 Potency and efficacy of Alexa-ATP on P2X1 receptors and the chimera: (A) Representative current 
traces generated by 1µM ATP followed by 1µM Alexa-ATP and again followed by 1µM ATP on the same 
oocyte expressing P2X1 receptors. Each agonist application was separated by a 1 min ligand free washing step. 
(B) Mean current generated on P2X1 receptors during ATP and Alexa-ATP applications. Data are presented as 
mean ± SE of 3 cells for each agonist application. (C) Representative current traces generated by 300nM ATP Results 
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and Alexa-ATP on the same oocyte expressing the chimera. (D) Comparison of dose-response curve for ATP 
and Alexa-ATP on the chimera. Data are presented as mean ± SE of 5-8 cells for each concentration. 
 
Table 3.6: EC50 values and Hill coefficients of ATP and Alexa-ATP on the chimera 
Ligand *  EC50 (nM)  Hill coefficient  
ATP (8)  3 ± 0.1  1.6 ± 0.1 
Alexa-ATP (5)  28 ± 7  1.2 ± 0.2 
* Number of cells for each ligand concentration is given in parentheses. 
 
On  P2X1  receptors,  the  EC50  value  of  receptor  activation  by  ATP  is  ~1µM,  which  is 
determined  under  non-steady  state  conditions  (a  detailed  description  is  given  in  the 
introduction section 1.5.2); therefore, complete dose response curve of P2X1 activation by 
Alexa-ATP was not determined due to the high cost of Alexa-ATP. However, an estimate of 
EC50 value of Alexa-ATP was determined using the Hill equation (equation 3.7).  
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In  this  calculation,  it  is  considered  that  the  EC50  value  for  ATP  is    ~1µM  at  the  P2X1 
receptors i.e. 1µM ATP would produce 50% of the peak current response [99]. In equation 
3.7,  I denotes  the  current  produced by  1µM  Alexa-ATP  with  respect  to  1µM  ATP,  Imax 
denotes the maximum current produced by ATP at highest concentration, [A] denotes 1µM 
Alexa-ATP concentration, EC50 denotes the half maximal concentrations of Alexa-ATP, n 
denotes the Hill coefficient of ATP. Using this equation, EC50 value for Alexa-ATP on P2X1 
receptors is estimated to be ~2µM.  
Complete dose response curve of Alexa-ATP could be determined on the chimera, due to its 
nanomolar sensitivity for various ligands (Fig. 3.11D) [88]. For differences in the potency of 
ATP on P2X1 receptors and chimera see a detailed description in the introduction section 
1.5.2. Dose response curve for Alexa-ATP on the chimera was found to be rightward shifted 
as  compared  to  ATP,  which  indicates  that  Alexa-ATP  is  less  potent  compared  to  ATP. 
Corresponding values for Hill coefficient and EC50 of ATP and Alexa-ATP on the chimera 
are listed in Table 3.6. However, saturating concentration of ATP (300nM) and Alexa-ATP Results 
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(300nM) elicited the same maximum amplitude of current on the same cell, thus indicating 
that both agonists have a similar efficacy on the chimera (Fig. 3.11C). 
 
3.2.2 Optimization of conditions for studying ligand-receptor interactions 
3.2.2.1 Optimization of light irradiation protocol 
Time course of dissociation of bound radio-ligand in the presence of high concentrations of 
non-labeled competing ligands has been used as a parameter for cooperative interactions in 
the hB2 (human bradykinin) receptors [159]. Similarly, we have exploited the fluorescence 
properties  of  Alexa-ATP  to  study  the  subunit  interactions  in  P2X1  receptors  where 
dissociation  of  bound  Alexa-ATP  from  the  desensitized  state  of  P2X1  receptors  was 
measured. I used the voltage-clamp fluorometry setup for concurrent current and fluorescence 
measurements from the same set of receptors (Fig. 2.3). The receptor current served as a 
parameter for the functional state of P2X1 receptors and the level of fluorescence was used as 
a parameter for the occupancy state of the binding sites.  
In continuous presence of light, photobleaching is a common problem associated with the 
fluorescent probes. As the bound agonist dissociates slowly from desensitized P2X1 receptors 
and the fluorescence of Alexa-ATP is susceptible to photobleaching, a protocol was optimized 
to  minimize  photobleaching.  This  was  achieved  by  exposing  the  receptors  to  light  for 
different periods of time during the dissociation of bound Alexa-ATP from the desensitized 
state of P2X1 receptors (Fig. 3.12, Table 3.7). 300nM Alexa-ATP was used to elicit current 
responses  and  to  induce  complete  desensitization  in  P2X1  receptors.  For  the  first  15s, 
washout of Alexa-ATP was done in the absence of light in order to wash non-specifically 
bound  Alexa-ATP.  The  time  course  of  decay  of  bound  Alexa-ATP  fluorescence  was 
monitored in real time under voltage clamp condition in the continuous presence of ligand 
free  buffer  (MgORI buffer).  After  15s  from the onset  of  washout, dissociation  of  bound 
Alexa-ATP was monitored either in the continuous presence of light, or light was applied for 
2s every 10 to 40s intervals (Fig. 3.12C). With decreasing frequency of light exposure during 
the measurement, a reduction in photobleaching is expected. As expected, faster time course 
(faster time constant of decay) of Alexa-ATP dissociation was observed from protocols in 
which light was applied continuously as compared to the protocol where light was applied 
less frequently. However, 30s and 40s light irradiation protocols gave similar results (Fig. 
3.12C).  Therefore,  all  the  future  experiments  were  performed  with  30s  light  irradiation Results 
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protocol.  In  order  to  further  minimize  the  photobleaching  component  (if  any),  light  was 
irradiated for 1s every 30s interval in all subsequent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.12  Association  and  dissociation  of  Alexa-ATP  and  light  irradiation  protocol:  Representative 
fluorescence traces for association and dissociation of 30nM Alexa-ATP on the (A) control oocyte (No RNA 
injected), (B) P2X1 expressing  oocyte. Blue and red  bars indicate the non-specific (background) and P2X1 
specific  Alexa-ATP  fluorescence  respectively.  In  both  cases,  the  dissociation  of  bound  Alexa-ATP  was 
performed in the  presence  of ligand  free  buffer (MgORI).  In the control cells, the washout of non-specific 
fluorescence was completed within 15s from the onset of washout. (C) Time course of decay of Alexa-ATP 
fluorescence  from  P2X1  receptors  under  different  light  irradiation  protocols.  During  the  optimization  of 
measuring conditions for Alexa-ATP dissociation, light was applied for 2s every 10 to 40s. All traces were 
individually normalized to the level of fluorescence obtained after 15s from the onset of Alexa-ATP dissociation 
in each measurement. All fluorescence responses were monitored in real time under voltage clamp conditions. 
Data are  presented as  mean ± SE of 3-8 cells  for each  protocol. (D) The correlation between  fluorescence 
amplitude and the Alexa-ATP activated current in 32 individual oocytes expressing P2X1 receptors. The peak 
current was determined at 300nM Alexa-ATP  and the specific  fluorescence  amplitudes were determined  by 
subtracting the level of fluorescence after 15s of washout in MgORI buffer (fluorescence amplitude A1) to the 
level of fluorescence left at the end of extended washout (after 2500s) in MgORI buffer (fluorescence amplitude Results 
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A2). The solid line represents linear regression to the data points with an intercept of 15 ± 2 and slope of 0.02 ± 
0.003. 
 
Table 3.7: Kinetics of decay of Alexa-ATP fluorescence during various intervals of light 
application 
Light  
protocol (s)* 
Time 
constant  
(τ τ τ τ fast) (s) 
Time 
constant  
(τ τ τ τ slow) (s) 
Fluorescence 
Amplitude 
(A1, 15s) 
Fluorescence 
Amplitude 
(A2, 2500s) 
Current  
(I) (µA) 
Continuous   
light (3) 
304 ± 0.02  -  41 ± 15  -  0.9 ± 0.1 
2/10 (3)  303 ± 4  861 ± 12  24 ± 2  3 ± 0.4  0.8 ± 0.04 
2/20 (3)  437 ± 11  970 ± 38  39 ± 10  5 ± 1.3  1.8 ± 0.5 
2/30 (8)  377 ± 9  1427 ± 43  31 ± 7  6 ± 2  0.6 ± 0.1 
2/40 (6)  439 ± 11  1297 ± 101  36 ± 3  6 ± 1  0.7 ± 0.1 
* Number of cells for each irradiation time is given in parentheses.  
 
Using  voltage-clamp  fluorometry  setup  I  have  measured  concurrent  receptor  activation 
(represents the functional state) and the level of fluorescence (represents occupancy state) on 
the same population of receptors. To see if there exists a correlation between the observed 
fluorescence  and  current  from  the  receptors,  300nM  Alexa-ATP  was  applied  to  P2X1 
receptors to activate and fully desensitize them. After washing the non-specific fluorescence 
for  15s,  level  of  Alexa-ATP  fluorescence  bound  to  P2X1  receptors  was  determined  by 
irradiating  individual  oocyte  for  1s  every  30s.  A  direct  correlation  was  found  between 
fluorescence  amplitude  and  the  current  response  i.e.  increase  in  the  number of  receptors 
(current)  showed  correspondingly  increase  the  number  of  bound  Alexa-ATP  molecules 
(fluorescence amplitude) (Fig. 3.12D). 
Interestingly, a trace amount of residual fluorescence was always found to be associated with 
the receptors even at the end of extensive washout which decayed on a very slow time scale 
(Fig. 3.12C), resulting in a bi-exponential time course of decay of Alexa-ATP fluorescence. In 
the  past,  the  slow  component  of  biphasic  fluorescence  quenching  in  EGF  receptor  was 
attributed  to  receptor  internalization [160],  whereas,  presence  of  similar biphasic  kinetics 
during  fluorescent  ligand dissociation in torpedo nAChR receptors was attributed to non-Results 
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equivalent  agonist  binding  sites  [161].  However,  considering  all  the  binding  sites  in 
homomeric P2X1 receptors are the same, we speculated that the residual fluorescence at the 
end of extensive washout and the bi-exponential decay of Alexa-ATP fluorescence possibly 
originated  from  the  internalization  of  Alexa-ATP  bound  P2X1  receptors  and  their  slow 
recycling to the surface. We have tested the hypothesis in the following section. 
 
3.2.2.2 Membrane trafficking of receptors 
P2X1 receptors undergo constant receptor trafficking and agonist mediated internalization 
[105-107],  which  changes  receptor  density  on  the  cell  surface.  Therefore,  to  probe  the 
possibility that the residual fluorescence in Alexa-ATP dissociation experiments might have 
originated  from  the  internalization  of  Alexa-ATP  bound  P2X1  receptors  and  their  slow 
recycling to the surface, the time course of decay of Alexa-ATP fluorescence was monitored 
from phenyl arsine oxide (PAO) treated oocytes expressing P2X1 receptors. PAO has been 
shown to inhibit receptor trafficking in oocytes [162]. Oocytes expressing P2X1 receptors 
were treated with 100µM PAO at 18
0C for 1hr. PAO treated cells showed complete decay of 
Alexa-ATP fluorescence with a mono-exponential time course (Fig. 3.13A) (Table 3.8).  
 
 
 
 
 
 
 
 
 
 
Fig. 3.13 Effect of PAO on P2X1 receptors trafficking: Time course of Alexa-ATP fluorescence from PAO 
treated and untreated cells expressing P2X1 receptors during (A) Dissociation (when receptors were activated 
with 300nM Alexa-ATP) measured in the presence of ligand free buffer, (B) Association (100nM Alexa-ATP). 
All traces were individually normalized to the level of fluorescence obtained after 15s from the onset of Alexa-
ATP association or dissociation in each measurement. All fluorescence responses were monitored in real time 
under voltage clamp condition.  Data are presented as mean ± SE of 5-6 cells for each treatment.  
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Table  3.8:  Comparison  of  time  constants  of  Alexa-ATP  fluorescence  between  PAO 
treated and untreated oocytes 
Experiment  Alexa-ATP  Treatment*  τ τ τ τ fast (s)  τ τ τ τ slow (s) 
No PAO treatment (6)  394 ± 20   1910 ± 364 
Dissociation  300nM 
PAO treatment (5)  850 ± 7  - 
No PAO treatment (5)  69 ± 6  848 ± 48 
Association  100nM 
PAO treatment (5)  223 ± 3   
* Number of cells for each measurement is given in parentheses. 
 
These results suggest that the fast time constant in the time course of decay of Alexa-ATP 
fluorescence  from  the  non-PAO  treated  oocytes  is  contributed  by  two  components  i.e. 
dissociation  of  bound  Alexa-ATP  from  the  surface  receptors  and  agonist  mediated 
internalization of P2X1 receptors. Whereas, the slow constant is possibly contributed by the 
slow trafficking of Alexa-ATP bound internalized P2X1 receptors back to the surface. The 
results from PAO treated oocytes suggest that PAO treatment blocked the agonist mediated 
receptor internalization, thus not only abolishing the residual fluorescence but also resulting in 
a  time  course  of  decay  of  Alexa-ATP  fluorescence  which  could  be  described  by  mono-
exponential function.  
In Alexa-ATP association experiments, a continuous increase in Alexa-ATP fluorescence was 
observed on the P2X1 receptors from the non-PAO treated oocytes, even after prolonged 
application  of  100nM  Alexa-ATP  (Fig.  3.13B).  This  resulted  in  the  bi-exponential  time 
course of increase in Alexa-ATP associated fluorescence (Table 3.8). We thought that the 
receptor  trafficking  on the membrane was  possibly  responsible  for  changing the receptor 
density (number of binding sites) on the cell surface. Therefore, the effect of PAO was also 
assessed on the steady-state fluorescence of  Alexa-ATP upon binding to P2X1 receptors. 
PAO treated cells not only showed saturation in Alexa-ATP fluorescence upon binding to 
P2X1 receptors, but also resulted in the time course which could be described by mono-
exponential function (Fig. 3.13B) (Table 3.8). Thus, these results indicate that PAO not only 
blocks the receptor internalization (as seen by the lack of residual fluorescence in Alexa-ATP 
dissociation experiments, Fig 3.13A) but also blocks receptor trafficking to the membrane (as 
seen by steady-state binding in Alexa-ATP fluorescence during the association experiments, 
Fig 3.13B). Therefore, all further experiments were performed with PAO treated cells.  Results 
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3.2.3 Allosteric interactions between subunits regulate the dissociation of 
bound agonist 
The desensitized state of P2X1 receptors has a high affinity to the bound agonist and the 
recovery from desensitization is thought to involve dissociation of bound agonist from the 
desensitized state [104]. Presence of allosteric sites on P2X receptors have been shown to 
modulate the affinity of agonist binding sites e.g. potentiation of ATP induced current on 
P2X2  receptors by  zinc  ions  [53].  Therefore,  we  hypothesized  that  allosteric  interactions 
between subunits may contribute to the change in the affinity of agonist binding site which in 
turn would control the dissociation of bound agonist  from the desensitized state of P2X1 
receptors. In order to probe this hypothesis, 300nM Alexa-ATP was used to activate and fully 
desensitize P2X1 receptors. The time course of dissociation of bound Alexa-ATP was then 
monitored in the presence of various allosteric/competing ligands (Fig. 3.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.14 Kinetics of the decay of Alexa-ATP fluorescence from P2X1 receptors in presence of various 
ligands: (A) MgORI buffer and CaORI buffer. (B) MgORI buffer, 10µM, 1µM (EC50) and 3nM ATP. (C) 
MgORI buffer, 300nM (ICmax) and 6nM (IC50) TNP-ATP. (D) MgORI buffer, 100nM (ICmax) and 0.3nM (IC50) 
NF449. Data are represented as mean ± SE of 3-11 cells for each concentration. Results 
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Table 3.9: Effect of various cations, agonist and antagonists on the dissociation of bound 
Alexa-ATP from P2X1 receptors 
Properties  Ligand  Concentration*  τ τ τ τ (s)  k (10
-3 s
-1) 
Mg
+2  2mM (5)  874 ± 74  1.17 ± 0.10 
Cation 
Ca
+2  2mM (5)  > 8000  - 
10µM (3)  554 ± 35  1.81 ± 0.10 
1µM (EC50) (7)  452 ± 21  2.24 ± 0.11  Agonist  ATP 
3nM (11)  832 ± 36  1.22 ± 0.05 
300nM (ICmax) (5)  474 ± 8  2.11 ± 0.03 
TNP-ATP 
6nM (IC50) (7)  918 ± 46  1.10 ± 0.05 
100nM (ICmax) (7)  587 ± 32  1.73 ± 0.10 
Antagonist 
NF449 
0.3nM (IC50) (9)  > 4000  - 
* Number of cells for each ligand concentration is given in parentheses. 
 
If the allosteric/competing  ligands would accelerate the dissociation of bound Alexa-ATP 
from  the  desensitized  state  of  P2X1  receptors  it  would  indicate  negative  cooperative 
interactions between subunits, whereas a reduction in the dissociation rate would indicate 
positive  cooperative  interactions  between  subunits.  All  the  time  courses  of  Alexa-ATP 
dissociation were fitted with a mono-exponential function (Table 3.9).  
ATP was used as an agonist because it would compete for the agonist binding site. Different 
concentrations of ATP (3nM, 1µM and 10µM) were used to monitor the time course of decay 
of bound Alexa-ATP fluorescence. It is expected that at 3nM ATP receptors are partially 
liganded and at 1µM or 10 µM ATP concentrations all binding  sites would be occupied. 
Therefore, the effect of occupancy state of the P2X1 receptors at these concentrations was 
assessed on the dissociation rate of bound Alexa-ATP.  
The dissociation of Alexa-ATP was also monitored in presence of P2X1 antagonists. Two 
antagonists,  TNP-ATP  and  NF449  were  used.  TNP-ATP  is  structurally  similar  to  ATP, 
whereas NF449 is different (Fig. 1.5), but both were shown to be competitive antagonists with 
nanomolar  potency  on  P2X1  receptors  [95,99,163].  The  dissociation  of  Alexa-ATP  was 
monitored at IC50 and ICmax concentrations of these antagonists. All these competing ligands 
were prepared in MgORI buffer.  Results 
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As a divalent cation, the effect of calcium ions was monitored on the dissociation rate of 
Alexa-ATP; because calcium ions have been shown to modulate P2X receptors activities e.g. 
enhance the recovery from desensitization in P2X3 receptors [164].  
The time course of decay of Alexa-ATP in the presence of Mg
+2 ions (as MgORI) was taken 
as  control  and  all  the  time  courses  of  decay  of  Alexa-ATP  in  the  presence  of 
allosteric/competing ligands were compared with the time course of decay in the presence of 
MgORI buffer. The decay of Alexa-ATP fluorescence in MgORI buffer could be described by 
a mono-exponential function with a time constant of ~870s. Replacement of magnesium ions 
by calcium ions in the dissociation buffer dramatically decreased the decay of Alexa-ATP 
fluorescence (Fig. 3.14A). This observation contradicts earlier observations on desensitizing 
P2X receptors that the presence of calcium ions in the buffer has either no effect on the rate of 
recovery  of  P2X1  receptors from desensitization  [101]  or enhanced effect on  the  rate  of 
recovery of P2X3 receptors from desensitization [103,164].  
Presence of EC50 or higher concentrations of ATP in the dissociation buffer accelerated the 
decay of Alexa-ATP fluorescence. However, 3nM ATP concentration, which is sufficient to 
desensitize ~50% of P2X1 receptors [104], showed similar time course of decay of Alexa-
ATP fluorescence as observed in MgORI buffer, probably due to slow rate of binding of ATP 
to the P2X1 receptors at this concentration [104]. Thus, due to lack of substantial binding of 
ATP at 3nM concentration, dissociation of bound Alexa-ATP occurred without the influence 
of ATP; hence, the time course of fluorescence decay was similar to the decay monitored in 
MgORI buffer (control conditions).  
Antagonists like TNP-ATP or NF449, used at ICmax concentration in the dissociation buffer, 
accelerated  the  decay  of  Alexa-ATP  fluorescence.  However,  at  IC50  concentration  both 
antagonists showed different effect. Similar time course of decay of Alexa-ATP fluorescence 
was  observed in  the  presence  of  TNP-ATP at  IC50 concentration  as  observed in  MgORI 
buffer, whereas, NF449 at IC50 concentration slowed the decay of Alexa-ATP fluorescence.  
These results indicate that ATP, TNP-ATP and NF449 at high concentrations (EC50 or more 
and ICmax), accelerated the dissociation of bound Alexa-ATP, therefore, indicating negative 
cooperative interactions between subunits. Divalent calcium ions (2mM) and NF449 at IC50 
concentration  significantly  slowed  down  the  dissociation  of  bound  Alexa-ATP;  thus, 
indicating positive cooperative interactions.  Results 
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The positive cooperative interactions between subunits induced by calcium ions and NF449 
(at  IC50  concentration)  would  mean  that  in  the  presence  of  these  ligands  the  affinity  of 
desensitized P2X1 receptors for the bound ligand would increase, therefore, less Alexa-ATP 
would dissociates from the binding sites. Due to the fact that agonist will remain bound to the 
binding sites, less receptors would recover from the desensitization. These results were also 
confirmed functionally on P2X1 receptors (Fig. 3.15).  
 
 
 
 
 
 
 
 
 
 
Fig. 3.15 Effect of calcium ions and 0.3nM NF449 on the functional recovery of P2X1 receptors from 
desensitization:  (A)  First  application  of  30µM  ATP  elicited  peak  currents  (peak  1)  from  P2X1  receptors. 
Receptors were allowed to recover from desensitization for 5 min in the continuous presence of either 2mM 
Mg
+2, 2mM Ca
+2 ions or 0.3nM NF449. Second application of 30µM ATP elicited peak currents (peak 2) from 
the receptors recovered from desensitization. Peak 2 of MgORI was compared with the peak 2 of NF449 and 
CaORI treated oocytes using one-way ANOVA followed by bonferroni’s post test for paired comparison. NF449 
and  CaORI  treatment  significantly  reduced  the  peak  2  response (p  <  0.01)  as  compared  to  MgORI  treated 
oocytes. Peak 1 of MgORI, NF449 and CaORI were not significantly different from each other. Asterisk sign (*) 
indicates level of significance (p < 0.01). (B) Percent recovery of P2X1 receptors from desensitization when the 
recovery was done either in 2mM Mg
+2, 2mM Ca
+2 ions or 0.3nM NF449 (Fig. 3.15A) is plotted against the 
percent decay of Alexa-ATP fluorescence after 5 min when the dissociation was monitored in 2mM Mg
+2, 2mM 
Ca
+2 ions or 0.3nM NF449 (Fig. 3.14). Data are presented as mean ± SE of 5-9 cells per treatment. The solid line 
represents linear regression to the data points with an intercept of 2.8 ± 1.3 and slope of 2.5 ± 0.17. 
 
30µM ATP was used to elicit peak current (peak 1) and to completely desensitize P2X1 
receptors. Desensitized receptors were allowed to recover for 5 min in the presence of MgORI 
buffer, CaORI buffer or 0.3nM NF449. 30µM ATP was again used to elicit current (peak 2) 
on  the  same  oocyte  to  determine  the  percentage  recovery  of  P2X1  receptors  from 
desensitization. If these ligands would have no effect on the affinity of desensitized state of Results 
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P2X1 receptors, receptors would show similar percentage of recovery from desensitization. 
The recovery of P2X1 receptors from desensitization was found to be significantly reduced   
(p < 0.01) in presence of Ca
+2 ions and 0.3nM NF449 as compared to Mg
+2 ions (Fig. 3.15A). 
Thus,  these  functional  results  compliment  our  fluorescence  data  that  in  the  presence  of 
calcium  ions  and  0.3nM  NF449,  positive  cooperative  interactions  between  subunits  take 
place. These  positive  cooperative  interactions contribute  to  the  increase  in affinity  of the 
bound agonist molecules in the desensitized state of P2X1 receptors, which resulted in the 
reduced dissociation of bound agonist, thus reducing the recovery from desensitization. This 
is  also  evident  in  Fig.  3.15B,  where  an  inverse  relation  between  levels  of  Alexa-ATP 
fluorescence was found with the percentage of receptors recovered from desensitization i.e. 
higher the amount of Alexa-ATP specific fluorescence associated with the receptors, less 
receptor recovered from desensitization. The effect of 0.3nM NF449 on the decreased decay 
of Alexa-ATP fluorescence has been discussed in detail in the discussion section 4.2.   
 
3.2.4 Allosteric model for ligand-receptor interactions 
3.2.4.1 Negative cooperativity in P2X1 receptors  
Alexa-ATP dissociation in the presence of different ligands indicated positive and negative 
cooperative  interactions  between  subunits  (section  3.2.3).  In  order  to  understand  the 
mechanism of negative cooperative contributions between receptor subunits in the process of 
dissociation of bound Alexa-ATP, we propose a simple allosteric model (Fig. 3.16).  
In this model we propose that binding of three agonist molecules (Alexa-ATP) to the closed 
state  of  the  receptor  is required  to open and  thus desensitize  the  receptor (Scheme-I).  In 
Scheme-II, the dissociation of bound agonist molecules from the desensitized state in the 
presence of ligand free buffer would result in non-liganded closed state of the receptor (Fig. 
3.16).  In  Scheme-II,  if  the  dissociation  of  bound  agonist  molecules  would  occur  in  the 
presence of competing ligands, then the receptor would be fully liganded at all the times. 
Based on our earlier results (Fig. 3.14), we hypothesize that negative cooperativity exists only 
in the fully liganded state of the receptor (three ligand bound state) and under the influence of 
negative cooperativity the dissociation of the first of the three bound ligands would be faster.  
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Fig. 3.16 Allosteric model for ligand-receptor interactions in the P2X1 receptors: We propose that binding 
of three agonist molecules (Alexa-ATP) per receptor to the closed state leads to receptor opening followed by 
desensitization (Scheme-I). The desensitized state is then a ligand bound closed state. Scheme-II depicts the 
dissociation of bound Alexa-ATP from the desensitized state of P2X1 receptors in the presence of a ligand free 
buffer. From the fully liganded desensitized state, negative cooperative interactions between subunits induce a 
decrease in the affinity of binding sites, which facilitates the dissociation of bound agonist from the desensitized 
state (Scheme-II). Under the influence of negative cooperativity, dissociation of bound agonist molecules will 
occur with a faster rate. Various states of the P2X1 receptor subunits are depicted by single letter codes; C stands 
for non-liganded state, A stands for agonist bound state, O stands for agonist bound open state and D stands for 
agonist bound  desensitized  state. Solid  and  dotted  arrows  indicate  high and  low  probability  of  the reaction 
respectively. 
 
In order to understand the negative cooperativity and to validate our hypothesis we simulated 
the Scheme-II of our proposed model for the conditions similar to that of in the presence and 
absence  of  competing  ligands  using  Gepasi  3.0  software  [104].  Gepasi  is  a  Microsoft 
Windows based program intended for the simulation of kinetics (steady-state and time-course 
behavior) of systems of chemical reactions. For simulation, dissociation of bound Alexa-ATP 
from each binding site was taken into account. Fig 3.17 shows the schematic of dissociation 
of bound Alexa-ATP in the absence of competing ligands from the statistically distributed 
P2X1 receptors population based on Scheme-II. The dissociation of Alexa-ATP starts from Results 
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the fully liganded P2X1 receptors depicted as XXX (three Alexa-ATP molecules bound state) 
until all the bound Alexa-ATP would dissociate to produce non-liganded closed receptors 
depicted as CCC. However, in the presence of competing ligands (e.g. ATP), the probability 
of finding fully liganded receptors at any given time would be high, so each C in Fig. 3.17 
would be replaced by L (competing ligand bound receptors) (not shown in the figure).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.17 Statistical distribution of P2X1 receptors population under Scheme-II in the presence of MgORI 
buffer: Dissociation of bound Alexa-ATP will occur from fully liganded P2X1 receptors. The dissociation of 
any molecule of Alexa-ATP would occur with equal probability which would produce a statistical distribution of 
P2X1 receptors population. Each subunit is depicted by a single letter code i.e. C stands for non-liganded and X 
stands for Alexa-ATP bound subunit.  
 
Fluorescence signal from the receptors is contributed by each Alexa-ATP molecule (depicted 
as X in Fig. 3.17) i.e. receptors with three bound Alexa-ATP would produce two times more 
fluorescence signal as compared to receptors with only one bound Alexa-ATP. Accordingly, Results 
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the  dissociation  of  each  Alexa-ATP  from  the  receptors  would  lead  to  a  corresponding 
decrease in the fluorescence; therefore, the time course of dissociation of bound Alexa-ATP 
from the fully liganded receptors would be given by the mean distribution of population of 
receptors with 3, 2 and 1 bound Alexa-ATP molecules at any given time. From Fig. 3.17, the 
Alexa-ATP fluorescence is represented by following equation: 
 
3
[XCC]     [CCX]     [CXC]     [XXC])     [XCX]     2([CXX]     3([XXX])
    F
+ + + + + +
=  Equation 3.8 
First, we simulated Scheme-II  for the conditions as that of in the presence of competing 
ligands i.e. when receptors would be fully liganded at all the times and dissociation of all the 
bound Alexa-ATP would occur with same rate under the influence of negative cooperativity. 
The  simulation  rate  constants  were  manually  adjusted  in  order  to  exactly  match  τ  of 
dissociation of Alexa-ATP in presence of 1 µM ATP. In the simulation, the rate constant, 
which exactly reproduced the experimentally determined τ of dissociation of Alexa-ATP in 
the presence of ATP, was found to be 2.22 x 10
-3 s
-1.
 The rate of backward reaction was taken 
as 1 x 10
-9 s
-1 ~ 0, to account for the high concentration of ATP leading to virtually immediate 
replacement  of  the  dissociated  Alexa-ATP  by  ATP.  For  simulation  in  the  absence  of 
competing ligands, the dissociation rate constant of first Alexa-ATP was taken as 2.22 x 10
-3 
s
-1 (because it occurs from the fully liganded receptors) and the rates of remaining two bound 
Alexa-ATP  were  found  to  be  0.9  x  10
-3  s
-1.  Using  these  rate  constants,  the  decay  of 
fluorescence under control conditions (in MgORI) could be reproduced (Fig. 3.18 and Table 
3.10) 
 
 
 
 
 
 
 
 
 
Fig. 3.18 Experimental and simulated decay of Alexa-ATP fluorescence: Comparison of the time course of 
decay  of  Alexa-ATP  fluorescence  in  the  presence  and  absence  of  a  competing  ligand  (A)  Experimentally 
determined,  data  taken  from  Fig.  3.14.  (B)  Simulated  Scheme-II.  Thin  green  lines  represent  the  mono-
exponential fits for both conditions (in the presence and absence of competing ligand).  Results 
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Table  3.10:  Comparison  of  time  courses  of  Alexa-ATP  dissociation  between 
experimental and simulated data on P2X1 receptors 
Conditions*  τ τ τ τ-Experimental (s)  τ τ τ τ-Simulated (s)  k-1 
(10
-3 s
-1) 
k-2 
(10
-3 s
-1) 
k-3 
(10
-3 s
-1) 
MgORI buffer (5)  874 ± 74  874   2.22  0.9  0.9 
1 µM ATP (7)  452 ± 21  451   2.22  2.22  2.22 
* Number of cells for each experimental determination is given in parentheses. Here k-1, k-2 
and k-3 denotes the simulated dissociation rate of first, second and third bound Alexa-ATP 
from the fully liganded desensitized state of P2X1 receptors respectively.  
 
Thus, simulation of Scheme-II could reproduce the experimental findings with the manually 
derived  rate  constants  (Table  3.10)  and  fits  the  dissociation  of  bound  Alexa-ATP  from 
desensitized state of P2X1 receptors in presence and absence of a competing ligand with a 
mono-exponential function (Fig. 3.18). Our simulated results validated our hypothesis that 
under the influence of negative cooperativity, i.e. in presence of high concentrations of ATP, 
the dissociation of all the bound Alexa-ATP would be fast and occur with equal rate. These 
results further suggest that the dissociation of the remaining two Alexa-ATP molecules from 
the partially liganded state would occur without the influence of negative cooperativity which 
would be slow and also occur with equal rate (Table 3.10). Thus we refined the Scheme-II of 
our proposed model. Fig. 3.19 shows the refined Scheme-II of our model with rate constants 
when the dissociation of Alexa-ATP would occur from the fully liganded desensitized state in 
the presence and absence of competing ligands. 
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Fig. 3.19 Scheme-II with rate constants for each step: Dissociation of bound Alexa-ATP is shown from the 
fully liganded desensitized state of the receptors when the dissociation occurs in the (A) presence of competing 
ligand, (B) absence of competing ligand. In both these conditions, first Alexa-ATP molecule would dissociate 
under  the  influence  of  negative  cooperativity  with  fast  rate  constant,  leaving  behind  partially  liganded 
desensitized  receptors.  In  the  absence  of  competing  ligands,  both  subsequent  Alexa-ATP  molecules  would 
dissociate without the influence of negative cooperativity and therefore with a slower time course giving rise to 
bi-exponential time course of Alexa-ATP dissociation. On the other hand, if the dissociation of bound Alexa-
ATP would occur in the presence of a competing ligand (e.g. ATP), the receptor would remain fully liganded at 
all  times  and  due  to  negative  cooperative  interactions  between  subunits  (fully  liganded  desensitized  state), 
dissociation  of  every  Alexa-ATP  molecule  would  occur  with  a  fast  rate  constant,  thus,  suggesting  mono-
exponential  decay  of  Alexa-ATP  fluorescence.  From  the  fully  liganded,  mixed  occupancy  state  of  P2X1 
receptors (Alexa-ATP and ATP bound receptors); the probability of dissociation of ATP or Alexa-ATP would be 
the same. But, if ATP would dissociate, a new molecule of ATP would immediately bind to the receptor because Results 
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of the high concentration of ATP available to the receptors. However, if dissociation of Alexa-ATP would occur 
instead of ATP, it will be visible as a corresponding decrease in the level of fluorescence from the receptors. 
 
According  to  our  simulated  results,  Scheme-II  predicts  a  biphasic  decay  of  Alexa-ATP 
fluorescence  in  the  absence  of  a  competing  ligand  and  mono-exponential  decay  in  the 
presence of a competing ligand. Surprisingly, both experimental and simulated time course of 
Alexa-ATP dissociation could be described by a mono-exponential function. The explanation 
for this apparent mono-exponential behavior is that 1) the two time-constants differ only by a 
factor  of  two  and  2)  it  was  not  possible  to  resolve  the  first  tens  of  seconds  in  the 
experimentally determined fluorescence decay.  
 
3.2.4.2 Steady-state binding of Alexa-ATP to P2X1 receptors 
In the earlier section we showed that the occupancy levels (full and partial) in the desensitized 
state of the receptor could regulate the dissociation of bound Alexa-ATP (i.e. fast dissociation 
from  fully  liganded  desensitized  receptors  and  slow  dissociation  from  partially  liganded 
desensitized  receptors  in  the  Scheme-II).  In  order  to  determine  if  the  occupancy  levels 
(partial) in the non-desensitized state (Scheme-I) could also regulate the dissociation of bound 
Alexa-ATP, the following approach was used.  
First, to correlate the particular concentration of Alexa-ATP to the occupancy level of P2X1 
receptors, binding curve of Alexa-ATP was prepared on the P2X1 receptors. Next, the level of 
fluorescence at different concentrations of Alexa-ATP in the binding curve was correlated 
with the occupancy level of the receptors using binomial equation, i.e. fractional population of 
receptors with 0, 1, 2, and 3 Alexa-ATP bound receptors at each Alexa-ATP concentrations 
was determined. Then, the occupancy level was correlated with the functional state of the 
receptors using steady-state desensitization curve. Finally, to elucidate if the occupancy level 
(partial occupancy) of receptors in the non-desensitized state (Scheme-I) could also regulate 
the dissociation of bound Alexa-ATP, the dissociation of Alexa-ATP from the P2X1 receptors 
pre-equilibrated with different Alexa-ATP concentrations was monitored in the presence of 
MgORI buffer. We then compared this with the dissociation of Alexa-ATP in the presence of 
MgORI buffer from the fully occupied desensitized P2X1 receptors (Scheme-II). 
In order to generate the steady-state binding curve, different  nanomolar concentrations of 
Alexa-ATP were directly applied to PAO treated P2X1 expressing oocytes followed by a Results 
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reference Alexa-ATP  concentration.  All  concentrations  (including  reference) were applied 
until  steady-state  binding  (steady-state  level  of  fluorescence)  was  achieved.  As  a  control 
experiment, nanomolar concentrations of Alexa-ATP along with the reference concentration 
were also applied to the non-injected control cells (Fig. 3.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.20  Steady-state  binding  and  dissociation  of  Alexa-ATP  on  the  P2X1  receptors:  Representative 
fluorescence traces in presence of 10nM and 30nM Alexa-ATP to (A) a non-injected cell and (B) to a P2X1 
receptors expressing cell. Blue and red bars represent background and P2X1 specific Alexa-ATP fluorescence 
respectively.  (C)  P2X1  specific  Alexa-ATP  fluorescence  was  determined  by  subtracting  the  non-specific 
fluorescence from the total Alexa-ATP fluorescence after steady-state binding. Data are presented as mean ± SE 
of 3-9 cells for each concentration. (D) Binding curve for Alexa-ATP at P2X1 receptors. Data are presented as Results 
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mean ± SE of 3-9 cells for each concentration. (E) Rate constants of Alexa-ATP association to P2X1 receptors 
are plotted against different Alexa-ATP concentrations. Data are presented as mean ± SE of 5-11 cells for each 
concentration. (F) Time course of decay of Alexa-ATP fluorescence in the presence of MgORI buffer from the 
P2X1 receptors when the binding sites were pre-equilibrated with either 3nM, 30nM or 300nM Alexa-ATP. Data 
are presented as mean ± SE of 3-5 cells. All traces were fitted with mono-exponential functions and normalized 
to the level of fluorescence obtained after 15s from the onset of Alexa-ATP dissociation in each measurement. 
All fluorescence intensities were monitored in real time under voltage clamp conditions.  
 
Table 3.11 Kinetics of dissociation of Alexa-ATP from variable occupancy state 
[Alexa-ATP] nM*  τ τ τ τ (s)  k (10
-3 s
-1)  Fluorescent amplitude (A) 
300 (5)  874 ± 74  1.1   27 ± 0.1 
30 (3)  1045 ± 4  0.9   15 ± 0.1 
3 (4)  1680 ± 17  0.6   15 ± 0.1 
* Number of cells for each ligand concentration is given in parentheses. 
 
The kinetics of association of Alexa-ATP to P2X1 receptors were monitored in real time 
under voltage clamp conditions. Specific binding, i.e. fluorescence of Alexa-ATP associated 
with P2X1 receptors, was determined for each concentration by subtracting the non-specific 
fluorescence from the total fluorescence (Fig. 3.20C). Fig. 3.20D shows the binding curve of 
Alexa-ATP on P2X1 receptors. The binding curve for Alexa-ATP binding was fitted with the 
Hill equation. The half maximal binding constant (BC50) was found to be 1.8 ± 0.2 nM with a 
Hill coefficient of 0.9 ± 0.1. Fig. 3.20D suggests that at 3nM, 30nM and 300nM Alexa-ATP 
concentrations, the probability of receptor labeling is ~60%, ~90% and 100%, respectively. In 
addition, the dissociation of bound Alexa-ATP was monitored in the presence of MgORI 
buffer  after  equilibrating  the  binding  sites  with  3nM, 30nM  and  300nM  Alexa-ATP.  As 
compared to the desensitized state, Alexa-ATP dissociated with different rates from the P2X1 
receptors pre-equilibrated with different Alexa-ATP concentrations (Fig. 3.20F) (Table 3.11), 
suggesting that the non-desensitized, partial occupancy state of the receptors also regulate the 
dissociation of Alexa-ATP. 
 
3.2.4.3 Correlation between occupancy level and functional state of the receptors   
In order to correlate the average occupancy level (steady-state distribution between 0, 1 and 2 
Alexa-ATP  bound  receptors)  with  the  functional  state  (desensitized  and  non-desensitized Results 
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receptors), steady-state desensitization was determined after equilibrating them with different 
nanomolar Alexa-ATP concentrations. To this end, P2X1 expressing oocytes were incubated 
in Petri dishes with different concentrations of Alexa-ATP for different times (until steady-
state binding was reached) at room temperature. Then, each oocyte was voltage-clamped and 
30µM  ATP  was  immediately  applied  to  elicit  the  residual  peak  current  response  (PE1) 
(experimentally determined peak-1) by activating all the P2X1 receptors still present in the 
non-desensitized closed state. After allowing the completely desensitized receptors to recover 
for 1 min in ligand free conditions under voltage clamp, 30µM ATP was again applied on the 
same oocyte  to generate  current  response  (PE2)  (experimentally  determined  peak-2) from 
those  receptors  which  recovered  from  complete  desensitization  induced  by  the  first  ATP 
application. As a control experiment, P2X1 expressing oocytes were incubated in ligand free 
buffer for 1 hr at room temperature and PE1 and PE2 responses were generated by applying 
30µM  ATP.  These  experiments  showed  that  5.1  ±  1.2  percent  of  the  P2X1  receptors 
recovered  from desensitization after 1 min  (n  =  22) in  ligand  free  buffer. Now, the first 
response  which  would  have  been  elicited  without  Alexa-ATP  pre-incubation  was  also 
calculated for each oocyte from the individual peak-2 (PE2) response and termed “calculated 
peak response (PC). The normalized mean current responses (PE1/ PC1) generated by 30µM 
ATP on P2X1 receptors pre-equilibrated with different Alexa-ATP concentrations is plotted 
in Fig. 3.21 (blue curve) and fitted with Hill equation.  
  
 
 
 
 
 
 
 
 
Fig. 3.21 Correlation between average occupancy level and steady-state desensitization: The black curve 
represents the binding curve for Alexa-ATP (taken from Fig 3.20 D). The blue trace represents the Alexa-ATP 
concentration dependence of steady-state desensitization. All traces were fitted with the Hill equation. The half 
maximal binding (BC50) (black trace) was seen at 1.8 ± 0.2 nM Alexa-ATP with a Hill coefficient of 0.9 ± 0.1 (n Results 
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= 3-9 cells). The half maximal desensitization (DC50) (blue trace) was seen at 9 ± 0.5 nM Alexa-ATP with a Hill 
coefficient of 1.9 ± 0.1 (n = 5-33 cells). 
 
The half maximal desensitization (DC50) was found to occur at 9 ± 0.5 nM Alexa-ATP with a 
Hill coefficient of 1.9 ± 0.1. The black curve in Fig. 3.21 is taken from Fig. 3.20D and 
represents the average occupancy  level of P2X1 receptors i.e. Alexa-ATP fluorescence at 
different Alexa-ATP concentrations. The half maximal binding (BC50) was found to occur at 
1.8 ± 0.2 nM Alexa-ATP with a Hill coefficient of 0.9 ± 0.1. The inference from these results 
is that although 50% of binding sites are occupied at 1.8nM, a 5-fold higher Alexa-ATP 
concentration is needed for 50% steady-state desensitization. Therefore, at 1.8 nM Alexa-ATP 
almost no desensitization can be detected, indicating that the binding of more than two ATP 
molecules per receptor is required for desensitization.  
 
3.2.4.4 Dissecting  the number  of  agonist molecules required  to  desensitize  the  P2X1 
receptors    
Functional dose response curve for ATP on the P2X1 receptors pre-equilibrated with different 
Alexa-ATP concentrations suggests that ATP would only produce functional responses from 
the non-desensitized P2X1 receptors. Therefore, in order to dissect the fractional distribution 
of partially liganded receptors with 0, 1 and 2 Alexa-ATP bound from the fully liganded 
receptors with 3 Alexa-ATP bound, binomial equation (equation 3.5) was used. 
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Where n is the total number of ligand binding sites per receptor, p is the probability that a 
receptor is labeled; q is the probability that a receptor is not labeled (1-p), and x is the number 
of bound Alexa-ATP molecules.  
It is important to note that P2X1 receptor subunits are interacting in a cooperative manner. In 
order to determine the fractional population of 0, 1, 2, and 3 Alexa-ATP bound receptors 
using binomial equation, we need to consider that the ligand binding in P2X1 receptors is a 
random process. The presence of cooperativity can be neglected for the calculation purposes 
because the binding rate between the first two ligands and the last ligand is not much different 
(i.e. only by factor of two). Results 
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As  P2X1  receptors  are  thought  to  be  formed  by  the  trimeric  assembly  of  homologous 
subunits, therefore we assumed three binding sites per receptor. The probability of Alexa-
ATP binding (steady-state fluorescence level) of the receptors was taken from the binding 
curve (Fig. 3.20D) i.e. at 1nM, 3nM, 30nM and 300nM Alexa-ATP the probability that the 
receptor  is  labeled  is  38%,  63%,  91%  and  100%  respectively.  Thus,  with  the  binomial 
distribution,  fractional  population  (f(x))  of  0,  1,  2  and  3  Alexa-ATP  bound  receptors  at 
different nanomolar concentrations of Alexa-ATP was calculated (Table 3.12).  
 
Table 3.12: Calculated distribution of fractional population of 0, 1, 2 and 3 Alexa-ATP 
bound P2X1 receptors 
Alexa-ATP 
(nM) 
P  f(0)  f(1)  f(2)  f(3) 
0.1  3.67 ± 1.2  0.8939  0.1022   0.0039   4.9431E-5 
0.3  10.33 ± 2.73  0.721    0.2492   0.0287   0.0011 
1  38.78 ± 5.44  0.2294   0.436    0.2762   0.0583 
3  63.57 ± 6.1  0.0483   0.2531   0.4417   0.2569 
10  80.56 ± 3.1  0.0073   0.0913   0.3785   0.5228 
30  91.78 ± 4.23  5.5541E-4  0.0186   0.2077   0.7731 
100  100  1E-12    2.9997E-8  2.9994E-4  0.9997 
300  100  1E-12    2.9997E-8  2.9994E-4  0.9997 
*P stands for probability that receptor is labeled, f(0), f(1), f(2) and f(3) stands for fractional 
population of receptors with 0, 1, 2 and 3 Alexa-ATP bound receptors respectively.  
 
After determining the fractional distribution of 0, 1, 2 and 3 Alexa-ATP bound receptors at 
each Alexa-ATP concentration, we tested three hypotheses: 
1) Binding of three agonist molecules per receptor is required to desensitize P2X1 receptors: 
Three-site model. (Therefore, ATP would produce functional response from the 0, 1 and 2 
Alexa-ATP bound receptors i.e. fractional population of closed receptors under Scheme-I = 
f(0) + f(1) + f(2)). Results 
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2) Binding of two agonist molecules per receptor is required to desensitize P2X1 receptors: 
Two-site model. (Therefore, ATP would produce functional response from the 0 and 1 Alexa-
ATP bound receptors i.e. fractional population of closed receptors under Scheme-I = f(0) + 
f(1)). 
3) Binding of one agonist molecule per receptor is required to desensitize P2X1 receptors: 
One-site model. (Therefore, ATP would produce functional response from the 0 Alexa-ATP 
bound receptors i.e. fractional population of closed receptors under Scheme-I = f(0)). 
 
Fractional distribution of population of closed receptors for all these models (One, Two or 
Three-site model) is plotted in Fig. 3.22 and compared with the steady-state desensitization 
curve  determined  on  P2X1  receptors  pre-equilibrated  with  different  Alexa-ATP 
concentrations. 
 
 
 
 
 
 
 
 
Fig. 3.22 Fractional distribution of closed-state of the receptors for One, Two or Three-site model: (A) 
Using  binomial  equation,  fractional  distribution  (f(x))  of  0,  1,  2  and  3  Alexa-ATP  bound  receptors  was 
calculated.  According  to  these  three  models  (One,  Two  or  Three-site  model),  different  closed-states  were 
assumed and plotted against different Alexa-ATP concentrations. After fitting each distribution of population of 
closed-states with Hill equation, the half maximal distribution of population for One, Two and Three-site model 
was found to occur at Alexa-ATP concentration of 0.6 ± 0.01, 1.6 ± 0.1 and 8.6 ± 0.09 nM with Hill coefficient 
of 1.9 ± 0.05, 1.3 ± 0.01 and 1.1 ± 0.1 respectively. (B) Comparison of experimentally determined steady-state 
desensitization  curve  with the  Three-site  model  which  describes  that  binding  of  three  agonist  molecules  is 
required to desensitize the receptors. Near superimposition of closed-states formed by population of 0, 1 and 2 
bound Alexa-ATP  (Three-site  model) with  the  experimentally determined  steady-state  desensitization  curve 
support our first hypothesis that binding of three agonist molecules are required to desensitize the receptors. The Results 
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half maximal distribution of population of closed-states for Three-site model was found to be 8.6 ± 0.8 nM 
Alexa-ATP is comparable to the DC50 value of 9.0 ± 0.5 nM Alexa-ATP for steady-state desensitization curve.  
 
After fitting both curves (distribution of closed-states under Three-site model and steady-state 
desensitization  curve)  by  Hill equation we  found a direct relationship  between  these  two 
curves as the half maximal distribution of population of receptors for Three-site model was 
found to be 8.6 ± 0.9 nM Alexa-ATP concentration and the half maximal desensitization 
(DC50)  for  steady-state  desensitization  was  found  to  be  9.0  ±  0.5  nM  Alexa-ATP 
concentration. Near superimposition of both curves support our conclusion that binding of 
three agonist molecules are required to desensitize the P2X1 receptors and receptors with less 
than three agonist molecules are essentially in non-desensitized, closed state. Therefore, it is 
evident that the dissociation of bound Alexa-ATP in Fig. 3.20F at 3nM concentration most 
probably occurred from partially liganded closed state (Scheme-I), whereas, the dissociation 
of  bound  Alexa-ATP  at  30nM  or  300nM  concentrations  occurred  primarily  from 
partially/fully liganded desensitized state (Scheme-II).  
Hence, these results suggest that not only the full occupancy of the receptors (desensitized) 
(Scheme-II) but also the partial occupancy of the receptors (non-desensitized) (Scheme-I) 
could  regulate  the  allosteric  interactions  between  subunits  which  in  turn  controls  the 
dissociation of bound agonist from the binding sites of the receptors. 
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3.3  Probing  structural  rearrangements  in  P2X  receptors  using 
voltage clamp fluorometry 
Among the three superfamilies of ligand gated ion channels (i.e. Cys-loop, iGluR and P2XR) 
high resolution structural details are only available for ligand binding domains of Cys loop 
family members (e.g. AChR [150]) and iGluR [152]. There is no high resolution structural 
information available for P2X receptors and therefore, most of the structural understanding of 
P2X receptors came from site directed mutagenesis and biochemical analysis [28]. Although, 
crystal structures provide valuable “snapshots” of the protein under investigation, it fails to 
provide information about the various conformations of the protein during transition from 
closed  to  open  and  desensitized  states.  Consequently,  the  precise  mechanism  by  which 
binding of one  or  more ligand molecules  is  translated into structural  rearrangements  that 
trigger channel opening is still not well understood for these ligand gated ion channels. There 
are two methods of choice to study ligand receptor interactions i.e. ligand binding assay and 
electrophysiology. However, the former method alone cannot resolve receptor function and 
the latter method cannot resolve events that are electrophysiologically silent i.e. desensitized 
states. 
Voltage  clamp  fluorometry  (VCF)  offers  certain  advantages  over  these  techniques,  by 
simultaneously  monitoring  receptor  function  (through  changes  in  elicited  current)  and 
structural rearrangements in or around the domains of interest (through site specific changes 
in the fluorescence intensity of the attached fluorophore) in real time. Thus, this technique can 
serve as a real time correlate of the channel structure and function. VCF has been widely used 
to investigate structural rearrangements in the ligand binding domain of Cys-loop receptors 
[140,143,145,165].  It  was  found  that  agonists  and  antagonists  can  induce  distinct 
conformational changes in the Cys-loop receptors. 
It is hypothesized that, in P2X receptors ATP binding at the interface between neighboring 
subunits  initiates  structural  rearrangements  which  propagate  to  the  channel  gate  through 
conformational  waves.  Therefore,  to  understand  the  mechanism  of  activation  and 
desensitization  of  P2X1  receptors,  it  would  be  interesting  to  investigate  these  molecular 
motions induced by ligand receptor interactions. To this end, several mutants in the cysteine-
rich-domain  1  (CRD-1)  were  generated  by  site  directed mutagenesis  in  which  individual 
amino acids from position 118 to 125 were mutated to cysteine residues. Accessibility of the 
engineered  cysteine  residues  was  determined  by  covalently  attaching  an  environment Results 
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sensitive  cysteine  reactive  fluorophore  e.g.  tetramethylrhodamin-6-maleimide  fluorophore, 
TMRM. Any change in the local environment of the attached fluorophore during receptor 
activation or desensitization was monitored as a change in its fluorescence intensity using 
VCF.  
 
3.3.1 TMRM treatment does not affect the function of CRD-1 mutants 
The extracellular loop of P2X receptors contains ten conserved cysteine residues arranged in 
two  cysteine-rich-domains  (CRDs).  The  region  from  C117-C165  contains  six  disulfide 
bonded cysteine residues called CRD-1, while region  from C217-C270 has four disulfide 
bonded cysteine residues called CRD-2 (P2X1 numbering) (Fig. 1.1). In the present study, 
residues from position 118 to 125 were individually mutated to cysteine residue (i.e. A118C, 
E119C, N120C, P121C, E122C, G123C, G124C and I125C), thus creating one free cysteine 
in the CRD-1 region. These clones were generated by Benjamin Marquez-Klaka at the Max 
Planck Institute for Brain Research, Germany.  
The environmental sensitive fluorophore (TMRM) was used to label oocytes expressing these 
cysteine mutants. TMRM quantum yield increases when it lies in a hydrophobic milieu as 
compared to a hydrophilic one. Accordingly, change in the fluorescence intensity can be used 
to obtain information about the structural rearrangements that affect the surroundings of the 
residue to which TMRM is bound. TMRM treatment to the oocytes expressing single cysteine 
mutants was done by incubating the oocytes in CaSORI buffer containing 3µM TMRM for 15 
min on ice in the dark. The labeling was brought about by the ability of the maleimide moiety 
in TMRM to form a spontaneous covalent bond with  free cysteines. The excess dye was 
removed by extensive washing of the oocytes in dye free CaSORI buffer. The labeled oocytes 
were  then  stored  in  the  dark  at  room  temperature  until  the  beginning  of  measurements. 
Change in the fluorescence  intensity coupled to structural rearrangements during receptor 
activation and desensitization was determined under voltage clamp conditions in real time 
through the use of a photo diode (Fig. 2.3). Fig. 3.23 shows functional expression and specific 
TMRM labeling of CRD-1 cysteine mutants of P2X1 receptors.   
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Fig. 3.23 Functional expression and specific TMRM labeling of cysteine mutants of P2X1 receptors: (A) 
Normalized current response generated by 10µM ATP and 3µM ATP on the individual oocyte expressing wild 
type (WT) or CRD-1 mutants.  All currents were generated on oocytes not treated with TMRM. Average peak 
current generated by 10µM ATP on these receptors (WT or CRD-1 mutants) was >1µA, suggesting that all 
receptors were fully functional. Data are presented as mean ± SE of 3-9 cells for each group. (B) 10µM ATP 
evoked currents recorded from oocytes individually injected with wild-type (WT) or CRD-1 cysteine mutants. 
All currents were generated after TMRM treatment. Average peak current generated by 10µM ATP on these 
receptors (WT or CRD-1 mutants) was >1µA, suggesting that all receptors were fully functional after TMRM 
treatment. Data are presented as mean ± SE of 3-15 cells for each group. (C) Fluorescence intensity after TMRM 
treatment  to  control  cells  (No  RNA  injected),  wild-type  (WT)  and  CRD-1  cysteine  mutants.  The  level  of 
fluorescence was normalized with respect to the level of fluorescence obtained on the control oocytes treated 
with TMRM. Data are presented as mean ± SE of 5-25 cells for each group. Fluorescence intensity of TMRM 
treated  control  cells  was  compared  with  TMRM  treated  WT  or  CRD-1  mutants  using  one-way  ANOVA 
followed by bonferroni’s post test for paired comparison. Asterisk sign (*) indicates level of significance (p < 
0.01). (D) Direction of change in the fluorescence (∆F %) associated with five mutants that showed significant 
TMRM labeling. Data are presented as mean ± SE of 5-15 cells for each mutant.  
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All CRD-1 mutants were fully functional without TMRM treatment when tested using 10µM 
ATP (showed >1µA peak currents). They showed similar ratio of peak currents generated by 
10µM/3µM ATP when compared to  wild  type receptors, suggesting that they  maintained 
similar EC50 value as that of wild type receptors (Fig. 3.23A). The effect of TMRM treatment 
on these mutants was also compared with the TMRM treated wild type receptors (Fig. 3.23B). 
Peak current response  from wild type and mutant receptors upon 10µM ATP application 
indicates that TMRM treatment has no effect on the functionality of these receptors as all 
these receptors (WT or mutants) produced similar peak response. These experiments indicated 
that not only cysteine mutation at these places can be tolerated by P2X1 receptors without 
compromising the receptor’s function but also that TMRM treatment has no effect.  
These  experiments were  performed on  the  VCF  setup;  therefore,  concurrent  recording  of 
fluorescence and current signals could be performed from the same population of receptors. 
Thus, to test whether these endogenously or engineered cysteines are accessible to TMRM 
labeling, fluorescence signals from WT and these cysteine mutants treated with TMRM was 
also quantified by photodiode measurements (Fig. 3.23C). Fluorescence intensity from the 
control oocytes (no RNA injected) after TMRM treatment indicates non-specific binding of 
TMRM.  Similarly,  oocytes  expressing  wild-type  P2X1  receptors  were  not  significantly 
labeled by TMRM as compared to the control oocytes, indicating that the naturally occurring 
conserved cysteine residues in CRD-1 and CRD-2 regions in the wild type receptors are not 
accessible to TMRM labeling, most probably because they form pair-wise disulfide bonds. 
However, all except A118C, E119C and G124C cysteine mutants of CRD-1 region showed 
significant TMRM fluorescence (p < 0.01) when compared to the control cells, indicating that 
the engineered cysteine residue is accessible to TMRM binding at these positions. Fig. 3.23D 
shows corresponding percent change in the fluorescence (∆F %) upon 10µM ATP application 
on the mutants who showed significant TMRM labeling.  
 
3.3.2 Agonist mediated changes in the fluorescence intensity  
3.3.2.1 Different positions sense different structural rearrangements 
The  fluorescence  intensity  of  TMRM  strictly depends  upon  the  local  environment  of  the 
attached fluorophore i.e. TMRM quantum yield increases when it lies in a hydrophobic milieu 
as compared to a hydrophilic one. In this way, change in the fluorescence intensity can be 
used  to  obtain  information  about  the  agonist  mediated  structural  rearrangements  during Results 
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receptor’s activation and desensitization that affect the surroundings of the residue to which 
TMRM is bound. Fig. 3.23C shows that out of the eight cysteine mutants, six mutants showed 
more than 200% TMRM specific fluorescence as compared to control cells, indicating that 
TMRM was accessible to these positions. When concurrent measurement of the current and 
fluorescence  intensity  in  TMRM  labeled  CRD-1  mutants  was  done,  change  in  the 
fluorescence intensity (∆F) was found in all mutants except G124C when activated by 10µM 
ATP (Fig. 3.23D and 3.24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.24 Concurrent  measurement  of the current and fluorescence  on CRD-1  mutants: Representative 
traces of the change in the fluorescence and current in various CRD-1 mutants when activated by 10µM ATP. 
The dotted line indicates the position of peak current and corresponding fluorescence value on these mutants. Results 
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Mutant N120C, G123C  and  I125C  showed  decrease  in the  fluorescence intensity  upon  agonist  application. 
Mutant P121C and  E122C  showed  increase  in  the fluorescence  intensity  upon  agonist application,  whereas 
mutant  G124C  was  labeled  by  TMRM  but  showed  no  change  in  the  fluorescence  intensity  on  agonist 
application. All mutants were fully functional after TMRM labeling as judged by the current responses.  
 
Table 3.13: Agonist mediated change in the fluorescence intensity of CRD-1 mutants 
Mutants  Agonist  ∆ ∆ ∆ ∆F (%)  Direction  Imax (µA)  N (# cells) 
N120C  10µM ATP  5.6 ± 0.6  Decrease  4.3 ± 0.5  8 
P121C  10µM ATP  7.5 ± 1.2  Increase  4.3 ± 0.2  9 
E122C  10µM ATP  3.7 ± 0.3  Increase  3.3 ± 0.2  15 
G123C  10µM ATP  3.2 ± 0.4  Decrease  5 ± 0.3  6 
G124C  10µM ATP  Not detected  -  3.4 ± 0.1  5 
I125C  10µM ATP  2.1 ± 0.6  Decrease  3.4 ± 0.2  5 
* ∆F denotes percentage change in the fluorescence; Imax is the maximum peak current. 
 
Interestingly,  mutant  N120C,  G123C  and  I125C  showed  decrease  in  the  fluorescence 
suggesting exposure of these residues to more hydrophilic environment, while the other two 
mutants  (P121C  and  E122C)  showed  an  increase  in  the  fluorescence  upon  activation  by 
agonists suggesting an increase in the hydrophobic environment around these residues. Table 
3.13 compares change in the fluorescence intensity and current measured by the application of 
10µM  ATP  in  various  CRD-1  mutants.  Comparison  of  corresponding  changes  in  the 
fluorescence  and  peak  current  responses  in  these  five  mutants  revealed  some  interesting 
observations.  In  N120C  and  I125C  mutants  the  change  in  the  fluorescence  was  nearly 
complete,  for  G123C  the  change  was  almost  80%  complete  when  the  peak  current  was 
reached. In the mutant P121C, the change in fluorescence was nearly 50% when the peak 
current was reached. Whereas, in the mutant E122C, the change in fluorescence started to 
occur only  after the peak current was reached. Mutant  G124C  showed  no  change  in the 
fluorescence but showed TMRM labeling.  
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3.3.2.2 Fluorescence shift correlates with receptor activation and desensitization 
From the above results, it appears that these cysteine mutants are sensing progression of a 
conformational wave which originated after agonist binding. Therefore, to correlate change in 
the  fluorescence  (∆F)  at  these  positions  with  receptor  activation  or  desensitization,  time 
constants  were  determined  by  fitting  the  activation  or  desensitization  component  of  the 
current waveform. These time constants were then compared with the time constants derived 
from  fitting  the  change  in  the  corresponding  fluorescence  waveform  (Fig.  3.25).  Mono-
exponential function was used to fit both waveforms. Table 3.14 lists the kinetic properties of 
receptor activation, desensitization and change in the fluorescence for these CRD-1 mutants. 
Fig. 3.25 shows that for mutants N120C, G123C and I125C, the time constant of change in 
the fluorescence is kinetically correlated with the activation of receptors, whereas, in mutants 
P121C and E122C the time constant of change in the fluorescence is kinetically correlated 
with the desensitization of receptors. Thus, these results indicate that the positions N120C, 
G123C and I125C sense activation of the receptors after agonist binding and the positions 
P121C and E122C sense desensitization of the receptors.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.25 Onset of ∆ ∆ ∆ ∆F correlates kinetically with the activation or desensitization: ATP induced change in 
the fluorescence (∆F) of the attached TMRM and the onset of receptor activation and desensitization were fitted 
with a mono-exponential function. The time constants were determined after activating these mutants with 10µM 
and 30µM ATP. The τ (mean time constant) of ∆F was compared with the activation and desensitization of these 
five  cysteine  mutants using  one-way ANOVA  followed  by  bonferroni’s post test for  paired comparison. In 
mutants N120C, G123C and I125C, ∆F is kinetically correlated with receptor activation because τ of receptor 
desensitization is significantly different (p < 0.01) from τ of ∆F in these mutants. Whereas, in mutants P121C Results 
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and E122C, ∆F is kinetically correlated with the receptor desensitization, because τ of receptor activation is 
significantly different (p < 0.01) from τ of ∆F in these mutants. Asterisk sign (*) indicates level of significance 
(p < 0.01) when τ of receptor activation or desensitization is compared with τ of ∆F in the particular mutant. 
Data are presented as mean ± SE of n experiments. Number of cells for each mutant is listed in Table 3.14.  
 
Table 3.14: Kinetic properties of CRD-1 mutants when activated by ATP 
Mutants  Direction  
of ∆ ∆ ∆ ∆F 
Activation 
τ τ τ τ (s) 
Desensitization 
τ τ τ τ (s) 
∆ ∆ ∆ ∆F 
τ τ τ τ (s) 
Number  
(# cells) 
N120C  Decrease  0.4 ± 0.1  3.3 ± 0.3  1 ± 0.2  11 
P121C  Increase  0.1 ± 0.02  2.3 ± 0.2  2 ± 0.2  12 
E122C  Increase  0.2 ± 0.03  3.7 ± 0.2  3 ± 0.2  18 
G123C  Decrease  0.2 ± 0.04  4.2 ± 0.6  1 ± 0.1  6 
I125C  Decrease  0.04 ± 0.01  2.2 ± 0.5  0.2 ± 0.02  4 
*∆F denotes change in fluorescence; τ is the time constant of onset of receptor activation/ 
desensitization/ fluorescence change. 
 
3.3.2.3 Structural rearrangements during recovery from desensitization 
The rate of recovery from desensitization in three mutants (N120C, P121C and E122C) was 
also monitored. In these experiments, ATP-γS instead of ATP was used as an agonist to elicit 
peak  current  response  from  the  receptors,  because  it  has  been  shown  earlier  that  the 
dissociation of ATP-γS from P2X1 receptors occurs on a faster time scale as compared to 
ATP [88].  
 
 
 
 
 
 
 
Fig.  3.26  Structural  rearrangement  in  CRD-1  mutants  during  recovery  from  desensitization: 
Representative traces of current and corresponding change in the fluorescence in (A) N120C, (B) P121C and (C) 
E122C. 10µM ATP-γS was used to elicit peak current responses from these mutants. After the first application of 
agonist, receptors were washed for 5 min in the ligand free buffer in order to recover them from desensitization. Results 
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Current responses were again elicited on the same set of receptors that recovered from desensitization. The black 
bars  above  the  current  traces  indicate  the  time  of  agonist  application.  Traces  were  not  corrected  for 
photobleaching. Baseline in these individual traces was manually corrected by subtracting a straight line.  
 
Table 3.15: Recovery of mutants from desensitization in the presence of MgORI when 
activated by 10µM ATP-γ γ γ γS 
Ligand  Mutants 
(# cell)* 
Peak-1 
(µA) 
∆ ∆ ∆ ∆F1 
(%) 
Peak-2 
(µA) 
∆ ∆ ∆ ∆F2 
(%) 
% 
Current 
recovery 
% 
Fluorescence 
recovery 
120 (3)  3 ± 0.1  4 ± 0.7  2 ± 0.2  3 ± 0.1  61  68 
121 (3)  3 ± 0.3  14 ± 3  1 ± 0.1  8 ± 2.2  36  57 
MgORI 
 
122 (3)  2 ± 0.1  5 ± 0.7  1 ± 0.1  3 ± 0.6  56  69 
*Number of cells for each mutant is indicated in parenthesis.  
Note: Peak-1 and Peak-2 are the peak currents produced by first and second application of 10µM ATP-γS. ∆F1 
% and ∆F2 % are the corresponding percent change in the fluorescence during first and second application of 
10µM ATP-γS on these mutants. % Current and % Fluorescence recovery indicates the corresponding recovery 
of signals (current and fluorescence) during second application of 10µM ATP-γS when compared to the first 
application.  
 
In these experiments, first application of 10µM ATP-γS elicited peak current response (peak-
1) from TMRM treated mutants. After continuous washing for 5 min in the presence of ligand 
free buffer (MgORI buffer), 10µM ATP-γS was again applied on the same population of 
receptors in order to elicit second peak current response (peak-2) from the receptors which 
recovered from desensitization (Fig. 3.26). Percent change in the fluorescence (∆F %) and 
peak current responses during  first and second application of 10µM ATP-γS is shown  in 
Table 3.15. It was found that significant fraction of receptors recovered from desensitization 
(in terms of both current and ∆F %) when activated by 10µM ATP-γS. These results indicate 
that receptors recover from desensitization on a faster time scale when activated by ATP-γS 
due to the fast dissociation of the bound ATP-γS from the binding sites. The percent recovery 
of current signals after desensitization is also correlated with the percent recovery of the 
fluorescence signal (Table 3.15), suggesting that the recovery from desensitization not only 
involves dissociation  of  bound  agonist  from the desensitized receptors, but  also  involves 
reversal of structural rearrangements back to the closed state. Results 
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3.3.3 Antagonist mediated changes in the fluorescence intensity  
NF compounds (NF279, NF449) are known competitive antagonists of P2X1 receptors [94]. 
They are structurally different as compared to ATP (Fig. 1.5). Therefore, it was interesting to 
determine  if  binding  of  structurally  different  ligands  could  also  lead  to  structural 
rearrangements. 100nM NF449 (ICmax) alone was tested on TMRM labeled three mutants 
(N120C, P121C and E122C).  
 
 
 
 
 
 
 
 
 
Fig. 3.27 Fluorescence change induced by 100nM NF449: Representative traces of change in the fluorescence 
in (A) P121C (B) E122C. An increase in the fluorescence was seen in both mutants.  
 
Table 3.16: Antagonist mediated change in the fluorescence intensity of CRD-1 mutants 
Mutants  Antagonist  ∆ ∆ ∆ ∆F (%)  τ τ τ τF (s)  Direction  N (# cell) 
N120C  100nM NF449  Not detected  -  -  4 
P121C  100nM NF449  11.3 ± 2.4  29.2 ± 3.1  Increase  3 
E122C  100nM NF449  5.2 ± 0.7  30.4 ± 11.4  Increase  3 
*∆F denotes change in the fluorescence; τF is the time constant of onset of the fluorescence 
change. 
 
No current was observed (as expected), but binding of NF449 induced an increase in the 
fluorescence in two mutants (P121C and E122C) (Fig. 3.27). Fluorescence change in mutant 
N120C was not detected. The relative change in the fluorescence caused by NF449 at ICmax 
concentration was comparable to the change caused by 10µM ATP (at concentrations greater 
than EC50 on these mutants) (Table 3.13 and 3.16).  Results 
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Taken  together,  these results suggest  that  the  CRD-1  region  of  P2X1 receptors is  highly 
dynamic and is a part of the conformation wave which originates after ligand binding. Certain 
positions in the CRD-1 region could even differentiate between types of ligand bound in the 
binding site (e.g. position N120C showed a decrease in the fluorescence upon ATP binding 
but showed no change in the fluorescence upon NF449 binding).  
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4. Discussion 
4.1 Probing allosteric interactions between P2X receptor subunits 
in the gating process using photolabeling 
P2X receptors are thought to be formed by the trimeric assembly of homologous subunits 
[49,72], resulting either in homomeric or heteromeric channels [70,71]. Agonist binding at the 
interface  between  adjacent  subunits  is  thought  to  initiate  conformational  waves  which 
propagate to the receptor’s gate through an unknown allosteric mechanism. An important step 
towards understanding the allosteric mechanism of receptor activation is to determine the 
number  of  subunits  and  the  nature  of  their  contribution  in  the  gating  process.  Due  to 
continuous ligand binding and unbinding steps, defined contribution of each subunit towards 
gating is difficult to study. Therefore, in my thesis, I sought to answer above and related 
questions using homomeric P2X receptors with the help of a photolabeling technique.  
I used photolabeling to overcome the limitation of ligand unbinding events, where one or 
more ligands were  covalently attached  to  the  binding sites  of  P2X  receptors,  so that  the 
contribution of remaining binding sites to the gating process can be studied. As gating of P2X 
receptors is a complex process, it has been  necessary  in the present study to make some 
simplifying assumptions to analyze these results which are discussed later in this section. 
However, even under the limitations of these assumptions, the present work unequivocally 
favors the interpretation that the gating process in P2X receptors is an additive outcome which 
is contributed by each subunit of the receptor individually. 
 
Concurrent photolabeling and functional measurements  
Photoaffinity ligands provide tools for real time functional modification of the system under 
investigation. To date many photoaffinity analogs of purines with nearly all the photolysable 
groups have been synthesized and many are now commercially available. Benzophenone and 
azido based photoaffinity analogs of ATP have been used earlier in the structure-function 
studies of purinergic receptors [117,118]. Benzophenone based probes offer several distinct 
advantages over azido based probes. They are stable under ambient light conditions and can 
be activated with wavelengths greater than 300 nm thus reducing protein degradation and 
allow studies on cell cultures or other living systems. Even the relaxation process does not Discussion 
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require  a  scavenger  [112].    BzATP  (3’(2’)-O-(4-benzolybenzoly)-ATP)  a  benzophenone 
based photoaffinity  analog of ATP is  commercially  available  and  shown  to have  agonist 
activity on various P2X receptor subtypes [99]. Therefore, I used BzATP to cross-link it to 
the  binding  site  of  P2X  receptors  (P2X1,  P2X2  and  chimera)  that  were  expressed 
heterologously in Xenopus laevis oocytes.  
The combination of photolabeling to cross-link photoaffinity agonists in the binding site of 
receptors along with functional measurements with the help of patch clamp has been used at 
CNG  channels  [111,166]  and  nAChRs  [167].  In  this  study,  I  used  two-electrode  voltage 
clamp to measure functional responses from oocytes expressing P2X receptors. Therefore, for 
concurrent photolabeling and functional measurements from the same set of P2X receptors, a 
custom made oocyte chamber was used (Fig. 2.2). This chamber not only provided a rigid 
positioning of oocytes to minimize the artifacts induced by the movement of oocytes caused 
by the solution exchange but also allowed continuous and fast solution exchange. It allowed 
electrode impalement in the upper compartment for electrophysiological measurements, while 
the flow of solution in the lower compartment helped the oocyte to form a seal around the 
0.6mm hole due to venturi effect, thus minimizing solution exchange between the upper and 
lower  partition. This  type  of chamber has  been  used  earlier  to study  concurrent receptor 
activation  and  fluorescence  changes  to  monitor  the  structural  rearrangements  in  GABA 
receptors heterologously expressed in Xenopus laevis oocytes [140]. The only limitation with 
this chamber (also reported by Chang et al. [140]) was the diffusion of ligand around the 
0.6mm  hole  (seal)  especially  during  prolonged  ligand  application.  As  this  portion  of  the 
oocyte was outside the field of UV-light application, no photolabeling would occur on the 
receptors in this portion; however, an extended washout was used to completely deactivate the 
receptors (if any) in this portion of the oocyte especially during protocols in which agonist 
was applied for more than 60s. Therefore the diffusion of ligand around this hole is not likely 
to affect our interpretations of the experiments with this chamber. 
BzATP is found to be an effective agonist on the chimera, but a partial agonist on P2X2 
receptors. Efficacy of BzATP on P2X1 receptors is not determined in this study, although it 
has been previously published that BzATP is a partial agonist on P2X1 receptors [99]. 
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Photolabeling of P2X receptors 
Saturation of binding sites by the agonist (BzATP) in the absence of UV-light lead to the 
activation and desensitization of P2X1 receptors. However, covalent cross-linking of BzATP 
in  the  presence  of  UV-light  resulted  in  locking  of  the  receptor  in  an  agonist  bound 
desensitized state which was evident from the apparently reduced recovery of receptors from 
the  desensitized  state  as  compared  to  without photolabeling (Fig. 3.1). Recent  functional 
[104]  and covalent  cross-linking  studies  [118] on  P2X1  receptors also  suggested  that  the 
recovery of P2X1 receptors from desensitization possibly involves dissociation of the bound 
agonist. Our results are in agreement with these studies, that the agonist unbinding is a pre-
requisite for the recovery of P2X1 receptors from desensitization. P2X1 receptors could not 
be further used to study the contribution of each subunit towards gating due to the limitation 
of recovery of receptors from the persistent desensitization after photolabeling. Therefore, 
P2X2  receptors  were  explored  for  these  functional  studies  as  they  represent  the  non-
desensitizing phenotype of P2X receptors.  
BzATP is found to be a partial agonist on the P2X2 receptors when compared to ATP (Fig. 
3.3). ATP produced a maximal response from P2X2 receptors when all the binding sites were 
available (not cross-linked), but its response decreased gradually upon photolabeling with 
BzATP. Progressive photolabeling with BzATP lead to an increase in the number of binding 
sites  cross-linked  with  a  partial  agonist  i.e.  knocked  out  (not  available  for  the  maximal 
contribution by ATP) (Fig. 3.4). Recently, in a study based on the coexpression of P2X1 
mutants (T18A with K68A or wild type receptors), Ennion et al. [33] found that the response 
from the homo-trimeric T18A mutants was too low to be detected. But the hetero-trimers 
between T18A mutants and wild type P2X1 (in which one or two subunits of wild type P2X1 
present) showed a significantly higher response. There was a corresponding increase in the 
receptor’s activity as the number of wild type P2X1 receptor subunits increased in the hetero-
trimers, indicating an additive functional effect. In a similar study, Stoop et al. [168] studied 
the MTSET block of concatenated P2X2 receptors in which one or more subunits carried the 
T336C  mutation.  Mutation  of  an  amino  acid  to  cysteine  residue  renders  the  subunit 
susceptible to block by MTSET. Introduction of mutant subunits in a concatemeric construct 
lead to a progressive increase in the channel block by MTSET as long as the mutant subunit 
remains in the position in the construct where it can line the wall of the pore. Their results 
showed that a maximum of three subunits constituted the structural basis for the P2X2 gate 
which contributes equally to the formation of the receptor’s gate. Together with these studies, Discussion 
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our data lead to the conclusion that the gating process in P2X receptors is an additive outcome 
to  which  each  receptor  subunit  contributes  individually  i.e.  the  contribution  of  a  subunit 
bound by a partial agonist would be less as compared to the subunit bound by a full agonist 
and the overall gating would be determined by the additive outcome of all receptor subunits 
occupied by the type of ligand. Therefore, when one or two subunits in the functional P2X 
receptors were knocked out (either by cross-linking a partial agonist or by incorporating a 
non-functional subunit e.g. T18A) the maximal response from the receptor was decreased.  
To further dissect the contribution of unoccupied binding sites towards the gating process on 
the partially liganded receptors, the challenge was to first determine the number of covalently 
attached BzATP molecules per receptor. On P2X2 receptors, the use of BzATP as a cross-
linking agent lead to the selective knock-out of functional receptors i.e. maximal response of 
the receptors after covalent cross-linking was significantly reduced. Due to this limitation, 
number of covalently attached BzATP molecules per receptor could not be determined. Thus, 
a receptor was required which not only maintains the non-desensitizing phenotype but also 
retains the functional activity after the covalent attachment of BzATP. To this end, the use of 
a P2X2/P2X1 receptor chimera was tested. 
The chimera consisted of a portion of P2X2 (N-terminal and TM1 domain) and a portion of 
P2X1 receptors (full extracellular loop, TM2 and C-terminal domain). The chimera represents 
a valid model of P2X1 receptors because it preserves the ligand binding domain of the P2X1 
receptors [88]. In contrary to P2X1 receptors which have an EC50 value close to 1µM for 
receptor  activation,  the  chimera  has  nanomolar  potency  for  various  agonists  [88].  It  is 
assumed that the µM potency of agonists on P2X1 receptors accounts to non steady-state 
measurements because virtually all activated P2X1 receptors close rapidly by desensitization 
and  not  by  direct  transition  to  the  re-activable  closed  state.  Whereas,  by  elimination  of 
desensitization (the use of chimera), stationary currents become amenable to analysis that 
allows for a determination of an EC50 value under steady-state conditions [88,104].  
On the chimera, BzATP is a full agonist when compared to ATP (Fig. 3.5). Covalent cross-
linking of BzATP in the binding sites leads to persistent activation of the chimera. Due to the 
fact that once BzATP is cross-linked it cannot be dissociated from the binding sites, therefore, 
we speculate that persistent current originated from the fully liganded receptors in which all 
the binding sites were covalently attached by BzATP. Dose response curves for ATP on the 
P2X receptors in sensory neurons have a Hill coefficient close to three suggesting that three 
agonist molecules are needed to bind to the receptor to produce efficient channel activation Discussion 
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[169]. Therefore, it was  assumed that binding  of  three  agonist  molecules  per  receptor is 
required for the gating of the receptor and the persistent current after photolabeling on the 
chimera resulted from the receptors in which three BzATP were cross-linked in the binding 
sites. To specifically determine the level of persistent current through the permanently open 
chimera channels, Neomycin was applied externally as an open channel blocker. Neomycin 
(an aminoglycoside) has been shown to induce concentration and voltage dependent block
 in a 
variety  of  Ryanodine  [170]  and  P2X  receptors  [153].  Also,  on  the  chimera,  external 
application  of  3mM  Neomycin  showed  a  partial  block  of  cationic  current  through  open 
channels (unpublished results, Eva Bongartz).  
The time course of photolabeling (until all the binding sites in a given pool of receptors were 
cross-linked  by  BzATP)  was  also  determined.  The  progressive  photolabeling  of  P2X1 
receptors resulted in persistent desensitization (Fig. 3.2), on P2X2 receptors it resulted in 
selective knocking out of receptors (Fig. 3.4) and on the chimera it resulted in permanently 
active channels (Fig. 3.6). Our results are in agreement with similar studies done on P2X 
receptors demonstrating that P2X1 receptors undergo persistent desensitization after covalent 
cross-linking of agonists in the binding sites [118] and that incorporation of one or more non-
functional  subunits  leads  to  the  decrease  in  the  maximal  response  of  the  P2X  receptors 
[33,168]. After prolonged photolabeling, both P2X1 and the chimera showed different levels 
of apparent steady state photolabeling (~50% in P2X1 and ~80% in chimera) (Fig. 3.2 and 
3.6).  As  P2X  receptors  undergo  constant  receptor  trafficking  and  agonist  mediated 
internalization [105], such  processes  could be  responsible  for  the  incomplete  steady  state 
levels of photolabeling even after prolonged times. 
 
Modulation of potency and efficacy of agonists after photolabeling 
Modulation  of  agonist  generated  responses  from  the  photolabeled  chimera  receptors  was 
determined on the same oocyte by comparing the dose response curves for agonists (partial 
and  full  agonist)  before  and  after  photolabeling.  Upon  washout  of  ATP  or  BzATP,  the 
chimera deactivates slowly with a time constant (τ) of 63 ± 2s or 23.8 ± 0.5s, respectively 
[88]. Due to the slow dissociation of these agonists from the chimera, αβ-MetATP (another 
full agonist of chimera) was used, as the chimera deactivates after αβ-MetATP washout with a 
faster time constant (τ) of 2.5 ± 0.3s [88]. Thus, the use of αβ-MetATP permitted us to Discussion 
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generate complete dose response curves before and after photolabeling on the same oocyte 
expressing the chimera. 
Progressive photolabeling lead to a leftward shift in the dose response curve with progressive 
decrease in the EC50 value and Hill coefficient for αβ-MetATP when compared to the dose-
response curve prior to photolabeling (Fig. 3.8 and Table 3.3). A leftward shift in the dose- 
response curve would indicate an increase in the potency of the agonist. Similarly, Karpen et 
al. [110] found that the potency of a full agonist (cGMP) increased after photolabeling the rod 
channels with another full agonist. Hill coefficients gives lower estimate of number of ligands 
required to open the receptors. Agonist dose-response curves of P2X receptors often have Hill 
coefficient of more than one for different agonists [88,171], which seems to be reasonable 
since the channels are composed of three subunits [49]. Before photolabeling, when all the 
binding sites were available for αβ-MetATP to bind and produce functional response, the 
dose-response curve for αβ-MetATP  at  the  chimera  has  a  Hill  coefficient  of  1.6.  During 
progressive photolabeling, the number of covalently attached BzATP molecules per receptor 
would  increase  by  correspondingly  decreasing  the  number of  free  binding  sites  until  the 
receptor  would  need  binding  of  a  single  agonist  molecule  to  be  opened.  Under  these 
conditions, properties of such a receptor would be similar to a receptor with only one agonist 
binding site. The agonist dose-response curve of a receptor with a single agonist binding site 
would  have  a  Hill coefficient  of  one.  Accordingly, we  have  observed a  decrease  in  Hill 
coefficient of αβ-MetATP from 1.6 to ~1 during progressive photolabeling.  
These results also support our earlier interpretation that the process of gating in P2X receptors 
is an additive outcome to which each subunit of the receptor contributes individually. The 
contribution of each subunit liganded by full agonists (BzATP and/or αβ-MetATP) would be 
maximal. Therefore, when one or two subunits of the receptor were permanently occupied by 
a full agonist (e.g. BzATP), sub-saturating concentrations of another full agonist (e.g. αβ-
MetATP)  became  more  potent  because  the  probability  that  these  channels  will  be  fully 
liganded  at  any  given  αβ-MetATP  concentration  would  be  higher  (Fig.  3.8).  This  also 
explains the leftward shift in the dose response curves for αβ-MetATP after photolabeling 
compared to without photolabeling.  
Recently  Cao  et  al.  [172] demonstrated that the T339S  mutant of P2X2 receptors  shows 
constitutive receptor activation in the absence of ATP. Its increased sensitivity towards gating 
unraveled  that  not  only  the  P2X2  partial  agonist  αβ-MetATP,  but  also  the  competitive 
antagonist  TNP-ATP  could  favorably  shift  the  gating  equilibrium  towards  open  state. Discussion 
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Similarly in the current study, nanomolar sensitivity of chimera for various ligands not only 
unraveled the partial agonist properties of TNP-ATP but also permitted us to measure the 
change  in  the  efficacy  of  TNP-ATP  upon  progressive  photolabeling  (Fig.  3.5  and  3.9). 
Photolabeling of BzATP did not change the apparent affinity of TNP-ATP as judged by the 
comparison of dose response curves for TNP-ATP generated before and after photolabeling 
(Fig. 3.9). However, the ratio between the response generated by saturating concentrations of 
TNP-ATP and BzATP increased progressively upon photolabeling. The progressive increase 
in  the  ratio  would  indicate  an  increase  in  the  functional  response  by  TNP-ATP  upon 
progressive photolabeling.  
Historically,  it  is  believed  that  partial  agonists  have  low  affinity  for  the  open  state  and 
therefore stabilize the closed state of the receptors [4]. However, the absence of change in the 
apparent affinity of TNP-ATP during various levels of receptor activation ruled out the role of 
different affinities to explain the change  in the  efficacy of TNP-ATP after photolabeling. 
Single  channel  measurements  of  nicotinic  receptors  by  Lape  et  al.  [173]  demonstrated  a 
remarkable similarity in full and partial agonist affinity for open and closed conformations. 
They argued that partial agonism originated from the reduced ability of a ligand to shift the 
equilibrium from resting to flip state rather than the reduced ability to open the receptor. Our 
results are in agreement with Lape et al. [173] that before photolabeling full occupancy by 
TNP-ATP  alone  imparted  less  energy  to  the  receptors,  which  resulted  in  the  negligible 
response compared to the full agonist. Apparently, the energy barrier for channel opening was 
reduced when one or two ligand-binding sites were covalently labeled by BzATP molecules 
(full agonist), thereby increasing the efficacy of TNP-ATP. Thus, the increase in efficacy of 
TNP-ATP, when at least one or two binding sites of the chimera were covalently cross-linked 
by BzATP, unequivocally accounts for the allosteric interactions between subunits.  
In order to estimate minimum number of covalently attached BzATP required to increase the 
TNP-ATP efficacy, we first determined the statistical distribution of receptors with different 
numbers of cross-linked BzATP molecules using binomial distribution. In order to fit the 
progressive  increase in  the  ratio  of  response generated  by  the  saturating  concentration  of 
TNP-ATP to the saturating concentration of BzATP some assumptions were made. We first 
assumed  that  the  binding  of  three  ligands  is  required  to  open  P2X  receptors  and  those 
receptors with only one or two labeled binding sites are essentially closed. However, in the 
absence of single channel data the existence of sub-conducting states at sub-maximal binding-
site occupancy are difficult to rule out, although, evidence from sensory neurons indicates a Discussion 
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requirement  of  three  agonist  molecules  for  efficient  channel  activation  [169]  and  single 
channel studies by Ding et al. [171] also suggested that the sub-conductance level of partially 
liganded  P2X2  receptors  is  virtually  negligible.  We  considered  that  at  the  saturating 
concentration of BzATP (1µM) for the chimera, covalent cross-linking occurs randomly and 
not with efficiency based on the binding sites’ affinity. Moreover, it is expected that at 1µM 
BzATP concentration, all the binding sites should be occupied at all time irrespective of the 
individual  binding  site  affinity.  Based  on  these  assumptions  we  explored  two  theoretical 
possibilities,  in  which  the  maximal  response  generated  by  TNP-ATP  from  the  chimera 
occurred  either  from  the population  of  receptors  in  which  at  least  one  BzATP  (One-site 
model) or two BzATP (Two-site model) molecules were cross-linked. Under the limitations 
of these assumptions, our fitting results indicate that TNP-ATP would generate maximum 
response from P2X receptors in which two BzATP were cross-linked. Thus, we can conclude 
that in P2X receptors the contribution from each subunit to the gating process is an additive 
one in which each subunit contributes equally.  
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4.2 Probing allosteric interactions between P2X receptor subunits 
using fluorescent ligand   
Agonist binding to the closed state of P2X1 receptors initiates allosteric interactions between 
subunits which result  in opening of receptors followed by desensitization. Upon washout, 
receptors recover from desensitization on a slow time scale. Kinetic studies on recovery from 
desensitization  proposed  that  dissociation  of  the  bound  agonist  is  a  prerequisite  for  the 
process of recovery from desensitization [104]. We, therefore, hypothesized that allosteric 
interactions between subunits in desensitized state contribute to the change in the affinity of 
the binding sites of receptors which facilitates dissociation of the bound agonist molecules. To 
investigate  this  possibility,  I  have  studied  the  nature  of  interactions  between  subunits 
contributing to the process of dissociation of bound agonist from the desensitized state of 
P2X1 receptors.  
To  this  end,  occupancy  state  of  P2X1  receptors  at  different  agonist  concentrations  was 
determined because allosteric interactions between subunits initiate only after agonist binding. 
Desensitized P2X1 receptors represent a ligand bound closed state and channels would not 
evoke an electrophysiological functional response, therefore, I used Alexa-ATP (a fluorescent 
analog of ATP) to equilibrate the binding sites of P2X1 receptors. At high concentrations, 
binding of Alexa-ATP activated and fully desensitized P2X1 receptors. Level of fluorescence 
from Alexa-ATP bound P2X1 receptors was used as a parameter for occupancy state of these 
receptors. In this study we also propose a simple allosteric model for subunit interactions 
which describes P2X1 receptors activation, desensitization and recovery from desensitization. 
Our proposed model is compatible with our experimentally determined and computationally 
simulated results and favors our interpretation that negative allosteric interactions between 
subunits in the fully liganded desensitized state contributes to the decrease in the affinity of 
binding sites, which facilitates dissociation of the bound agonist. Based on these evidences, 
our interpretation suggests that binding of three agonist molecules per receptor are required to 
desensitize P2X1 receptors. 
 
Optimization of conditions for studying ligand-receptor interactions 
Many fluorescent ATP analogs are now commercially available [133], but little is known 
about  their  pharmacological  properties  on  P2X  receptors.  TNP-ATP,  a  fluorescent  ATP Discussion 
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analog, is characterized as a potent antagonist of P2X receptors [163] and has been used to 
map the extra-cellular ATP binding sites in inner and outer hair cells isolated from guinea pig 
organ of corti [135]. However, none of the fluorescent ATP analogs were analyzed for agonist 
potency on P2X receptors. To the best of our knowledge, our study for the first time describes 
the agonist efficacy of Alexa-ATP (a fluorescent ATP analog) on P2X1 receptors and the 
chimera (Fig. 3.11). Complete dose response curve of Alexa-ATP could not be generated on 
P2X1  receptors owing to  the  high  cost  of  Alexa-ATP.  However,  it  was  found that 1µM 
Alexa-ATP  has less potency  on P2X1 receptors  as  compared  to 1µM  ATP (Fig.  3.11A). 
Using the  Hill equation,  we  estimated  an  EC50  value  of  ~2µM  for  Alexa-ATP  on P2X1 
receptors. Nanomolar sensitivity of the chimera for various agonists offered us an advantage 
to generate complete dose response curve for Alexa-ATP. Although, on the chimera, Alexa-
ATP showed the similar efficacy as of ATP, the dose response curve of Alexa-ATP was 
rightward shifted, indicating that Alexa-ATP has a reduced potency on the chimera (Fig. 
3.11C, D).  
Although, 300nM Alexa-ATP does not generate maximum response, it could fully desensitize 
P2X1  receptors.  Therefore,  the  level  of  fluorescence  from  the  bound  Alexa-ATP  in  the 
desensitized state of P2X1 receptors could be used as a parameter for the occupancy state of 
the receptors. Of note, being a fluorescent probe, Alexa-ATP is susceptible to photobleaching. 
Because of this limitation, the dissociation of bound Alexa-ATP from the P2X1 receptors 
could not be monitored in continuous light. So, we optimized a  light irradiation protocol 
which allowed us to do fluorescence studies (association and dissociation of Alexa-ATP) with 
minimal photobleaching. We found that the time course of decay of Alexa-ATP fluorescence, 
when light was irradiated for 2s every 30s gave optimum result which was not different than 
light irradiated for every 40s. However, even under these conditions when the exposure of 
light to Alexa-ATP was severely reduced and after extensive washout, complete decay of 
Alexa-ATP  fluorescence was not observed from the P2X1 receptors (Fig. 3.12C, 3.13A). 
Likewise, in ligand association experiments, when Alexa-ATP was allowed to equilibrate the 
binding sites of P2X1 receptors, steady-state binding was not observed (Fig. 3.13B).  
P2X1 receptors are known to undergo agonist mediated receptor internalization [107] and  
therefore,  we  speculated  that  the  origin  of  the  bi-exponential  time  course of  Alexa-ATP 
fluorescence during association and dissociation experiments on the P2X1 receptors might be 
due  to  the  trafficking  of  receptors  on  the  membrane  (internalization  and  recycling  of 
internalized receptors back to the membrane). We therefore hypothesized that the fast time Discussion 
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constant in the time course of decay of Alexa-ATP fluorescence on the non-PAO treated 
oocytes is possibly contributed by two processes: dissociation of bound Alexa-ATP from the 
surface receptors and agonist mediated internalization of P2X1 receptors. Whereas, the slow 
time constant possibly was contributed by the slow trafficking of Alexa-ATP bound P2X1 
receptors back to the membrane. Similarly, the fast and slow time constants in the time course 
of association of Alexa-ATP fluorescence on the non-PAO treated oocytes is thought to be 
contributed  by  the  agonist  mediated  internalization  of  P2X1  receptors  and  slow 
recycling/trafficking of P2X1 receptors to the membrane. Due to this, the density of P2X1 
receptors (number of binding sites) constantly changes on the membrane which resulted in the 
lack of saturation during Alexa-ATP binding.  
To test these possibilities, phenyl arsine oxide (PAO) was used which is reported to inhibit 
internalization  of  surface  receptors  expressed  in  oocytes  [162]  and  receptor  mediated 
endocytosis of protein nexin [174], EGF [175] and insulin [176]. When the association and 
dissociation kinetics of Alexa-ATP was performed on PAO treated oocytes expressing P2X1 
receptors, not only complete decay of Alexa-ATP fluorescence (dissociation experiments) 
was seen but also steady-state binding of Alexa-ATP fluorescence (association experiments) 
was achieved (Fig. 3.13A, B). Taken together, these results confirmed that P2X1 receptors 
also undergo constant receptor trafficking and agonist mediated receptor internalization under 
our experimental conditions. Although, precise mechanism of PAO mediated block of P2X1 
receptors internalization is unknown, earlier studies point towards the involvement of vicinal 
sulfhydryl groups in the inhibitory action of PAO on receptor mediated endocytosis [177]. 
The trivalent arsenicals form stable ring like structures with molecules having appropriately 
spaced vicinal sulfhydryl groups (such as those in lipoic acid) present on the surface of oocyte 
membrane. The equilibrium of such reactions  strongly  favor the complex formation, thus 
imparting rigidity to the membrane, which is thought to inhibit receptor trafficking.  
 
Allosteric interactions between subunits depends on occupancy level of receptors 
Ligand  competition  studies  on  muscarinic  receptors  [178],  P2X7  and  P2X4  receptors 
[179,180] have shown that allosteric regulators could affect the rate of dissociation of bound 
radioligand from these receptors. Therefore, it is quite possible that in the desensitized state of 
P2X1 receptors, subunit interactions could contribute to the process of ligand dissociation 
which is a prerequisite of receptor’s recovery from desensitization. In the present study, to Discussion 
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investigate the  nature of  subunit  interactions  in the desensitized state of P2X1 receptors, 
dissociation  of  bound  Alexa-ATP  from  the  desensitized  state  of  P2X1  receptors  was 
monitored in the presence of various allosteric/competing ligands (divalent cations, agonist 
and antagonists).  
P2X receptors can be allosterically regulated by extracellular protons [52], divalent cations 
and various other ions [54,55]. Therefore we have also tested the dissociation of bound Alexa-
ATP  from  desensitized  P2X1  receptors  in  the  presence  of  various  cations,  agonists  and 
antagonists. Dissociation of bound Alexa-ATP in 2mM Mg
+2 (as MgORI buffer) was used as 
a  control  experiment.  The  dissociation  of  bound  Alexa-ATP  in  MgORI  buffer  could  be 
described  with  a  mono-exponential  function  (Fig.  3.14A),  indicating  that  dissociation 
occurred from a single population of desensitized receptors. In contrast to Mg
+2 ions, presence 
of  2mM  Ca
+2  (as  CaORI  buffer),  significantly  decreased  the  decay  of  Alexa-ATP 
fluorescence  from  the  desensitized  P2X1  receptors,  which  is  an  indicator  of  positive 
cooperative interactions between subunits. It is important to note that extracellular Ca
+2 ions 
have been shown to produce different effects on desensitizing P2X receptors. Cook et al. 
[164] showed that extracellular Ca
+2 ions could enhance the recovery of P2X3 receptors from 
the desensitized state, while Evans et al. [77] and Haines et al. [101] found no effect of 
extracellular Ca
+2 ions on the recovery of P2X1 receptors from desensitization. However, 
Michel  et  al.  [181]  found  that  P2X1  receptors  possess  high  affinity  for  αβ-MetATP  (an 
agonist of P2X1 receptors) in the presence of 4mM Ca
+2 ions compared to the absence of Ca
+2 
ions, further emphasizing an unknown regulatory role of  Ca
+2 ions. Therefore, the precise 
effect  of  Ca
+2  ions  on  the  desensitized  state  of  P2X1  receptors  is  at  present  debatable, 
although our experiments indicate positive cooperative interactions between subunits in the 
presence of Ca
+2 ions.  
Thus,  it  is  plausible  that  presence  of  extracellular  Ca
+2  ions  increases  the  affinity  of 
desensitized state of P2X1 receptors for the bound ligand (in this case Alexa-ATP), which is 
measured as decreased dissociation of bound Alexa-ATP from the desensitized state. If this is 
true, then the presence of extracellular Ca
+2 ions should also reduce the recovery of P2X1 
receptors from desensitization. Our functional experiments on the P2X1 receptors confirmed 
that the presence of extracellular Ca
+2 ions indeed significantly reduced the recovery of P2X1 
receptors from desensitization as compared to the control experiments (i.e. in the presence of 
MgORI buffer) (Fig. 3.15). Thus, these functional results complement our fluorescence data 
that  in  the  presence  of  extracellular  Ca
+2  ions,  positive  cooperative  interactions  between Discussion 
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subunits contribute to the increase in the affinity of desensitized P2X1 receptors to the bound 
agonist,  which  results  in  the  reduced  dissociation  of  bound  agonist,  thus,  reducing  the 
recovery of receptors from desensitization. 
On the other hand, increase in the dissociation of labeled compound by excess of unlabeled 
compound  from  orthosteric  or  allosteric  binding  sites  has  been  used  as  an  indicator  of 
negative cooperative interactions between subunits of the receptors (negative cooperativity 
model) e.g. insulin from insulin receptors [182], thyroid hormone from thyrotropin receptors 
[183], EGF receptor system [184] and P2X7 [179]. The dependence of dissociation of the 
labeled compound was also correlated to the structure of competing ligand and competition of 
ligands  for  individual  attachment  points  on  the  binding  sites  of  the  receptor  (multipoint 
attachment  model)  e.g.  (+)-cis-Diltiazem  from  L-type  Ca
+2  channels  [185].  When  we 
monitored the dissociation of bound Alexa-ATP in the presence of high concentrations of 
ATP (EC50 or more), TNP-ATP or NF449 (ICmax), accelerated dissociation of bound Alexa-
ATP was observed (Fig. 3.14B-D). The dissociation of Alexa-ATP from P2X1 receptors was 
found to be independent of the structure of the competing ligands, at least when these ligands 
were  present  in  high  concentrations,  thus,  suggesting  negative  cooperative  interactions 
between subunits.  
However, 3nM ATP which is sufficient to desensitize ~50% of P2X1 receptors [104] and 
6nM TNP-ATP (concentration at which ~50% inhibition of P2X1 current occurs), showed 
similar time course of decay of Alexa-ATP fluorescence as observed in MgORI buffer (Fig. 
3.14B-C). It has been shown earlier that the rate of entry of P2X1 receptors to the desensitized 
state at 3nM ATP concentration was slow (τ = 6.5 min) [104], probably due to the slow rate 
of binding of ATP to the P2X1 receptors. Therefore, we think that due to lack of substantial 
binding of competing ligands (ATP and TNP-ATP) at these nanomolar concentrations in our 
experimental conditions, dissociation of bound Alexa-ATP occurred without the influence of 
these competing ligands, hence, the time course of fluorescence decay was similar to the 
decay monitored in MgORI buffer (control conditions). 
Interestingly, the dissociation of Alexa-ATP at IC50 concentration of NF449 was also found to 
be decreased (similar to Ca
+2 ions) (Fig. 3.14D), suggesting that in the presence of 0.3nM 
NF449, affinity of the binding sites of P2X1 receptors also increases which is reflected in the 
form of decreased dissociation of bound Alexa-ATP from the desensitized P2X1 receptors. 
Decreased dissociation of Alexa-ATP also suggests positive cooperative interactions between 
subunits. When the effect of 0.3nM NF449 (IC50 concentration) was functionally analyzed, it Discussion 
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was found that NF449 being a competitive antagonist for P2X1 receptors resulted in 50% 
inhibition of ATP generated functional responses. This contradicts our fluorescence data that 
being a competitive antagonist, it would compete for the agonist binding site. Therefore, in 
the presence of 0.3nM NF449 we should either observe an increase in the dissociation of 
bound  Alexa-ATP  from  the  desensitized  P2X1  receptors  due  to  negative  cooperative 
interactions  between  subunits  (i.e.  when  both  Alexa-ATP  and  NF449  would  occupy  the 
agonist binding sites), or we should observe similar time course of decay of Alexa-ATP as 
that of in MgORI buffer due to slow rate of binding of NF449 to the binding sites at 0.3nM 
concentration. Instead, we have observed decreased decay of Alexa-ATP fluorescence in the 
presence of 0.3nM NF449. To this end, we speculate that the dissociation of Alexa-ATP 
indeed  started  from  the  fully  liganded  receptors  (three  bound  Alexa-ATP).  When  the 
dissociation  of  bound  Alexa-ATP  was  monitored  in  the  presence  of  0.3nM  NF449, 
dissociation of one of the three bound Alexa-ATP would occur due to negative cooperativity 
even before the binding of NF449 (as it is expected that at 0.3nM concentration binding of 
NF449 would be slow). Due to its huge structure, binding of NF449 to the partially liganded 
(one  or two Alexa-ATP bound receptors) P2X1  receptors could induce  constrains  on the 
dissociation  of  remaining  Alexa-ATP  from  the  receptors,  thus,  reducing  the  rate  of 
dissociation  of  bound  Alexa-ATP.  The  reduced  response  of  ATP  in  the  functional 
experiments, in which P2X1 receptors were washed in presence of 0.3nM NF449, suggest an 
example of mode of action of a classical competitive antagonist i.e. at 0.3nM concentration, 
50% of the binding sites of P2X1 would be occupied by NF449, thus, reducing the ATP 
generated responses to 50% (Fig. 3.15A). Based on above speculations, we suggest that the 
effect of 0.3nM NF449 on the dissociation of bound Alexa-ATP is due to its steric hindrance 
on the dissociation of bound Alexa-ATP rather than due to positive cooperative interactions 
between subunits or due to change in the affinity of the binding sites of the P2X1 receptors.  
Together, these results indicate that at high concentrations of competing ligands (when the 
probability  of  finding  fully  liganded  receptors  would  be  high),  negative  cooperative 
interactions  between  subunits  occurs.  However,  in  the  presence  of  allosteric/competing 
ligands (calcium ions or NF449 at IC50 concentration), decreased dissociation of Alexa-ATP 
occurs, possibly suggesting positive cooperative interactions between subunits in the presence 
calcium  ions  and  the  possible  role  of  steric  hindrance  caused  by  NF449  on  the  slow 
dissociation of bound Alexa-ATP. Thus, based on our experiments we conclude that presence Discussion 
  115
of allosteric/competing ligands regulates the dissociation of bound ligands through allosteric 
interactions between subunits. 
 
Allosteric model for ligand-receptor interactions 
Several  models  have  been  proposed  in  the  literature  to  understand  the  activation  and 
desensitization  mechanism  of  P2X  receptors.  Bean  [169]  proposed  a  linear  model  with 
independent subunits to understand the channel activation, based on the kinetics seen in the 
bullfrog sensory neurons. However this model cannot be used to interpret our results as it 
does not account for the accelerated dissociation of bound Alexa-ATP in our experiments. 
Ding  et  al.  [171]  proposed  a  kinetic  model  based  on  single  channel  analysis  on  P2X2 
receptors.  Although  their  model  took  subunit  interactions  during  receptor  activation  into 
consideration, their model also cannot be used to describe the desensitized state of P2X1 
receptors, since it was developed for the non-desensitizing P2X2 receptors.  
Recently,  Rettinger  et  al.  [104],  proposed  a  simple  kinetic  model  for  P2X1  receptors 
activation  and  recovery  from  desensitization  based on  functional  studies.  Their  model is, 
however, silent on the behavior of subunit interactions. Therefore, we extended the model 
proposed by Rettinger et al. [104] and incorporated kinetic steps to adequately explain the 
negative  cooperative  interactions  between  subunits  (Fig.  3.16,  3.19).  In  this  model,  we 
hypothesized that binding of three agonist molecules to the closed state of receptor would be 
required to open and desensitize P2X1 receptors, since the channels are composed of three 
subunits [49]. Dissociation of bound agonist molecules from the fully liganded desensitized 
state of the receptors in the presence of ligand free buffer would bring the receptors back in 
non-liganded closed state. Our model also predicts the possibility of partially liganded states 
of the receptors in Scheme-I and II (Fig. 3.16). Partially liganded receptors in Scheme-I would 
be non-desensitized and in the Scheme-II would be desensitized (Fig. 3.16). In this model, we 
further hypothesized that the negative cooperativity will exist only in the fully liganded state 
of the receptors (three ligand bound state) and under the influence of negative cooperativity 
(i.e. in presence of high concentrations of ligand) the dissociation of all the bound ligands 
would be fast and occur with same rate.  
Based on this model, we expect that the dissociation of all the bound Alexa-ATP molecules 
would  occur  under  the  influence  of  negative  cooperativity  in  the  presence  of  high 
concentration of competing  ligands (τ = ~500s)  (Table 3.9), as  receptors would be  fully Discussion 
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liganded at any given point of time. Due to this, the time course of decay of Alexa-ATP 
fluorescence is expected to be fast and mono-exponential, as the dissociation of each ligand 
would occur  with  same  rate.  Whereas,  in  the absence  of  a  competing  ligand  (i.e.  in the 
presence of MgORI buffer), dissociation of the first Alexa-ATP would be fast (as it would 
occur from a fully liganded state) but remaining two bound Alexa-ATP molecules would 
dissociate slowly (as it would occur without the influence of negative cooperativity), and thus 
is  expected  to  be biphasic  in  nature  (Table  3.9).  Interestingly,  the  dissociation  of  bound 
Alexa-ATP  in both the conditions (presence and absence of competing ligands) could be 
described by mono-exponential function in our experiments (Fig. 3.14). Nevertheless, when 
the dissociation of bound Alexa-ATP from the fully liganded desensitized state (Scheme-II in 
Fig. 3.16) was simulated on Gepasi 3.0 software [186,187] for both these conditions (presence 
and  absence  of  a  competing  ligand)  using  manually  adjusted  rate  constants  under  the 
framework of our hypotheses, the simulated dissociation could also be described by mono-
exponential function (Fig. 3.18, Table 3.10). Therefore, we think that as the binding rate 
between the first two ligands and the last ligand is not much different (i.e. only factor of two) 
and also because of the experimental limitations (i.e. due to the time required to wash non-
specifically bound Alexa-ATP and Alexa-ATP from the solution, it is difficult to resolve first 
tens of seconds), both simulated and experimentally determined time course of dissociation of 
bound  Alexa-ATP  from  the  P2X1  receptors  could  be  described  by  mono-exponential 
function.  
It  is also  interesting  to note  that  our proposed model predicts the possibility of partially 
liganded closed states of the receptors both in Scheme-I and II. The only difference between 
partially liganded states in Scheme-I and II is that these states in Scheme-I could be further 
activated by application of high concentrations of ATP, therefore, they represent partially 
liganded non-desensitized closed states, whereas, the states in Scheme-II would not produce 
current response upon application of high concentrations of ATP, therefore, they represent 
partially  liganded desensitized  closed  states.  However,  in  terms  of  occupancy  level,  both 
Scheme-I and II states can be partially liganded (i.e. one or two liganded states). We then 
asked  if  partially  liganded  non-desensitized  states  (Scheme-I)  could  also  influence  the 
dissociation of bound Alexa-ATP. To this end, occupancy states of Alexa-ATP at different 
nanomolar concentrations were determined using binding curve and were then correlated with 
the functional states of the receptors. After this correlation, the dissociation of Alexa-ATP Discussion 
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from  the  partially  liganded  receptors  (at  low  nanomolar  Alexa-ATP  concentrations)  was 
determined in the presence of MgORI buffer. 
At low nanomolar concentrations, it is expected that receptors would be partially liganded. 
Direct binding of Alexa-ATP to P2X1 receptors lead to an increase in the fluorescence until 
steady-state level is reached (Fig. 3.20). Half maximal binding (BC50) of Alexa-ATP (i.e. 50% 
occupancy of binding sites) was found to be at ~2nM. However, the level of desensitization in 
P2X1  receptors  at  ~2nM  of  Alexa-ATP  (i.e.  50%  occupancy  of  binding  sites)  remains 
speculative. In a  similar  study, Rettinger  et  al.  [104]  found that 50%  of  P2X1 receptors 
desensitize at 3nM ATP concentration, although occupancy at 3nM ATP was not determined 
in their study.  
Therefore, we tested three possibilities: binding of three agonist molecules per receptor is 
required to desensitize P2X1 receptors (Three-site model), binding of two agonist molecules 
per receptor is required to desensitize P2X1 receptors (Two-site model) or binding of one 
agonist molecule per receptor is required to desensitize P2X1 receptors (One-site model). It 
has been shown earlier in the single channel studies on P2X2 receptors that the channels do 
not open for a significant fraction of time in partially liganded states [171], therefore, for our 
different models we assumed that the fractional population of receptors in partially liganded 
states would primarily be expected to be in non-desensitized states (i.e. for each model in 
partially  liganded  states,  there  is  one  molecule  less  than  that  required  to  desensitize  the 
receptor in that model). If we assume that the binding of Alexa-ATP to P2X1 receptors is a 
random event with only two outcomes i.e. either the receptor is labeled or not labeled, then 
the statistical distribution of population of receptors at the steady-state binding of Alexa-ATP 
would be given by their binomial distribution. However, it is important to note that P2X1 
receptor subunits are interacting in a cooperative manner, but as the binding rate between the 
first two ligands and the last  ligand is  not much different (i.e. only a factor of two), the 
influence of cooperativity can  be  neglected  for ligand binding  events  in  order  to use  the 
binomial equation. Fractional distribution of population with 0, 1, 2 and 3 Alexa-ATP bound 
receptors was then calculated from binomial distribution for each Alexa-ATP concentration 
from the binding curve (Fig. 3.20D). Taken into consideration that P2X1 receptors need to 
open before they undergo desensitization [104], the fractional population of closed receptors 
based on these three proposed models (One, Two or Three-site model) were plotted against 
different Alexa-ATP concentrations and compared with the functional response generated by 
30µM ATP on the P2X1 receptors pre-equilibrated with different Alexa-ATP concentrations Discussion 
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(Fig. 3.22). After fitting all the curves with Hill equation, we found that the half maximal 
distribution  of  closed-states  for  Three-site  model  was  seen  at  8.6  ±  0.9  nM  Alexa-ATP 
concentration and half maximal desensitization (DC50) for steady-state desensitization curve 
was found to be 9.0 ± 0.5 nM Alexa-ATP concentration. This comparison between fractional 
population of closed-states (based on our models) and steady-state desensitization curve for 
ATP  indicates  that  the  Three-site  model  describes  best  the  behavior  of  the  functional 
desensitization curve. Therefore we suggests that at BC50 Alexa-ATP concentration (1.8nM) 
(Fig. 3.21, black trace), majority of receptors would be in partially liganded non-desensitized 
state (Scheme-I), whereas at DC50 Alexa-ATP concentration (9nM) (Fig. 3.21, blue trace), 
majority of receptors would be in partially liganded desensitized state (Scheme-II). When the 
dissociation of Alexa-ATP from the P2X1 receptors pre-equilibrated with 3nM, 30nM and 
300nM Alexa-ATP was monitored in the presence of MgORI buffer (Fig. 3.20F), different 
rates of dissociation of Alexa-ATP was observed indicating that not only the full occupancy 
of the receptors (negative cooperativity) but also the partial occupancy of functional state of 
the receptors regulates the allosteric interactions between subunits and therefore can influence 
the dissociation of the bound agonist.  
To conclude, the use of Alexa-ATP, a fluorescent analog of ATP allowed us to distinguish 
between  various  functional  states  of  P2X1  receptors.  We  successfully  demonstrated  the 
existence  of  negative  cooperative  contributions  between  P2X1  receptor  subunits  which 
controls  the  dissociation  of  bound  agonist  molecules.  Our  proposed  model  is  highly 
compatible with our experimental results and can possibly be used to describe similar events 
even in some related ligand gated receptors. Based on these evidences, we estimated that 
binding of three agonist molecules per receptor is required to desensitize the P2X1 receptors.  
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4.3 Probing structural rearrangements in P2X receptors during 
ligand-receptor interactions 
Various mutagenesis and chemical labeling studies have been performed on P2X receptors to 
probe the domains involved in ligand binding. These studies have so far been confined to 
identify  the  key  residues  which  form  the  part  of  ligand  binding  pockets  [37,41,42,188], 
transmembrane domains [189,190] and the channel pore [57]. However, the events that lead 
to channel opening after ATP binding remain unanswered.  
To  enhance  our understanding  of  the  molecular  mechanisms  involved  in  P2X1  receptors 
activation and desensitization, I used engineered cysteine mutants of CRD-1 region of the 
P2X1  receptors.  The  accessibility  of  free  cysteine  was  determined  by  an  environmental 
sensitive  cysteine  reactive  fluorophore,  TMRM.  We  monitored  changes  in  the  TMRM 
fluorescence  intensity  in  the  TMRM  accessible  mutants  with  concurrent  measurement  of 
current  using  voltage  clamp  fluorometry (VCF). Changes  in  the  fluorescence  intensity  at 
different  positions  were  found  to  be  kinetically  correlated  with  receptor  activation  or 
desensitization. We speculate that the CRD-1 region of P2X1 receptors is highly dynamic and 
is an active part of the conformational wave which originates after ligand binding.  
 
Functional expression of CRD-1 mutants 
P2X  receptors  contain  ten  conserved  cysteine  residues  (designated  as  C1  to  C10)  in  the 
extracellular region  arranged in two “cysteine-rich-domains” (CRDs). Earlier studies have 
suggested a unique pattern of disulfide bridges in these regions, in which, C1 pairs with C6, 
C2 pairs with C4, C3 pairs with C5 in CRD-1 region and C7 pairs with C8, C9 pairs with C10 
in  CRD-2  region  [45,46].  Although,  P2X  receptors  show  no  sequence  homology  to  any 
known protein, they share an apparent structural homology with acid sensing ion channels 
(ASICs). Recently, high resolution structure of ASIC1 was solved [26], which revealed that 
the “thumb” domain which lies at the interface between subunits shows extensive interactions 
with the “palm” domain of the neighboring subunit. The “thumb” domain of ASIC1 which is 
a part of CRD-1 region of ASICs is structurally comparable to the CRD-1 region of P2X 
receptors. This led us to speculate that the CRD-1 region of P2X1 receptors might also lie at 
the  interface  between  subunits  and  is  therefore  likely  to  be  involved  in  subunit-subunit 
interactions. To this end, eight amino acids from A118 to I125 were individually mutated to Discussion 
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cysteine residue in P2X1 receptors in order to generate a free cysteine residue in the CRD-1 
region. Earlier findings have shown that the construction of a free cysteine residue in the 
CRD-1 region by individual deletion of these six endogenously occurring cysteine residues 
has  no  effect  on  receptor trafficking,  EC50 value and  mean  current  produced by  mutated 
receptors  as  compared  to  the  wild  type  receptors  [46].  Similarly,  we  found  that  all  the 
engineered cysteine mutants (A118C to I125C) were functionally expressed on the oocyte cell 
membrane (Fig. 3.23). Also, they (WT and CRD-1 mutants) showed similar ratio of peak 
currents generated by 10µM/3µM ATP, suggesting that they maintained similar EC50 value of 
receptor  activation  (Fig.  3.23A).  Surprisingly,  these  results  suggest  that  changes  in  the 
conserved CRD-1 region can be tolerated without compromising the receptor function.  
 
TMRM accessibility to CRD-1 mutants 
Substituted-cysteine  accessibility  method  (SCAM)  is  a  powerful  technique  that  uses  the 
specificity of sulfhydryl chemistry [191]. Cysteine residues contain sulfhydryl groups that 
react  with  a  variety  of  sulfhydryl-specific  reagents.  By  using  site  directed  mutagenesis, 
individual amino acids in the protein can be mutated to a cysteine residue. The sulfhydryl 
group of the cysteine residue in a membrane protein (e.g. ion channel) could be in one of the 
three environments: the water accessible surface, the lipid-accessible surface or in the protein 
interior. In aqueous media sulfhydryl reagents react with ionized sulfhydryl groups billion 
times faster than with un-ionized –SH groups [192]. On the other hand, if a sulfhydryl group 
is in the lipid-accessible surface or in the protein interior, it will not be reactive, because 
ionization of –SH is suppressed due to the low dielectric constant of the environment [193]. 
TMRM is a cysteine reactive fluorophore and its fluorescence intensity depends on its local 
environment. Its fluorescence increases when there is an increase in the hydrophobicity in its 
close vicinity. The maleimide moiety in the TMRM spontaneously forms a covalent bond 
with a free cysteine; therefore it can be used to specifically label any accessible engineered or 
endogenous cysteine residue(s) in the protein of interest. Any change in the fluorescence of 
the attached TMRM will be associated with the local change in the environment around that 
residue. Due to this advantage, TMRM has been successfully used in the past to sense the 
conformational changes associated with the structural rearrangements in various ion channels 
[140,143,145,165] and ion pumps [144]. For CRD-1 mutants we found that TMRM was only 
accessible to six positions from N120C to I125C. The other two engineered cysteine residues 
(A118C and E119C) showed no TMRM labeling (Fig. 3.23C) which suggests that residues Discussion 
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A118 and E119 are probably deeply embedded in the structure of P2X1 and are therefore not 
available for spontaneous TMRM labeling. 
 
Agonist and antagonist binding induces structural rearrangements in the CRD-1 region of 
P2X1 receptors 
Concurrent measurement of current and change in the fluorescence intensity of the attached 
fluorophore to the engineered cysteine residues in nicotinic acetylcholine [143] and glycine 
receptors [145] showed that two different agonists could induce distinct protein movements 
during activation. It is an interesting observation as it suggests that although the end result of 
agonist binding to the receptor is activation of the receptor, but activation can be achieved by 
different transitions in the receptor itself. Thus, VCF could give an unprecedented resolution 
to  study  ligand-receptor  interactions  in  real  time  which  is  otherwise  not  possible  using 
conventional electrophysiology or fluorescence methods alone. It has been shown that similar 
to Cys-loop receptors, the agonist binding site in P2X receptors is formed at the interface 
between  subunits  [42].  It  is  therefore  likely  that  allosteric  interactions  between  subunits, 
originated after binding of agonist, are translated to the pore region of the receptors which 
finally leads to the process of gating. However, competitive antagonists like NF279, NF449 
[94],  also  compete  for  the  same  binding  site  as  that  of  an  agonist,  but  the  allosteric 
interactions between subunits originated after binding of an antagonist are not translated into 
the process of gating. Therefore, to detect agonist and antagonist mediated transitions in P2X1 
receptors,  we used  VCF.  Of  note,  the  expression  level  of  the  cysteine mutants  has been 
suggested as a limiting factor in observing any change in the fluorescence in VCF [165]. We 
have  also  observed that a  high  level  of  expression  (>2µA) of these  CRD-1  mutants  was 
needed  to  observe  any  change  in  the  intensity  of  TMRM  fluorescence  during  structural 
rearrangements in the receptor. Therefore all our data is recorded from the cells expressing 
>2µA of current which avoided any ambiguities arising from lower expression.   
In our allosteric model of ligand-receptor interactions (Fig. 3.16), we proposed that binding of 
three agonist molecules leads to opening and then desensitization of P2X1 receptors. When 
change in the fluorescence intensity of the attached TMRM was monitored after binding of 
ATP to the receptors, we detected some of the several transitions induced by agonist in five 
mutants  (N120C,  P121C,  E122C,  G123  and  I125C) of  the  P2X1  receptors  (Fig.  3.23D). 
Interestingly, during these conformational rearrangements, three mutants (N120C, G123C and Discussion 
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I125C) showed decrease in the TMRM intensity, while, the other two mutants (P121C and 
E122C) showed an increase in the fluorescence (Fig. 3.23D and 3.24). These results suggest 
that there are some structural rearrangements occurring in the receptors after agonist binding, 
where,  different  residues  move  independently  and  therefore  are  exposed  to  different 
environments leading to an increase or decrease in the intensity of TMRM attached to them. 
However, it is not possible to comment on different conditions responsible for such changes 
in TMRM fluorescence i.e. if change in the fluorescence intensity is occurring due to the 
physical movement of the particular residue of interest in different environments or if change 
in  fluorescence  is  due  to  the  movement  of  some  quenching  groups  (portion  of  protein) 
towards or away from the fluorophores.  
Nevertheless,  the  kinetics  of  fluorescence  change  could  be  used  to  extract  valuable 
information about different states of the receptor e.g. kinetics of change in the fluorescence 
correlated with the desensitization phase in acetylcholine receptors [143], kinetics of change 
in the fluorescence correlated with the displacement of gating charges in shaker K
+ channel 
[128]. Similarly, we correlated the kinetics of change in the TMRM fluorescence (∆F) during 
activation and desensitization in these mutant receptors with different states of the receptor 
(Fig. 3.24 and Fig. 3.25). In mutants N120C, G123C and I125C the fluorescence change was 
nearly complete when the peak current was reached and therefore was strongly correlated 
with the activation of receptors, whereas, in the mutants P121C and E122C the fluorescence 
change was still incomplete or not started when the peak current was reached and accordingly 
was strongly correlated with the onset of desensitization.  
During the recovery from desensitization when receptors were activated with 10µM ATP-γS, 
significant fractions of receptors were recovered from desensitization after 5 min washout in 
the presence of ligand free buffer (Fig. 3.26). Due to a constant drift in the fluorescence 
baseline probably due to photobleaching, it is difficult to kinetically analyze the recovery of 
fluorescence signals. However, the percent recovery of current signals after desensitization is 
correlated with the percent recovery of the fluorescence signal (Table 3.15), suggesting that 
the recovery from desensitization not only involves dissociation of bound agonist from the 
desensitized receptors, but also involves reversal of structural rearrangements back to the 
closed state. In the Cys-loop receptors, Chang et al.  have demonstrated agonist mediated 
changes in the fluorescence of attached fluorophore in loop A, C and E, where they concluded 
that the movements in these loops are likely to represent the closure of the agonist binding 
pocket upon agonist binding [140]. The CRD-1 region of P2X receptors also forms a loop like Discussion 
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structure, therefore, it is likely that the CRD-1 region is a part of the conformational wave 
which initiates on activation of receptors and continues until closing of the agonist binding 
pocket.  The  movements  in  the  CRD-1  mutants  are  therefore  likely  to  represent  this 
conformational wave.   
Chang et al. [140] further revealed interesting observations that even competitive antagonists 
could alone induce distinct conformational changes in the loops A and E. Thus, suggesting 
that competitive antagonists do not merely occupy the ligand binding site, but also induce 
discrete conformations by “actively” stabilizing the closed state of the channel. In the P2X1 
receptors, suramin analogs (NF279, NF449) have been shown to have competitive antagonist 
properties [94], indicating that if NF449 occupies the binding pocket, ATP cannot bind to the 
receptors.  In  the  present  study,  when  the  effect  of  NF449  was  tested  on  three  mutants 
(N120C, P121C and E122C), an increase in the fluorescence was observed in P121C and 
E122C similar to that induced by agonist binding (Fig. 3.27). It is quite surprising that binding 
of  agonists  and  antagonists produced  a  similar change in  the  fluorescence  in P121C  and 
E122C mutants. However, the kinetics of increase in fluorescence induced by NF449 was 
nearly an order of magnitude slower as compared to increase in the fluorescence intensity 
induced by ATP in these mutants (Table 3.14 and 3.16). Possibly the huge structure of NF449 
as compared to ATP (Fig. 1.4 and 1.5) is responsible for the observed slow changes in the 
fluorescence induced by NF449 as it might induce constraints in the movement of the CRD-1 
loop around the binding site.  
These results provide a stronger clue in P2X1 receptors that both agonist and antagonists 
could induce structural rearrangements. Although, our finding is unique for P2X superfamily, 
Chang et al. have also reported similar findings in Cys-loop receptors i.e. on loop C of GABA 
receptors [140], where loop C which is thought to be a key element in triggering channel 
activation responds with similar changes for both agonists and antagonists. The reason for 
apparent lack of discrimination between agonists and antagonist by these mutants in P2X1 
receptors is currently unknown. However, it is interesting to note that NF449 showed no 
detectable change in the fluorescence on N120C mutant, where ATP showed a significant 
change in the fluorescence at this position, suggesting that N120 position is possibly a part of 
agonist specific conformational change.  
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An insight into the scheme for ligand-receptor interactions in P2X1 receptors  
It is known for P2X receptors that the rate of recovery from desensitization depends on the 
agonist used to induce the desensitization [194], and dissociation of bound agonist is the 
limiting  factor  in  the  process  of  recovery  from  desensitization  [88].  Based  on  such 
observations, we have proposed a simple allosteric model of ligand-receptor interactions of 
P2X1 receptors (Fig. 3.16), that binding of three agonist molecules to the resting state would 
transform the receptors to the open and then to the desensitized states. Desensitized receptors 
transform more slowly to the resting state by dissociating the bound agonist after hundreds of 
seconds. As binding of antagonists does not induce functional response from the receptors, it 
is difficult to study antagonist-receptor interactions. Therefore, it is currently unknown if the 
binding of an antagonist would also induce a desensitized state in the P2X1 receptors by 
bypassing the open state.  
To understand the molecular mechanisms of ligand-receptor interactions at the resolution of 
amino  acid  level,  we  monitored  ligand  induced  changes  in  the  fluorescence  intensity  of 
TMRM  attached  to  various  mutants  of  CRD-1  region.  It  was  found  that  N120C  mutant 
showed  change  in  the  fluorescence  only  upon  agonist  binding  and  not  upon  antagonist 
binding (Fig. 3.24) (Table 3.13 and 3.16). On the other hand P121C and E122C mutants 
showed similar change in fluorescence upon both agonists and antagonists binding (Fig. 3.24 
and 3.27). Moreover, kinetic analysis of change in the fluorescence and current waveform 
(after agonist binding) of these mutants suggests that change in the fluorescence of N120C 
could be correlated with the onset of receptor activation and change in the fluorescence in 
P121C and E122C mutants could be correlated with the onset of desensitization. In P2X1 
receptors, desensitization can only be induced after activation of receptors [104], suggesting 
that the desensitized state of P2X1 receptors is an agonist bound closed state. Therefore, if 
mutants P121C and E122C sense the desensitization phase of P2X1 receptors after agonist 
binding and if the antagonist (NF449) also induced similar changes in these positions, then it 
is possible that binding of an antagonist could also induces desensitization in P2X1 receptors. 
Thus, we speculate that ATP (agonist) would induce desensitization in P2X1 receptors after 
opening  the  receptors,  whereas,  NF449  (antagonist)  would  induce  desensitization  by 
bypassing the open state. However, the rate of recovery from the desensitized state will be 
governed by the rate of dissociation of bound ligand either agonist or antagonist from the 
desensitized closed state. Discussion 
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To conclude, our findings demonstrate for the first time that in P2X receptors, binding of both 
agonist and antagonist could induce structural rearrangements in the CRD-1 region. Different 
positions  could  sense  different  structural  rearrangements.  Antagonists  could  also  induce 
desensitization  in  P2X1  receptors  without  opening  them.  We  strongly  believe  that  these 
results would serve as a milestone in the P2X research to understand its structure-function 
relationship.  
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5. Miscellaneous results 
5.1 Introduction 
In  1935,  Dr.  Aleksander  Jablonski  proposed  an  illustration  of  the  electronic  states  of  a 
molecule and the transitions between them. The states are arranged vertically by energy and 
grouped horizontally by spin multiplicity (2S+1, i.e. spin multiplicity denotes the number of 
possible quantum states of a system with principal quantum number S). At room temperature, 
fluorescent  molecules  are  predominantly  present  in  the  lowest  vibrational  level  of  the 
electronic ground state S0 (Fig. 5.1).  
 
 
 
 
 
 
 
 
 
 
Fig.  5.1  Excitation  and  emission  of  a  fluorophore:  (A)  Jablonski  diagram,  showing  ground  state  of 
fluorophore as S0. Upon absorbing a photon with energy (hνEX), fluorophore reaches excited state (S1*). After 
dissipating part of the energy, the molecule reaches to singlet state (S1) (ground state of the excited state). From 
S1 state,  molecule would emit photons  of lower energy (hνEM) and reach to ground state (S0). (B) Spectral 
properties of TMRM and Alexa-647 fluorophores. The gray area in the spectral diagram represents the overlap 
within  the  emission  spectra  of  TMRM  and  absorption  spectra  of  Alexa-647.  It  means,  if  two  different 
fluorophores (TMRM and Alexa-647) are in “close-proximity” (1-10nm) then the first fluorophore (TMRM) 
would  non-radiatively  transfer  energy  from  S1  state  to  the  other  fluorophore  (Alexa-647),  leading  to  the 
excitation of other fluorophore (Alexa-647). Finally the other fluorophore would emit photons of lower energy 
(hνEM). This non-radiative transfer of energy from one fluorophore to other is termed as FRET.  
 
A molecule can absorb a photon of energy (hνEX) supplied by an external source such as a 
lamp or a laser, thus creating an excited electronic singlet state (S1*). The absorption of a 
photon is achieved within about 10
-15s. The excited state exists  for a finite time (10
-12s). 
During this time, the fluorophore undergoes conformational changes and is also subjected to a Miscellaneous results 
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multitude of possible interactions with its molecular environment. These processes have two 
important consequences. First, the energy of S1* is partially dissipated,  yielding a relaxed 
singlet excited state (S1) from which the fluorescence emission originates. Second, not all the 
molecules excited initially by absorption return to ground state (S0) by fluorescence emission. 
Other processes such as collisional quenching, fluorescence resonance energy transfer (FRET) 
and inter-system crossing may also depopulate S1 [195]. From the relaxed excited state (S1), 
the molecule finally returns to ground state (S0) by emitting photon of energy hνEM. Due to 
energy  dissipation  during  excited  state  lifetime,  the  energy  of  this  photon  is  lower  and 
therefore of longer wavelength than excitation photon (hνEX). The difference in energy or 
wavelength  is  called  Stokes  shift.  The  Stokes  shift  is  fundamental  to  the  sensitivity  of 
fluorescence  technique  because  it  allows  the  emission  photons  to  be  detected  against  a 
background isolated from excitation photons. The fluorescence quantum yield is measured as 
a ratio between the number of fluorescence photons emitted from relaxed excited state (S1) to 
the number of photons absorbed during the transition from S0 to S1* (Fig. 5.1).  
 
5.2 Fluorescence resonance energy transfer (FRET)  
Electronic  excitation  energy  can  be  efficiently  transferred  non-radiatively  between  a 
fluorescent energy donor and a suitable energy acceptor over a distance as large as 10nm. In 
1948,  Förster  proposed  a  theory  for  this  dipole-dipole  energy  transfer  process  which 
postulated that the rate of energy transfer (kT) depends on the inverse sixth power of the 
distance between the donor and acceptor [196]. Later, Stryer and Haugland suggested that the 
energy transfer could be used as a spectroscopic ruler in the 1-6nm range to reveal proximity 
relationships in biological macromolecules [197]. According to Förster’s theory, the rate of 
energy transfer (kT) and the efficiency E are given by following equation: 
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The geometric variables in the above expressions are: R0, the distance at which the transfer 
efficiency is 50%; r, the distance between the centers of the donor and acceptor fluorophores; 
K
2, the orientation factor for dipole-dipole interactions. The spectroscopic variables in the 
above expressions are: J, the spectral overlap integral; n, the refractive index of the medium Miscellaneous results 
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between donor and acceptor; kF, the rate constant for fluorescence emission by the energy 
donor; and Q0, the quantum  yield of fluorescence of the energy donor in the absence of 
acceptor. Efficient transfer requires that the energy donor and acceptor must be in resonance, 
which  means  that  the  fluorescence  emission  spectrum  of  the  donor  must  overlap  the 
absorption spectrum of the acceptor, as measured by the spectral overlap integral J (cm
3 M
-1) 
in the following equation: 
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In  the  above  expression,  F(λ)  is  the  fluorescence  intensity  (a.u.)  of  the  energy  donor  at 
wavelength λ (cm), and ε(λ) is the extinction coefficient (cm
-1 M
-1) of the energy acceptor. 
The medium between energy donor and acceptor has a relatively small effect on the energy 
transfer process (n
-4) provided that it is transparent over the range of wavelengths at which the 
donor emits [198].  
From the above equations, it is clear that the rate of transfer depends on three important 
parameters: (1) the overlap of the donor emission and acceptor absorption spectra (parameter: 
J);  (2)  the  relative  orientation  of  the  donor  absorption  and  acceptor  transition  moments 
(parameter: K2, range 0 to 4); (3) the refractive index (parameter: n
-4, range ~1/3-1/5) [199]. 
 
5.3 Structural information about P2X receptors 
Mutagenesis experiments have given some insight into the structural details of P2X receptors. 
Since year 2000, many attempts have been made to determine the three-dimensional structure 
of P2X receptors. A low resolution structure of rP2X2 receptors based on electron microscopy 
of single particles indicated that P2X2 receptors would have a volume of ~1200nm
3 [73].  
However,  the  orientation  of  the  molecule  was  not  assigned.  Later  using  atomic  force 
microscopy (AFM), Barrera et al. suggested a smaller molecular volume of 490nm
3 [72]. 
Only recently, Young et al. suggested a distance of 5.6nm between the C-terminal tails of 
subunits [200] using FRET between yellow (YFP) or cyan (CFP) fluorescent protein tags at 
the C-terminal tails of P2X4 receptors. Furthermore, using single particle analysis and domain 
specific  labeling  they  determined  the  three-dimensional  structure  of  P2X4  receptors  at  a 
resolution of 21Å and its orientation with respect to the lipid bilayer. They found that P2X4 
receptors are globular torpedo like molecules with a volume of ~270nm
3. P2X4 ectodomain Miscellaneous results 
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has a compact propeller-shaped structure (Fig. 5.2). In a similar study based on single particle 
analysis  using  cryo-electron  microscopy  of  P2X2  receptors,  Mio  et  al.  have  proposed  a 
refined structure of P2X2 receptors at the resolution of 15Å [201]. Their study revealed a 
closed state of P2X2 receptors in an elongated vase-shaped structure of 202Å in height and 
160Å in major diameter (Fig. 5.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2 Three-dimensional structures of P2X receptors as revealed by cryo-electron microscopy: (A) Side 
view of human P2X4 receptors in upright position (Ectodomain at top and C-terminal tail region at bottom). 
Yellow ball like structures at the C-terminal region are the gold particles. The distance between them was found 
to be 5.6nm. MSD denotes “membrane spanning domain”. Scale bar represents 50Å. Structure of P2X4 receptors 
appears  to  be  a  shape  of  “torpedo”  [200].  (B)-(C)  Top  and  side  view  of  rat  P2X2  receptors  respectively 
determined at the resolution of 15Å. The diameter and the height of P2X2 receptors were estimated to be ~160Å 
and ~202Å respectively. Structure of P2X2 receptors appears to be a shape of “elongated vase” [201]. 
 
When compared  to acetylcholine receptors (AChR),  whose  structure  was  also determined 
using  cryo-electron  microscopy  [202],  both  AChR  and  P2X2  receptors  showed  many 
structural similarities. Both of them have tall, fin shaped extracellular walls, wider at the 
outside  and  narrower  at  the  transmembrane  regions,  forming  a  low  density  funnel  like 
structure. However, AChR was found to be 160Å in height and P2X2 receptors was found to 
be taller (202Å in height).  Miscellaneous results 
  130
P2X receptors show  no obvious sequence  similarities to known crystallized proteins; this 
reduced  the  possibilities  to  produce  homology  based  models.  However,  acid-sensing  ion 
channel subtype-1 (ASIC-1) whose structure was recently determined at 1.9Å resolution [26], 
showed striking similarities with P2X receptors i.e. trimeric subunit topology, central pore 
lined primarily by TM2 [26,203], large extracellular loop with cysteine-rich domains (CRDs). 
High resolution structure of ASIC-1 revealed that the “thumb” domain, which lies at the 
interface  between  subunits,  shows  extensive  interactions  with  the  “palm”  domain  of  the 
neighboring subunit [26]. The “thumb” domain of ASIC1, which is a part of CRD-1 region, is 
structurally  comparable to  the  CRD-1  region  of  P2X  receptors (Fig. 5.3). This  led  us  to 
speculate that the CRD-1 region of P2X1 receptors might lie at the interface between subunits 
and is therefore likely to be involved in subunit-subunit interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3 Structural representation of ASIC-1 and P2X receptors: (A) Experimentally determined membrane 
topology for ASIC-1 [26]. (B) Schematic representation of P2X receptors based on the current understanding. 
Thumb region (orange color) in ASIC-1 structure (CRD-1 domain) is structurally comparable to the CRD-1 
region of P2X receptors. In ASIC-1 thumb region, green color represents the C309 and C362. In P2X receptors it 
represents C117 and C165 (P2X1 numbering). 
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Therefore, in the following section, spatial proximity of C117 with respect to the binding 
pocket of P2X1 was determined using FRET between TMRM attached to C117 (in the mutant 
C165S) and Alexa-ATP bound to the ATP binding pocket.  
 
5.4  FRET  between  TMRM  and  Alexa-ATP  in  C165S  mutant  of  P2X1 
receptors 
Alexa-647 ATP (a fluorescent ATP analog) has agonist potency on wild type P2X1 receptors 
(Fig. 3.11). Spectral properties of TMRM and Alexa-ATP allowed their use as a FRET pair, 
in which TMRM acts as a donor fluorophore and Alexa-ATP acts as the acceptor fluorophore 
(Fig. 2.4) (Table 5.1).  
 
Table 5.1: R0 values for Alexa Fluor dyes* 
 
 
 
 
 
 
 
 
*  R0  values  in  Å represent  the  distance at  which  fluorescence  resonance energy  transfer 
(FRET) from the donor to the acceptor dye is 50% efficient. The table is reproduced from 
Molecular Probes Handbook. The emission maximum of TMRM is 580nm, thus indicating 
the R0 of 82-85nm during FRET between TMRM and Alexa-647. 
 
We used FRET signal between TMRM attached to an engineered cysteine residue and the 
Alexa-ATP  bound  to  the  binding  site  of  the  receptor,  to  map  the  spatial  location  of  the 
engineered cysteine residue with respect to the binding site. Interestingly, the CRD-1 region 
of P2X1 has six endogenous cysteine residues that form a unique pattern of disulfide bridges 
as follows: C117 (C1) pairs with C165 (C6), C126 (C2) pairs with C149 (C4) and C132 (C3) 
pairs with C159 (C5) (Fig. 1.1). Published observations from other groups suggest that the Miscellaneous results 
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individual deletion of these endogenous cysteine residues in CRD-1 region does not affect the 
functionality  of  receptors,  but  renders one  corresponding  free  accessible  cysteine  residue 
which can be specifically labeled by cysteine reactive probes [46]. In the present study, one of 
the mutant i.e. C165S (which renders the C117 residue as free cysteine), was used. As a 
preliminary experiment, spatial proximity of C117 residue to the agonist binding site was 
determined with the help of FRET between TMRM bound at C117 residue and Alexa-ATP 
bound at the binding site of the mutant (Fig. 5.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4 FRET between TMRM and Alexa-ATP: Concurrent recording  of  current and  change in  TMRM 
fluorescence  during  different  agonist  application  (A)  300nM  Alexa-ATP  applied  to  the  control  cell.  This 
represents a control experiment for the FRET filter sets used in the present study. Mere presence of Alexa-ATP 
in the solution/medium showed no change in the fluorescence signal indicating FRET filter sets of appropriate 
cutoff.  (B)  C117  mutant  activated  with  300nM  Alexa-ATP  only.  Specific  FRET  (as  decreased  TMRM 
fluorescence)  signal  suggests  that  TMRM  is  accessible  to  C117  position  and lies  in  close  proximity  to  the 
binding  site  of  P2X1  receptors.  (C)  C117  mutant  activated  with  100µM  ATP  only.  Application  of  high 
concentrations of ATP to TMRM labeled C117 showed an increase in TMRM fluorescence during receptor 
activation. Level of increased fluorescence remained constant over a long period indicating that binding of ATP Miscellaneous results 
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initiates some structural rearrangements in or around C117 position and their slow reversibility as sensed by 
TMRM  alone.  (D)  C117  mutant  activated  with  co-application  of  10µM  ATP  +  300nM  Alexa-ATP.  Only 
increase in TMRM fluorescence was observed suggesting saturation of all the binding sites with ATP, therefore 
Alexa-ATP could not bind. This also suggests that FRET between TMRM and Alexa-ATP is highly specific and 
cannot occur by the mere presence of Alexa-ATP in solution. (E) C117 mutant first activated with 10µM ATP 
followed by 300nM Alexa-ATP. This suggests that all the binding sites were first occupied by ATP. When ATP 
was washed in the presence of Alexa-ATP, a slow decrease in TMRM fluorescence was observed due to FRET, 
because of the slow dissociation of ATP and replacement of the vacant binding sites by Alexa-ATP. In all the 
above experiments, TMRM was excited by incident light and change in TMRM fluorescence (up as decrease, 
down as increase) was measured during different agonist application using FRET filter sets (Fig. 2.4). TMRM 
fluorescence is expected to decrease as a result of FRET when TMRM and Alexa-ATP are in spatial proximity 
of 1-10nm. 
 
In these experiments, TMRM treatment to control oocytes (No RNA injected) or oocytes 
expressing  C117  cysteine  mutant  was  done  by  incubating  the  oocytes  in  CaSORI  buffer 
containing 3µM TMRM for 15 min on ice in dark. The labeling was brought about by the 
ability of the maleimide moiety in TMRM to form spontaneous covalent bond with the free 
cysteine.  The  excess  dye  was  removed  by  extensive  washing  of  the  oocytes  in  dye  free 
CaSORI buffer. Labeled oocytes were then stored in dark at room temperature until beginning 
of measurements. 300nM Alexa-ATP was used to elicit concurrent current response and the 
FRET.  TMRM  was  excited  in  the  presence  of  Alexa-ATP  and  change  in  the  emitted 
fluorescence of TMRM due to transfer of energy to the Alexa-ATP was used as a parameter 
for FRET. Above results indicate that the endogenously occurring cysteine residue (C117) is 
accessible to TMRM labeling which contradicts earlier observations by Ennion et al. [46]. In 
their study they used MTSEA-biotinylation and found that positions C117 and C165 positions 
were not accessible for covalent modification. However, we speculate that the position C117 
is only  accessible to small  molecules like TMRM  for  covalent modification  which  could 
explain the difference between their and our findings. Fig. 5.4 shows that FRET between 
TMRM and Alexa-ATP is highly specific and occurs only when Alexa-ATP binds to the 
binding site and not just in the solution.  
After inducing FRET by Alexa-ATP application, the reversibility of the FRET signal was 
found to be very slow and incomplete when the C117 mutant was washed in the presence of 
ligand free buffer in order to dissociate Alexa-ATP,. It was too slow to account for receptor’s 
recovery  from  desensitization  (Fig.  5.5).  As  P2X1  receptors  undergo  agonist  mediated 
internalization (see section 3.2.2), a possible explanation for this slow reversibility could be Miscellaneous results 
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internalization of Alexa-ATP bound receptors. The decrease in TMRM fluorescence could be 
associated  with  the  FRET  between  Alexa-ATP  bound  to  the  desensitized  receptors  and 
TMRM attached to the C117 residue and (or) the quenching of TMRM fluorescence by the 
acidic environment of the endosomes (receptor bound internalized vesicles). Also, washout of 
Alexa-ATP could be hampered in the population of receptors which were internalized after 
Alexa-ATP activation. Therefore, we thought that the slow trafficking of these internalized 
receptors  back  to  the  surface  of  the  oocyte  membrane  is  responsible  for  the  slow  or 
incomplete recovery of TMRM fluorescence during ligand free washout, qualitatively similar 
to observations described in chapter 3.2 (section 3.2.2.2). In order to probe this possibility, 
FRET was measured on phenyl arsine oxide (PAO) treated oocytes. Fig. 5.5 shows the FRET 
effect and its recovery from PAO treated and non-treated oocytes expressing C117 cysteine 
mutant.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.5 FRET between TMRM bound to C117 residue and Alexa-ATP bound to the agonist  binding 
pocket of this mutant receptor: Representative traces of FRET signal and its reversibility after Alexa-ATP 
washout from (A) Non-PAO treated oocyte; (B) PAO treated oocyte. FRET was observed as a decrease in the 
fluorescence of TMRM (black) upon Alexa-ATP binding to the receptor. Decay of FRET signal after Alexa-
ATP washout (red) is slow and incomplete in non-PAO treated oocytes indicating possible internalization of 
receptors  and  their  slow  trafficking  back  to  the surface. Pretreatment  of  oocytes  with  PAO  (a  non-specific 
internalization blocker) inhibited the agonist mediated receptor internalization, which is evident as the complete 
reversibility of FRET signal upon Alexa-ATP washout. Fluorescence during Alexa-ATP washout was measured 
with the light irradiation protocol in which light was applied for 2s every 30s.  
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It is interesting to note that the recently published 15Å resolution structure of P2X2 receptors 
[201] suggests that although the diameter of P2X2 receptors is ~160Å, the major portion of 
the extracellular region of P2X subunits lies in the range of less than 100Å with respect to the 
interface between subunits where binding of agonist (Alexa-ATP) occurs. Therefore, in the 
light of the currently available P2X structure, it is highly probable that FRET would occur 
between bound Alexa-ATP and any engineered cysteine residue in the extracellular region 
accessible to TMRM. Therefore, due to this limitation further experiments related to FRET 
studies were not pursued. However, an obvious advantage of the FRET technique in P2X 
research is to use it as a tool to study association and dissociation kinetics of different ligands. 
Washing of receptors (bound with non-fluorescent ligands) in the presence of Alexa-ATP will 
lead to the dissociation of already bound ligands (agonist or antagonist molecules) and thus 
resulting in the occupancy of Alexa-ATP in the vacant binding sites, which can be observed 
as  an  increase  in  the  FRET  signal  between  TMRM  and  Alexa-ATP.  Thus,  the  rate  of 
occurrence of FRET signal can be used to assess cooperative interactions between subunits or 
rate of association or dissociation of different ligands.   
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Summary 
P2X receptors are ligand gated ion channels with ATP as their natural ligand. P2X receptors 
are non-selective cation channels, which upon activation, mediate membrane depolarization 
and  Ca
2+  influx  and  have  physiological  roles  ranging  from  fast  excitatory  synaptic 
transmission, modulation of pain-sensation, LTP to apoptosis etc. Currently seven subtypes of 
P2X  receptors  are  known  in  mammals  designated  from  P2X1  to  P2X7.  These  receptors 
express in a variety of cells/tissues which include smooth muscles, dorsal root ganglions and 
cells of immune origin. Because of their wide expression and diverse roles they may represent 
an attractive drug target. However, their potential as a drug target is limited by the lack of 
structural information available. Neither their high resolution structure is available, nor do 
they show any sequence homology with any known ATP binding proteins, and therefore, 
most of  the  structural  understanding  of  P2X receptors  comes  from  their  biochemical  and 
biophysical analysis. Based on collective evidences,  it  is proposed that P2X receptors by 
themselves constitute the third super-family of ligand gated ion channels, the other two being 
pentameric Cys-loop receptors and tetrameric ionotropic glutamate receptors. P2X receptors 
have been proposed to have trimeric subunit topology with cytoplasmic N and C terminal 
domains. Two putative transmembrane domains in P2X receptors are connected by a large 
extracellular  loop  which  incorporates  the  ATP  binding  domain.  Our  previous  work  has 
proposed that ATP binding domain is located at the interface between receptor subunits. In 
spite of the structural details available from mutagenesis studies, basic understanding about 
the  structure-function  relationship  of  these  receptors  is  still  unclear.  In  order  to  better 
understand how their structure relates to their function and the specific domains involved, I 
have asked three questions in my thesis:  
1) If P2X receptor subunits function independently or interact with each other after ATP 
(ligand) binding? 
2) If interacting, what is the nature of these interactions? 
3) Precisely, what are the molecular motions involved in these ligand-receptor interactions?  
 
To determine the behavior of individual subunits in P2X receptors, I have taken advantage of 
Xenopus laevis oocytes heterologous expression system where I expressed recombinant rat 
P2X1, P2X2 and P2X2/1 receptor chimera (referred as chimera) and activated them using 
either their natural ligand ATP or other commercially available analogs of ATP. I have used Summary 
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photo labeling or fluorescence labeling coupled to electrophysiological measurements in order 
to address the questions stated above. It was a prerequisite for my studies that the number of 
receptors remains constant, in other words concurrent labeling and current measurement from 
the same set of receptors in real time was required. I have designed a custom made oocyte 
chamber which allowed us to do concurrent photolabeling or fluorescence labeling along with 
the electrophysiological measurements.  
Photolabeling causes the irreversible binding of the ligand to the ligand binding site of P2X 
receptors  which  overcomes  the  limitation  of  ligand  unbinding  events.  After  covalently 
attaching one or more photo-affinity ligands in the binding sites of P2X receptors, one can 
determine the contribution of the remaining binding sites to the gating process with the help 
of electrophysiology. Among various photo-affinity ATP analogs available, Benzophenone 
based ATP analog (BzATP) was found to be best suited for our studies as it can be photolyze 
at wavelength greater than 300nm, which minimizes the photo induced damage to the cell. In 
the absence of UV-light BzATP maintained agonist profile on all the three P2X receptors 
investigated  in  the  present  study.  Prolonged  application  of  1µM  BzATP  on  the  P2X1 
receptors in the absence of light had no effect on the subsequent recovery of receptors from 
desensitization which indicates that it behaves like the natural ligand ATP in the absence of 
light. Covalent attachment of BzATP to the ligand binding site of P2X1 receptors occurred 
only in the presence of UV-light, which was evident by the low recovery of receptors from 
desensitization in my experiments. This clearly demonstrates that the dissociation of bound 
agonist constitutes the recovery of P2X1 receptors from desensitization.  
On the non-desensitizing P2X2 receptors, BzATP was found to have partial agonist profile. 
Again, after covalent labeling, the response generated by full agonist (ATP) from the same set 
of receptors was found to be decreased in P2X2 receptors. These results suggest that if one or 
two binding sites in P2X2 receptors were covalently occupied by a partial agonist then the 
efficacy  of  full  agonist  decreases.  One  can  infer  from  these  results  that  all  the  receptor 
subunits are contributing towards the gating. On the chimera, BzATP maintained the agonist 
profile, although it was less potent compared to ATP as was revealed by the complete dose 
response curve of BzATP and ATP on chimera. Progressive photolabeling of the chimera by 
saturated concentration of BzATP (1µM) showed an increase in the persistent current which 
could be specifically blocked by the external application of an open channel blocker i.e. 3mM 
Neomycin. We  speculate that the persistent current  from the chimera originated from the 
receptors  in  which  all  the  binding  sites  were  covalently  attached  by  BzATP,  therefore, Summary 
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limiting the dissociation of bound ligands. In order to support our conclusion that all the 
subunits of the P2X receptors are contributing equally to the gating process, we generated 
complete dose response curves of full and partial agonists on the chimera before and after 
different levels of photolabeling. The levels of photolabeling were controlled by the amount 
of  exposure  of  UV-light.  We  found  that  after  progressive  photolabeling,  sub-saturating 
concentration of another full agonist (αβ-MetATP) became more potent as suggested by a 
leftward shift in the dose response curve. We propose that after photolabeling, the probability 
that these channels will be fully liganded at any given αβ-MetATP concentration would be 
higher. In contrary to P2X2 receptors where covalent attachment of a partial agonist (BzATP) 
decreased  the  response  of  full  agonist  (ATP),  we  expect  on  the  chimera  that  covalent 
attachment  of  a  full  agonist  (BzATP)  should  increase  the  response  of  a  partial  agonist. 
However, none of the ATP analogs have been tested for partial agonist profile on the chimera. 
As  the  chimera  has  high  sensitivity  towards  different  ligands,  we  found  that  saturating 
concentrations of TNP-ATP (300nM), which is a known potent antagonist of P2X1 receptors, 
elicited  a  weak inward current  on the chimera  suggesting  a partial  agonist profile.  Upon 
progressive photolabeling, the efficacy of TNP-ATP on chimera was increased although we 
found no change in the apparent affinity of TNP-ATP on the chimera. We further estimated 
that at least two covalently attached BzATP were required to increase the efficacy of TNP-
ATP  to  a maximum.  Together,  these  results suggest  that  every  subunit  in P2X receptors 
contributes to the gating and that the contribution of each subunit towards the gating process 
is an additive one i.e. as the number of partial agonist in binding sites would increase, receptor 
response generated by full agonist would decrease and vise versa.  
As described above, with the help of photolabeling technique coupled to electrophysiology we 
investigated the contribution of each receptor subunit to the gating process. Next, with the 
help of fluorescence labeling of the binding site coupled to electrophysiology, we provide 
further evidences that P2X receptor subunits are not independent but interacting with each 
other. It is known that the desensitized state of P2X1 receptors has a high affinity for the 
bound agonist, which is often associated with the slow dissociation and thereby slow recovery 
of receptors from desensitization. Moreover, the desensitized state of P2X1 receptors is an 
electrophysiologically silent state. Therefore, a fluorescent ATP analog was required which 
could activate and induce desensitization in the P2X1 receptors, so that we could measure the 
rate of dissociation of bound agonist from the desensitized state. Unfortunately, none of the 
fluorescent ATP analogs were analyzed for agonist potency on the P2X receptors. To the best Summary 
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of our knowledge, our study for the first time describes the agonist potency of Alexa-ATP (a 
fluorescent ATP analog) on the P2X1 receptors and the chimera.  
In order to determine the behavior of P2X1 receptor subunits, we used an approach similar to 
what  is  commonly  used  in  classical  radio-ligand  binding  experiments  i.e.  increased 
dissociation of radio-ligand bound to the receptors in the presence of high concentrations of 
unlabeled ligand suggest negative cooperativity, whereas reduced dissociation of radio-ligand 
indicates positive cooperativity. When we measured the dissociation of bound Alexa-ATP (as 
decay of fluorescence) in the presence and absence of various allosteric (Mg
+2 and Ca
+2) and 
competing  ligands  (ATP,  TNP-ATP  and  NF449),  we  found  that  the  rate  of  decay  of 
fluorescence was dependent on both, the concentration and the type of competing ligands. 
However, in all conditions the time course of decay of Alexa-ATP could be described by a 
mono-exponential function. High concentrations of competing ligands accelerated the rate of 
dissociation of bound Alexa-ATP suggesting negative cooperativity. On the other hand, in the 
presence  of  Ca
+2  or  NF449  (IC50  concentration)  decreased  rate  of  dissociation  of  bound 
Alexa-ATP was found suggesting positive cooperative interaction between subunits. When 
the  recovery  of  P2X1  receptors  from  desensitization  was  functionally  monitored  in  the 
presence of Ca
+2 or NF449 (IC50 concentration), less receptors recovered from desensitization 
which  again  indicates  positive  cooperative  interactions  and  thus,  complement  our 
fluorescence measurements. 
In order to understand the negative cooperative interactions between subunits, we propose a 
simple  allosteric  model  for  ligand-receptor  interactions.  In  this  model,  we  speculate  that 
negative  cooperativity  only  occurs  in  fully  occupied  receptors  and  this  leads  to  the  fast 
dissociation of one of the bound Alexa-ATP from the receptors. Our model predicts mono-
exponential decay of Alexa-ATP in the presence of high concentrations of competing ligands 
as the receptors would be fully liganded at all times. Further it predicts biphasic decay of 
Alexa-ATP in the absence of competing ligands as first Alexa-ATP would dissociate fast 
under negative cooperativity, whereas, the remaining two bound Alexa-ATP will dissociate 
slowly  without  the  influence  of  negative  cooperativity.  However,  our  experimentally 
determined time courses could be described by mono-exponential function in both conditions 
i.e. presence and absence of competing ligands. In order to understand this ambiguity, the 
model was simulated using Gepasi 3.0 (MS windows based software) under the framework of 
our hypothesis proposed for the model. Interestingly, the simulated results exactly replicated 
our experimental results where, the dissociation of bound Alexa-ATP could be fitted with Summary 
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mono-exponential  function  for  both  the  conditions  (presence  and  absence  of  competing 
ligands). The fact that the two rate constants (fast and slow) differ only by a factor of two and 
the  difficulty  in  resolving  the  first  tens  of  seconds  (time  taken  for  wash  of  nonspecific 
binding) in the experimentally determined fluorescence decay, could be the reason for this 
apparent mono-exponential behavior.  
Desensitizing P2X receptors immediately undergo desensitization upon activation. However, 
the number of agonist molecules required to desensitize the P2X1 receptors is still a matter of 
debate. Therefore as a next study, we have tried to answer this intriguing question. To this 
end, we tested three hypotheses that binding of one, two or three agonist molecules is required 
to  desensitize  P2X1  receptors.  First,  the  occupancy  of  receptors  at  different  Alexa-ATP 
concentrations was determined using binding curve and then fractional distributions of 0, 1, 2 
and 3 Alexa-ATP bound receptors were calculated for each Alexa-ATP concentration using 
the binomial equation. In order to use the binomial equation, we considered that the ligand 
binding  in  P2X1  receptors  is  a  random  process  and  occur  without  the  influence  of 
cooperativity because the binding rate between the first two ligands and the last ligand is not 
much different (only factor of two). After pre-equilibrating the binding sites with different 
Alexa-ATP concentrations, functional activation of P2X1 receptors was determined by near 
saturating concentrations of ATP (30µM) under voltage clamp conditions. These experiments 
showed a direct relationship between fractional population of closed-states (0, 1 and 2 bound 
Alexa-ATP) and the percentage of current generated from these receptors by near saturating 
concentration  of  ATP,  suggesting  that  binding  of  three  agonist  molecules  is  required  to 
desensitize P2X1 receptors.  
With the use of fluorescent ATP analog and electrophysiology, we found that subunits in 
P2X1 receptors are not independent but interacting  in a cooperative manner. The type of 
cooperativity however depends on the type of ligands used and their concentrations.  
Finally,  in  order  to  get  some  insights  into  the  structure-function  relationship  of  P2X1 
receptors,  I  have  investigated  the  role  of  different  domains/structures  in  P2X1  receptors 
during gating and desensitization. To this end, I used TMRM fluorophore as its fluorescence 
intensity is sensitive towards changes in hydrophobicity. The maleimide group in TMRM can 
form spontaneous covalent bond with any accessible cysteine residue available in the ionized 
form. Using site directed mutagenesis; one can engineer a free cysteine in nearly any part of 
the protein and label it with TMRM.  However, the pre-requisite of this technique is to have a 
free and accessible cysteine on the functionally expressed mutants in the region which could Summary 
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physically move in such a way that there would be a change in hydrophobicity in or around 
the engineered cysteine residue. Any change in the hydrophobicity would then be sensed by 
the attached TMRM during different states of the receptor. The lack of high solution structure 
of P2X receptors and also the absence of any  sequence homology with any  known ATP 
binding protein imposed a limitation for site directed mutagenesis. Luckily, recently solved 
high resolution structure of ASIC-1 channel is structurally quite correlated with the putative 
structure of P2X receptors. We intuitively hypothesized that the cysteine-rich-domain (CRD-
1) of ASIC-1 is structurally comparable to the CRD-1 domain of P2X1 receptors, in which 
CRD-1 region acts like a loop, which moves around the ligand binding pocket in order to 
close it after ligand binding. We mutated eight individual amino acids (position 118 to 125) in 
the CRD-1 region of P2X1 receptors and their accessibility to TMRM labeling and change in 
TMRM fluorescence upon activation was determined. Quite surprisingly, all these mutants 
were fully functional before and after TMRM labeling suggesting that cysteine mutation in 
this  conserved  CRD-1  region  can  be  tolerated  without  compromising  receptor  function. 
However, only six positions (120-125) were accessible for TMRM labeling. Upon activation 
with an agonist, kinetics of decrease in fluorescence was significantly correlated with the 
receptor  activation  at  positions  N120,  G123  and  I125C, whereas at  positions P121C  and 
E122C the increase in fluorescence was significantly correlated with the desensitization of 
P2X1 receptors, suggesting that different positions in the receptor sense different structural 
rearrangements. Not only the agonist, but also binding of competitive antagonist (NF449) 
induced  some  structural  rearrangements  in  P2X1  receptors.  Interestingly,  no  change  in 
fluorescence at position N120C was seen when NF449 (antagonist) was applied, although  
binding of NF449 induced similar increase in TMRM fluorescence at positions P121C and 
E122C  as  induced  by  agonist  suggesting  that  binding  of  antagonist  also  induced 
desensitization in P2X1 receptors. Taken together, our results suggest that not only agonists 
but  also competitive  antagonists  like NF449 could induce  structural rearrangements  in  or 
around CRD-1 region of P2X1 receptors.  
We have been successful in answering some of the interesting questions in the field of P2X 
research which opens our avenues to many other questions that may be interesting to many of 
us like the physiological relevance of subunit-subunit interactions. Could it modulate synaptic 
responses  or  mediate  synaptic  plasticity?  Other  intriguing  questions  like  single  channel 
conductance of 1 or 2 covalently attached BzATP might shed more light in the field. We Summary 
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strongly believe that our results would serve as a milestone in the P2X research to understand 
its structure-function relationship and take the P2X research to a next level. 
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Zusammenfassung 
P2X-Rezeptoren sind ligandenaktivierte Ionenkanäle, deren natürlicher Agonist ATP ist. Sie 
sind  nichtselektive  Kationenkanäle,  die  nach  Aktivierung  Membrandepolarisation  und 
Kalziumeinstrom vermitteln. Sie sind an einer Vielzahl physiologischer Prozesse wie z.B. 
excitatorische  synaptische  Übertragung,  Modulation  des  Schmerzempfindens,  Langzeit-
Potenzierung und Apoptose beteiligt. Bislang sind sieben verschiedene Suptypen bekannt, die 
als  P2X1  bis  P2X7  bezeichnet  werden.  P2X-Rezeptoren  werden  in  einer  Vielzahl  von 
Geweben  bzw.  Zelltypen  exprimiert,  wie  zum  Beispiel  in  der  glatten  Muskulatur,  den 
dorsalen Wurzelganglien und verschiedenen Immunzellen. Wegen ihrer diversen Expression 
und der Beteiligung an einer Vielzahl physiologischer Prozessen repräsentieren sie ein viel 
versprechendes  Target  für  die  Medikamentenentwicklung.  Eine  zielgerichtete 
Wirkstoffentwickung  wird  jedoch  durch  fehlende  Strukturdaten  erschwert,  da  weder  eine 
hoch  aufgelöste  Struktur  verfügbar  ist,  noch  Sequenzhomologien  zu  bekannten  ATP-
bindenden  Proteinen  vorliegen.  Demzufolge  müssen  strukturelle  Informationen  aus 
biochemischen  und  biophysikalischen  Untersuchungen  abgeleitet  werden.  Die  P2X-
Rezeporfamilie  bildet,  neben  der  Cys-Loop-Rezeptorfamilie  und  der  Glutamatrezeptor-
Familie,  die  dritte  Superfamile  der  ligandenaktivierten  Ionenkanäle.  Ein  funktioneller 
Rezeptor wird aus drei homologen Proteinuntereinheiten gebildet. C- und N-Termini einer 
Untereinheit liegen intrazellulär, die zwei transmembranären Domänen sind durch eine große 
extrazelluläre  Schleife  verbunden.  Erst  kürzlich  konnte  gezeigt  werden,  dass  die  ATP-
Bindungsstelle  an der Grenzfläche zwischen zwei  Untereinheiten  gebildet wird. Trotz der 
strukturellen Informationen, die aus Mutagenese-Studien abgeleitet wurden ist die Kenntnis 
über Struktur-Funktionsbeziehungen nach wie vor sehr begrenzt.  
Um ein besseres  Verständnis darüber zu gewinnen, wie Struktur und Funktion  ineinander 
greifen  und  welche  spezifischen  Strukturen  an  der  Aktivierung  und  Desensibilisierung 
beteiligt sind, habe ich meiner Dissertation drei Fragen zu Grunde gelegt: 
1) Funktionieren die drei Untereinheiten unabhängig voneinander oder interagieren sie nach 
der Bindung von ATP oder anderen Liganden? 
2) Was ist die Natur einer eventuellen Interaktion? 
3) Was sind die molekularen Umlagerungen, die an der Rezeptor-Ligand Interaktion beteiligt 
sind?  
 Zusammenfassung 
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Um  das  Verhalten einzelner  Untereinheiten  zu untersuchen,  habe  ich  das Xenopus laevis 
Expressionssystem  benutzt  und  P2X1,  P2X2  und  eine  P2X2/P2X1-Rezeptorchimäre 
heterolog in Xenopus Oozyten exprimiert und diese dann mit ATP und anderen kommerziell 
verfügbaren  Liganden  aktiviert.  Für  meine  Untersuchungen  habe  ich  die  Methode  der 
Zweielektroden-Spannungsklemme  unter  gleichzeitiger  Anwendung  von  Photoaffinitäts-
markierung  und  Fluoreszenzmarkierung  benutzt.  Eine  Vorbedingung  für  diese 
Untersuchungen  war,  dass  die  Markierung  und  der  gemessene  Rezeptorstrom  von  dem 
gleichen  Rezeptorpool  stammten.  Um  dies  zu  gewährleisten,  wurde  eine  spezielle 
Messkammer entwickelt. Das hier angewandte Prinzip der Photoaffinitätsmarkierung beruht 
auf einer irreversiblen Bindung von Liganden an oder nahe der P2X-Rezeptor-Bindungsstelle, 
was letztlich die Dissoziation des Liganden verhindert. Nach irreversibler Bindung eines oder 
mehrerer Liganden an den Rezeptor kann dann der Beitrag der noch freien Bindungsstellen 
bzw. unbesetzten Untereinheiten elektrophysiologisch untersucht werden. 
Aus  den  potentiell  verfügbaren  Kandidaten  wurde  BzATP  ausgewählt,  da  es  bei 
Wellenlängen  >300  nM  aktiviert  wird,  und  dadurch  lichtunduzierte  Schäden  minimiert 
werden konnten. Im Weiteren konnte gezeigt werden, dass BzATP ein Agonist an allen drei 
untersuchten Rezeptortypen ist. Eine verlängerte Applikation von BzATP (ohne Belichtung) 
hatte keinen Effekt auf die Reversibilität der P2X1-Rezeptor Desensibilisierung im Vergleich 
zu Kontrollmessungen mit ATP. Eine kovalente Bindung von BzATP erfolgte nur während 
der Belichtung mit UV-Licht, was durch die verminderte Reversibilität der Desensibilisierung 
nachgewiesen  wurde.  Dies  zeigte,  dass die  Reversibilität  der Desensibilisierung  nur  nach  
Dissoziation des Agonisten erfolgen kann. 
Am nicht-desensibilisierenden P2X2-Rezeptor wirkt BzATP als partieller Agonist. Es konnte 
gezeigt  werden,  dass  der  ATP-vermittelte  Rezeptorstrom  nach  kovalenter  Bindung  von 
BzATP zunehmend vermindert wird. Dieser Befund legt nahe, dass die „efficacy“ von ATP 
abnimmt, wenn eine oder mehrere (zwei) Bindungsstellen bereits mit BzATP besetzt sind. 
An der P2X2/P2X1-Rezeptorchimäre wirkt BzATP als voller Agonist mit einer im Vergleich 
zu  ATP  leicht  verminderten  Wirkstärke.  Photoaffinitätsmarkierung  mit  BzATP  führte  zu 
permanenter  Aktivierung  der  Chimäre,  wobei  der  persistierende  Rezeptorstrom  zur 
Quantifizierung  spezifisch  durch  den  „open-pore“  Blocker  Neomycin  gehemmt  werden 
konnte.  Wir  interpretieren  dieses  Ergebnis  dahin  gehend,  dass  der  persistierende 
Rezeptorstrom von der Rezeptorpopulation stammt, in der alle Bindungsstellen kovalent von 
BzATP besetzt sind. Zusammenfassung 
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Um die Hypothese des individuellen Beitrags einzelner Untereinheiten weiter zu untersuchen, 
wurden  Dosiswirkungskurven  vor  und  nach  Photoaffinitätsmarkierung  aufgenommen.  Um 
das  Ausmaß  der  Markierung  zu  kontrollieren,  wurden  die  Rezeptoren  dem  UV-Licht  für 
verschiedene Zeitdauern ausgesetzt. Dadurch konnte gezeigt werden, dass mit zunehmendem 
Ausmaß  der  Markierung  der  volle  Agonist  αβ-MetATP  in  seiner  Wirkstärke  scheinbar 
zunahm,  was  sich  in  einer  Linksverschiebung  der  Dosiswirkungskurve  manifestierte.  Wir 
erklären diesen Befund dadurch, dass eine Markierung einer oder mehrerer Bindungsstellen 
die  Wahrscheinlichkeit  der  Bindung  von  freiem  αβ-MetATP  an  die  verbleibenden  freien 
Bindungsstellen erhöht. 
Da die Markierung mit dem am P2X2-Rezepor partiellen Agonisten BzATP die Wirkung von 
ATP (voller Agonist an P2X2) vermindert, sollte untersucht werden, ob ein partieller Agonist 
an der Rezeptorchimäre vergleichbare Effekte hervorruft. Allerdings waren bis zum Zeitpunkt 
meiner Untersuchungen keine partiellen Agonisten an der Rezeptorchimäre untersucht. Daher 
wurde  TNP-ATP,  ein  hochpotenter  P2X1-Antagonist,  auf  partiellen  Agonismus  an  der 
Chimäre hin untersucht. Wir konnten zeigen, dass TNP-ATP in einer Konzentration von 300 
nM tatsächlich ein sehr schwacher Agonist der Chimäre ist. Nach Photoaffinitätsmarkierung 
mit BzATP wurde die „efficacy“ von TNP-ATP erhöht, wobei es zu keiner Änderung der 
Dosiswirkungskurve von TNP-ATP kam. Durch eine statistische Analyse konnte abgeschätzt 
werden,  dass  erst  die  kovalente  Markierung  von  zwei  Bindungsstellen  mit  BzATP  die 
„efficacy“-Erhöhung von TNP-ATP bedingt. Zusammenfassend zeigen diese Ergebnisse, dass 
jede  einzelne  Untereinheit  des  Rezeptors  nach  Ligandenbindung  einen  Beitrag  zu  den 
Konformationsänderungen liefert, die letztlich zum Öffnen des Kanals führen. 
In  den oben  angeführten Experimenten wurde die Methode der Photoaffinitätsmarkierung  
und  gleichzeitiger  Analyse  des  Rezeptorstroms  genutzt,  um  den  Beitrag  einzelner 
Untereinheiten  zur  Rezeptoraktivierung  nach  Bindung  verschiedener  Liganden  zu 
untersuchen. Im folgenden Abschnitt wird unter Zuhilfenahme von Fluoreszenzmarkierung 
der  Bindungsstellen  gezeigt,  dass  die  Rezeptoruntereinheiten  abhängig  von  der 
Ligandenbindung miteinander interagieren, d.h. Kooperativität zeigen. 
Es ist bekannt, dass der desensibilisierte Zustand des P2X1-Rezeptors eine hohe, nanomolare 
Affinität  für  ATP  besitzt,  was  sich  in  einer  sehr  langsamen  Reversibilität  des 
desensibilisierten Zustands niederschlägt. Da der desensibilisierte Zustand nicht direkt durch 
elektrophysiologische  Methoden  abgebildet  werden  kann,  sollte  dieser  Zustand  durch 
Nutzung  eines  fluoreszierenden  ATP-Analogon,  das  sich  in  Bezug  auf  Aktivierung  und Zusammenfassung 
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Desensibilisierung möglichst ähnlich wie ATP verhält, untersucht werden. Zum Zeitpunkt des 
Beginns  dieser  Arbeit  war  keines  der  kommerziell  erhältlichen  fluoreszierenden  ATP-
Analoge an P2X-Rezeptoren getestet, so dass die in dieser Arbeit beschriebenen Experimente 
erstmals den Einsatz von fluoreszenzmarkiertes ATP als Agonist am P2X1-Rezeptor und der 
Chimäre beschreiben. Um das Verhalten der Rezeptoruntereinheiten zu untersuchen, wurde 
ein Ansatz gewählt, der dem bei klassischen Radioligand-Bindungsexperimente ähnelt: eine 
beschleunigte  Dissoziation  des  Radioliganden  in  Anwesenheit  einer  hohen  Konzentration 
eines  unmarkierten  Liganden  bedeutete  negative  Kooperativität,  eine  verlangsamte 
Dissoziation deutet auf eine negative Kooperativität hin. Durch die Messung der Dissoziation 
von  Alexa-ATP  (durch  Messung  der  Fluoreszenzintensität)  in  An-  und  Abwesenheit 
verschiedener allosterischer Modulatoren (Mg
2+ und Ca
2+) und kompetitiver Liganden (ATP, 
TNP-ATP und NF449), konnten wir zeigen, dass die zeitliche Abnahme der Fluoreszenz von 
der  Konzentration  und  der  Art  des  anwesenden  Liganden  oder  Modulators  abhing.  Der 
zeitliche Verlauf der Abnahme konnte dabei in allen Fällen durch eine monoexponentielle 
Funktion  beschrieben  werden.  Hohe  Konzentrationen  der  kompetitiven  Liganden 
beschleunigten  die  Dissoziation  von  Alexa-ATP,  gleichbedeutend  mit  negativer 
Kooperativität. Im Gegensatz dazu wurde die Dissoziation in Anwesenheit von 2 mM Ca
2+ 
und der IC50 Konzentration von NF449 (0.3 nM) verlangsamt, was positive Kooperativität 
bedeutet. Die funktionelle Untersuchung der Reversibilität der Desensibilisierung des P2X1 
Rezeptors ergab eine starke Verlangsamung in Anwesenheit von Ca
2+ und konnte damit die 
Befunde  aus  den  Flureszenzmessungen  bestätigen.  Zur  Beschreibung  der  vorgenannten 
Befunde wurde ein einfaches Reaktionsmodell für die Rezeptor-Liganden-Interaktion heran 
gezogen. Dieses Modell beinhaltet, dass die negative Kooperativität nur im vollständig mit 
Ligand besetzten Zustand des Rezeptors vorliegt, was zu einer beschleunigten Dissoziation 
des jeweils ersten von den insgesamt drei gebundenen Liganden führt. Das Modell sagt in 
Anwesenheit sättigender freier Ligandenkonzentrationen einen monoexponentiellen Verlauf 
der Alexa-ATP Dissoziation voraus, was sich mit unseren experimentellen Befunden deckt. In 
Abwesenheit von freien Liganden sollte hingegen ein biphasischer Verlauf auftreten, da unter 
diesen  Bedingungen  der  erste  Ligand  mit  einer  schnelleren  Reaktionsrate  als  die  beiden 
folgenden  dissoziiert.  Letztere  Vorhersage  steht  in  scheinbarem  Widerspruch  zu  den 
experimentellen  Ergebnissen,  die  einen  monoexponentiellen  Verlauf  unter  allen 
Versuchsbedingungen – wenn auch mit unterschiedlichen Zeitkonstanten - ergab. Zusammenfassung 
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Um diesen Widerspruch aufzulösen wurde der Zeitverlauf unter verschiedenen Bedingungen 
auf Basis des kinetischen Reaktionsmodells durch Einsatz der Simulationssoftware Gepasi 3.0 
numerisch simuliert. Mit einem geeigneten Satz von Ratenkonstanten konnten die simulierten 
Zeitverläufe mit den experimentellen in Einklang gebracht werden; die simulierten Datensätze 
konnten  für  An-  und  Abwesenheit  kompetitiver  Liganden  hinreichend  genau  mit  einer 
Exponentialfunktion  beschrieben  werden.  Gründe  für  das  apparente  monoexponentielle 
Verhalten sind zum einen, dass sich die schnelle und langsame Ratenkonstante nur um den 
Faktor zwei unterscheiden und zum anderen, dass im Experiment die ersten Sekunden nach 
Beginn  des  Lösungswechsels  wegen  der  großen  Hintergrundfluoreszenz  des  in  Lösung 
befindlichen Fluorophors nicht dargestellt werden können.  
P2X1-Rezeptoren desensibilisieren vollständig unmittelbar nach Aktivierung mit ATP, wobei 
die  Frage  wie  viele  der  wahrscheinlich  drei  Bindungsstellen  zur  vollständigen 
Desensibilisierung  mit  ATP  besetzt  werden  müssen,  ungeklärt  ist.  Um  diese  Frage 
aufzuklären,  wurden  die  experimentellen  Ergebnisse  darauf  hin  getestet,  ob  sie  mit  einer 
bestimmten  zur  Desensibilisierung  notwendigen  Anzahl  von  gebundenen  Liganden 
kompatibel sind. Aus der Konzentrationsabhängigkeit der Alexa-ATP-Bindung wurden die 
relativen Rezeptorpopulationen berechnet, die 0, 1, 2, oder 3 Alexa-ATP-Moleküle gebunden 
hatten.  Diese  Verteilung  wurde  mit  funktionellen  Daten,  der  Alexa-ATP-
Konzentrationsabhängigkeit  der  Gleichgewichtsdesensibilisierung,  verglichen.  Die  beste 
Übereinstimmung beider Datensätze konnte unter der Annahme erzielt werden, dass erst die 
Bindung von drei ATP-Molekülen den Rezeptor öffnet und nachfolgend desensibilisiert. 
Durch  die  sich  ergänzende  Nutzung  von  Fluoreszenzmessungen  und  Elektrophysiologie 
konnte  gezeigt  werden,  dass  eine  Kooperativität  zwischen  den  Untereinheiten  des  P2X1-
Rezeptors existiert.  Art und Ausmaß  dieser Kooperativität  hängen  dabei  von  der  Art der 
jeweiligen Liganden ab. 
Als letztes ergänzendes Teilprojekt dieser Arbeit wurde die Methode der Voltage-Clamp-
Fluorometrie  eingesetzt,  um  Einblicke  in  die  strukturelle  Dynamik  des  P2X1-Rezeptors 
währen der Aktivierung und Desensibilisierung  zu gewinnen. Dazu wurde als Fluorophor 
Rhodamin-Malemid  (TMRM)  eingesetzt,  das  eine  kovalente  Bindung  mit  freien  Cystein-
Resten  eingeht  und  dessen  Fluoreszenzintensität  von  der  Hydrophobizität  seiner  nächsten 
Umgebung abhängt. Durch ortsgerichtete Mutagenese von einzelnen Aminosäuren zu Cystein 
kann  das Fluoreszenzlabel  TMRM dann  an  definierten Stellen  der Rezeptoruntereinheiten 
angeheftet  werden.  Allerdings  ist  die  Voraussetzung  für  eine  effektive  Markierung  die Zusammenfassung 
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Zugänglichkeit  des  Cysteins  für  TMRM  und  der  Erhalt  der  Rezeptorfunktionalität  nach 
Mutagenese  und  Markierung.  Nach  erfolgreicher  Markierung  erfolgt  eine 
Fluoreszenzänderung, wenn durch die Konformationsänderung des Rezeptors eine Änderung 
der  Hydrophobizität  in  unmittelbarer  Umgebung  des  Rhodamins  erfolgt.  Die  Auswahl 
geeigneter  Residuen  zur  Mutagenese  wurde  durch  das  Fehlen  jeglicher  detaillierter 
Strukturinformationen    und  Sequenzähnlichkeiten  zu  anderen  Proteinen  für  den  P2X1-
Rezeptor erschwert. Daher wurde die kürzlich publizierte Kristallstruktur des ASIC-1 (acid 
sensing  ion  channel  1)  aufgegriffen,  da  ASIC-1  ebenfalls  wie  der  P2X1-Rezeptor  eine 
Cystein-reiche  Domäne  aufweist,  von  der  beim  ASIC-1  angenommen  wird,  dass  sie  als 
Schleife  fungiert,  die  nach  Ligandenbindung  eine  Konformationsänderung  erfährt.  Durch 
diese Analogie angeregt, wurden die ersten acht Residuen (Aminosäuren 118-125 zwischen 
dem ersten und zweiten endogenen Cystein) der ersten Cystein-reichen Domäne (CRD-1) des 
Rezeptors einzeln zu Cystein mutiert. Die elektrophysiologische Analyse der Mutanten ergab 
überraschenderweise,  dass  alle  Mutanten  funktionell  waren  und  sich  nur  marginal  vom 
Wildtyp-Rezeptor  unterschieden.  Eine  effektive  Markierung  mit  TMRM  konnte  für  die 
Mutanten  120C-125C  nicht  aber  für  die  beiden  Mutanten  118C und 119C  nachgewiesen 
werden.  Eine  Fluoreszenzänderung  nach  Rezeptoraktivierung  mit  ATP  konnte  bei  allen 
markierbaren Mutanten detektiert werden. Bei den Mutanten N120C, G123C und I125C war 
die Fluoreszenzabnahme zeitlich mit der Rezeptoraktivierung  korreliert, bei den Mutanten 
P121C und E122C bestand eine zeitliche Korrelation zwischen einer Fluoreszenzzunahme 
und der Rezeptordesensibilisierung. Diese Befunde zeigen, dass die verschiedenen mutierten 
Residuen  unterschiedliche  spezifische  Konformationsänderung  während  Aktivierung  und 
Desensibilisierung des Rezeptors erfahren. Darüber hinaus zeigte sich, dass der kompetitiv 
wirkende  P2X1  Antagonist  NF449  an  den  Mutanten  P121C  und  E122C  ebenfalls  eine 
Fluoreszenzänderung ähnlich der bei Gabe von ATP hervorrief, was vermuten lässt, dass die 
antagonistische  Wirkung  von  NF449  auf  einer  Rezeptordesensibilisierung  ohne 
vorhergehende Aktivierung beruhen  könnte. Somit  kann am P2X1-Rezeptor nicht nur die 
Bindung von Agonisten, sondern auch die von Antagonisten eine Konformationsänderung  
bewirken. 
In  der  vorliegenden  Arbeit  konnten  einige  ungeklärte  Fragen  der  P2X-Rezeptorforschung 
erfolgreich  behandelt  werden.  Aus  den  vorliegenden  Befunden  ergeben  sich  weitere, 
interessante  Fragestellungen  wie  zum  Beispiel  die  physiologische  Bedeutung  der 
Kooperativität  bei  der  Reversibilität  der  Rezeptor-Desensibilisierung.  Eine  mögliche Zusammenfassung 
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Bedeutung  könnte  diese  Kooperativität  zum  Beispiel  bei  der  Modulation  synaptischer 
Signaltransduktion oder in der synaptischen Plastizität haben.  
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